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Scope of the investigation
Endothelial cell sprouting is a multi-step process, tightly regulated by diverse signalling 
pathways. Vascular endothelial growth factor (VEGF) is an essential inducer for angiogenesis as 
evidenced by in vivo and in vitro studies. Transforming growth factor (TGF)-β remodels the vascular 
morphogenesis in vivo and regulates the expression of VEGF and VEGF receptors in vitro. However, 
little is known about how these two factors orchestrate the modulation of endothelial cell function. 
The scope of the research presented in this thesis is to study the interplay between TGF-β and 
VEGF signalling on endothelial cell function, with the focus on the effect of TGF-β signalling on 
VEGF- induced endothelial cell function. 
TGF-β transduces its effect by binding to two distinct TGF-β type I receptors, ALK1 and ALK5 
on endothelial cells. In addition, the concentration of TGF-β affects the degree of activation of 
these two receptors. In Part I, to investigate the influence of ALK5 activity in response to VEGF 
stimulation, a selective inhibitor of ALK5 (SB-431542) was applied to investigate the role of ALK5 in 
VEGF-induced vascular network formation; to address the role of ALK1 in VEGF-induced endothelial 
cell behavior, BMP9 as a potent ALK1 ligand was used in the presence of VEGF. 
Endoglin is a co-receptor for TGF-β and functions as a modulator for ALK1 and ALK5 in 
endothelial cells. The involvement of endoglin in VEGF-induced endothelial cell function remains 
unclear. In Part II, the studies were designed to elaborate the role of endoglin and its soluble 
form on VEGF-stimulated endothelial cell sprouting. Of note, Chapter 6 discusses  the pathological 
contribution of elevated soluble endoglin levels to pre-eclampsia. 
In conclusion, TGF-β and VEGF signalling intimately intertwine and crosstalk with each other 
to affect endothelial cell function accordingly. Since the aim of the thesis was to elucidate the 
underlying mechanism of vascular pathologies that are associated with perturbed TGF-β and VEGF 
signalling, the work of this thesis may open new opportunities for future development of new 
treatment modalities.
10
Thesis Outline
Thesis Outline
The studies presented in this thesis have focused on the crosstalk between the TGF-β, BMP9 
and VEGF signalling pathways and their roles on EC function, and how endoglin, a co-receptor of 
TGF-β signalling influences VEGF-induced endothelial sprouting.
Chapter 1 provides a general overview of the role of TGF-β family signalling in vascular development 
concerning its role in endothelial cell and mural cells as well as the impact of TGF-β signalling in 
pathological conditions.
Part I: The effect TGF-β signalling in endothelial cell function in response to VEGF 
Chapter 2 demonstrates that inhibition of the TGF-β signalling pathway using the TGF-β receptor I 
inhibitor SB-431542 enhances VEGF-induced endothelial cell function. Sub-optimal doses of VEGF 
and SB-431542 synergistically induce endothelial cell migration and sprouting. 
Chapter 3 reports the new ligand BMP9 for ALK1 signalling and its inhibitory role in endothelial 
cell function.
Part II: The role of endoglin in endothelial cell function in response to VEGF 
Chapter 4 describes the new observation that endoglin is required for efficient VEGF-induced 
endothelial cell sprouting. 
Chapter 5 demonstrates that endoglin is cleaved by MMP14, and that the derived soluble form of 
endoglin exerts inhibitory effect on VEGF-induced endothelial cell sprouting
Chapter 6 gives an overview of the role of soluble endoglin and soluble Flt1 in pre-eclampsia.
Part III: General Discussion
Chapter 7 discusses the perspectives of the main focuses of this thesis reflected towards the 
current literature.
TGF-β signalling in vascular biology and dysfunction
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TGF-β signalling in vascular biology and dysfunction
Marie-José Goumans, Zhen Liu, Peter ten Dijke
Department of Molecular Cell Biology and Centre for Biomedical Genetics, Leiden University Medical Center, 
PO Box 9600, 2300 RC Leiden, The Netherlands
Cell Research 19:116-127. doi: 10.1038/cr.2008.326; published online 30 December 2008
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Abstract
Transforming growth factor (TGF)-β family members are multifunctional cytokines that 
elicit their effects on cells, including endothelial and mural cells, via specific type I and type II 
serine/threonine kinase receptors and intracellular Smad transcription factors. Knock-out mouse 
models for TGF-β family signalling pathway components have revealed their critical importance in 
proper yolk sac angiogenesis. Genetic studies in humans have linked mutations in these signalling 
components to specific cardiovascular syndromes such as hereditary hemorrhagic telangiectasia, 
primary pulmonary hypertension and Marfan syndrome. In this review, we present recent advances 
in our understanding of the role of TGF-β receptor signalling in vascular biology and disease, and 
discuss how this may be applied for therapy.
Keywords: angiogenesis, BMP, Marfan syndrome, Smad, pre-eclampsia, pulmonary 
hypertension, TGF-β
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Introduction
Transforming growth factor (TGF)-β is the prototypic member of a large family of evolutionarily 
conserved pleiotropic cytokines. Thirty three members are present in mammals, including three 
TGF-β isoforms, activins, and bone morphogenetic proteins (BMPs) [1-3]. TGF-β family members 
have critical and specific roles during embryogenesis and in maintaining the homeostasis of adult 
tissues. Perturbations in their signalling pathways have been linked to a diverse set of developmental 
disorders and diseases, including cancer, fibrosis, auto-immune and cardiovascular diseases.
All TGF-β family ligands are generated as dimeric precursor proteins and subsequently cleaved 
by proteases and secreted [4]. Members of the TGF-β family elicit their cellular effects by binding to a 
complex of type II and type I serine/threonine kinase transmembrane receptors (Figure 1). Five type 
II receptors and seven type I receptors, also termed activin receptor-like kinases (ALKs) are present 
in mammals [1-3]. Within the ligand-induced heteromeric receptor complex, the constitutively active 
type II receptor phosphorylates the type I receptor on specific serine and threonine residues in the 
intracellular juxtamembrane region. TGF-β signals in most cells via TGF-β type II receptor (TβRII) 
and ALK5, activins via activin receptor type IIA (ActRIIA) and IIB and ALK4, and BMPs via BMP type II 
receptor (BMPRII), ActRIIs and ALK1, 2, 3 and 6. In endothelial cells (ECs) TGF-β can, in addition to ALK5, 
also signal via ALK1 [5, 6]. Upon type I receptor activation, receptor-regulated Smads (R-Smads) are 
recruited to, and phosphorylated by the type I receptor at the two serine residues in their extreme 
carboxyl termini. ALK4 and 5 (and 7) induce R-Smad2 and 3 phosphorylation, while ALK1, 2, 3 and 6 
mediate phosphorylation of R-Smad1, 5 and 8. Activated R-Smads form complexes with the common 
mediator Smad4, and translocate into the nucleus, where they can regulate, together with other 
partner proteins, the transcription of specific target genes. Inhibitory (I)-Smads, i.e. Smad6 and -7, 
can inhibit the activation of R-Smads by competing with R-Smads for type I receptor interaction and 
by recruiting specific ubiquitin ligases or phosphatases to the activated receptor complex thereby 
targeting it for proteosomal degradation or de-phosphorylation, respectively [1-3].
Access of ligands to the signalling type I and type II receptors is regulated by soluble ligand 
binding proteins and by accessory type III receptors. Examples of the latter class that have been 
most intensively studied are endoglin and betaglycan [4, 7]. Both receptors are structurally related 
trans-membrane proteins with long extracellular and short intracellular domains and without an 
enzymatic motif. Compared with the type I and type II receptors, betaglycan is present in higher 
abundance and binds TGF-β1 and 3 with lower affinity [8]. When TGF-β encounters a target cell 
expressing betaglycan, it is likely to interact first with betaglycan, which then presents it to TβRII. 
Betaglycan facilitates TGF-β signalling, in particular for TGF-β2 that binds with very weak affinity 
to TβRII alone [9, 10]. Endoglin (CD105) is a homodimer that interacts with TGF-β1 and TGF-β3, 
but only when it is associated with TβRII [11, 12]. Both the endoglin extracellular and intracellular 
domains interact with TβRII and ALK5 [7]. Endoglin is able to bind directly to BMPs [13-15].
14
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In contrast to factors such as vascular endothelial growth factors (VEGFs) and angiopoietins 
that have prominent effects on EC behavior [16], TGF-β was initially discovered through its effects 
on fibroblasts [17] and subsequently shown to affect among other cell types, epithelial-, immune-, 
stem-, endothelial- and mural cells. This together with its highly cellular context dependent 
properties, frequently having opposite effects depending on the cellular differentiation state 
or the presence of other specific extracellular cues, has left the elucidation of the complex role 
of TGF-β family members in the cardiovascular system somewhat under-investigated. However, 
phenotypic and molecular characterizations of knock-out mice for TGF-β signalling components 
have demonstrated their critical role in angiogenesis, and importantly several cardiovascular 
syndromes were directly linked to mutations in their genes [4]. TGF-β family members have 
now gained a prominent spot among other key cytokines that control vascular function. Our 
understanding of their complex role in cardiovascular biology and interplay with VEGF and other 
angiogenesis regulators is proceeding at a rapid pace. In this review we focus on recent insights into 
the function of TGF-β family members in the cardiovascular system and discuss how dys-regulation 
of their signalling pathways contributes to vascular pathologies.
Fig.1 Signal transduction by TGF-β family members is mediated via specific heteromeric complexes of type I and type 
II serine/threonine kinase receptors. In most cells TGF-β interacts with TβRII and ALK5, but in endothelial cells it can 
also signal via ALK1. BMPs signal via BMPRII, ActRIIA and ActRIIB, and type I receptors ALK1, 2, 3 and 6. Co-receptors 
betaglycan and endoglin can facilitate TβRII/ALK5 and TβRII/ALK1 signalling. Soluble versions of the co-receptors 
betaglycan and endo- glin have been shown to sequester TGF-β and BMP9, respectively. Intracellular signalling can 
be divided into two main Smad signalling pathways: ALK5 induces phosphorylation of Smad2 and Smad3, and ALK1, 
2, 3 and 6 mediate phosphorylation of Smad1, 5 and 8. Activated R-Smads form heteromeric complexes with common 
mediator Smad4, which accumulate in the nucleus, where they can act as transcription factor complexes and regulate 
the expression of specific target genes
TGF-β signalling in vascular biology and dysfunction
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Vascular morphogenesis
Neovascularization, the formation of new functional microvascular networks, is a tightly 
controlled process regulated by several converging signalling pathways that are tightly coordinated 
in time and space. The formation of new blood vessels can occur via two processes, vasculogenesis 
and angiogenesis, both of which result in the formation of endothelial-lined tubes [16]. During 
vasculogenesis new vessels arise de novo from a mass of proliferating cells, classically forming 
an inner core of hematopoietic precursor cells and an outer layer of ECs termed a blood island, 
followed by their subsequent migration, fusion and organization into a primary capillary plexus 
[18]. Angiogenesis refers to the formation of new capillary networks by sprouting from pre-existing 
vessels [18, 19]. Neovascularization is involved in growth and development, wound healing and 
several pathological situations such as tumor growth and metastasis, and cardiovascular disorders 
[20]. While angiogenesis occurs during embryogenesis and in adult life, vasculogenesis was initially 
thought to occur only in the embryo, but some studies have suggested that circulating endothelial 
progenitor cells may also contribute to vessel formation in the adult [21]. The formation of new 
capillaries involves EC activation, migration, alignment, proliferation, tube formation, branching 
and maturation of intercellular junctions and the surrounding basement membrane. All new blood 
vessels begin as simple EC-lined capillaries, but during vessel maturation, some vessels remain as 
capillaries covered by pericytes, and others develop into large vessels with support from a layer of 
smooth muscle cells (SMCs), forming a strong vessel wall.
Angiogenesis is a carefully balanced process, under the control of and fine tuned by a multitude 
of factors, including stimulators like VEGF and inhibitors such as thrombospondin [20]. Considering 
the context-dependent effects of TGF-β in other cell systems, it is not surprising that its effect on 
blood vessel formation is biphasic [4]. It can act as both a promoting and an inhibitory factor of 
angiogenesis for which the underlying mechanisms are starting to be uncovered.
Insights from knock-out mice
In vivo studies show that loss of TGF-β signalling components leads to abnormal formation 
of the primitive vascular plexus and decreased vessel wall integrity caused by irregular capillary 
vessel formation or impaired differentiation and recruitment of vascular SMCs. Targeted deletions 
of ALK1, ALK5, TβRII and endoglin in mice result in remarkably similar phenotypes (Figure 2). 
Embryos lacking any one of these components die during mid-gestation due to impaired vascular 
development, exhibiting hyper-dilated, leaky vessels [22], highlighting the importance of TGF-β 
signalling in the vascular sys- tem. The primary target cell for TGF-β is the EC since mice deficient 
in endothelial TβRII or ALK5 expression showed vascular defects in the yolk sac and embryonic 
lethality at embryonic day (E)10.5, which pheno-copied mice lacking receptors in all cells [23]. TGF-β 
16
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not only affects the ECs, but is also important for proper differentiation and function of SMCs and 
pericytes. Mice lacking TβRII specifically in vascular SMCs also showed vascular defects in the yolk 
sac but at later stages of development, allowing the embryo to survive to E12.5 [23].
Fig.2 TβRI/ALK5-deficient embryos exhibit severe defects in vascular development. Gross morphology of whole-
mount yolk sacs in mutant embryos is compared with wild type littermates. Arrow indicates the pericardial 
effusion in the mutant embryo probably caused by a circulation defect [116].
At the intracellular level Smad1-, Smad2- or Smad4- deficient mice demonstrate pre-
angiogenesis lethality in embryos [22]. In Smad1-deficient embryos this is accompanied with 
defects in chorion-allantoic circulation [24, 25]. Smad5 knock-out and endothelial specific Smad4 
knock-out have phenotypes reminiscent of TGF-β receptor knock-out mice [26, 27]. Smad3-lacking 
mice are viable but die of impaired immunity and colon cancer [22].
The I-Smads, Smad6 and 7 were initially identified as EC shear stress response genes [28] and 
are highly expressed in specific regions of the heart [29, 30]. Both I-Smads are strongly induced by 
TGF-β family members and participate in a negative feedback loop [1-3]. Studies of mice deficient 
in Smad6 or Smad7 demonstrated their critical role in development and heart homeostasis [30, 31]. 
Mice lacking Smad6 are born, but develop multiple heart abnormalities, including septation defects, 
ossification of the aorta, and have high blood pressure. While some of the Smad7-deficient mice 
die shortly after birth because of heart complications and abnormal heart rate, the majority die 
in utero due to cardiovascular defects, including outflow tract malformation and abnormality in 
ventricular septum and non-compaction.
TGF-β signalling in vascular biology and dysfunction
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Role of TGF-β signalling in ECs
TGF-β has been proposed to regulate the activation state of ECs by differentially activating 
two type I receptors, ALK5 and ALK1 [5, 6]. ALK5 is widely expressed in almost all tissues, but the 
expression of ALK1 is restricted to ECs and during embryogenesis at sites of angiogenesis [32].
TGF-β/ALK5 signalling induces Smad2/3 phosphorylation and blocks angiogenesis by inhibiting 
EC proliferation, tube formation and migration [6, 33]. ALK5 induces the expression of fibronectin 
and plasminogen activator inhibitor type 1 (PAI-1), a negative regulator of EC migration [34]. 
Interestingly, in mouse embryonic stem cell-derived ECs, the ALK5 kinase inhibitor SB-431542 
enhances EC growth and integrity via up-regulation of the tight junction component Claudin-5, 
suggesting a role for ALK5 signalling in regulating vascular permeability [35]. ALK5 indeed has 
been reported to increase TGF-β-induced EC permeability and actin cytoskeleton remodeling [36]. 
By enhancing TβRII/ALK5 assembly clustered VE-cadherin promotes persistent and elevated TGF-
β-induced Smad2/3 activation, indicating a positive role for VE-cadherin in TGF-β/ALK5-induced 
vessel stabilization [37]. Taken together, TGF-β/ALK5 signalling plays an important role in keeping 
the endothelium quiescent.
 
In contrast to TGF-β/ALK5, TGF-β/ALK1 signalling induces Smad1/5 activation and has been 
shown to stimulate EC migration, proliferation and tube formation [33]. Caveolin1 was shown 
to associate with ALK1 and to promote TGF-β/ALK1-induced responses [38]. An important 
intracellular effector of ALK1 is Id1; its upregulation was shown to be required for TGF-β/ALK1- 
induced EC migration and tube formation [6]. However, an inhibitory effect of ALK1 signalling on EC 
proliferation, migration and spouting has also been reported [39, 40]. BMP9, identified as a ligand 
for the ALK1 and BMPR-II complex in ECs, was shown to inhibit EC migration and VEGF-induced 
angiogenesis [13, 14]. These observations suggest that the effect of ALK1 signalling on angiogenesis 
is dependent on the context and specific ligand by which it is activated.
ALK1 and ALK5 signalling not only elicit opposite responses, but also physically interact with 
each other in ECs. ALK5-deficient ECs are not only defective in TGF-β/ALK5 signalling but also exhibit 
impaired TGF-β/ ALK1 responses; ALK5 was found to be necessary for recruitment of ALK1 into a 
TGF-β receptor complex, and the kinase activity of ALK5 is essential for maximal ALK1 activation 
[33]. Furthermore, ALK1 can directly antagonize ALK5/Smad2/3 signalling at the level of Smads [5, 6]. 
The cross-talk between ALK1 and ALK5 signalling provides ECs with a TGF-β-dependent switch to 
fine tune EC function.
BMPs also play an important role in EC function. BMP6 promotes EC migration and tube 
formation via Smad1/5/8 phosphorylation [41]. BMP4 was shown to induce proliferation and 
migration of ECs via stimulation of VEGF-A and Tie-2 signalling [42]. In vivo BMPs were also found 
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to induce tumor angiogenesis [43]. BMP endothelial cell precursor-derived regulator (BMPER) 
interacts with BMP4, and regulates BMP4-mediated angiogenesis [44]. Interestingly, inhibition of 
BMPRII using specific siRNA in human pulmonary arterial ECs was found to induce EC apoptosis 
via an increase in activated caspase-3 [45]. Upon exposure to hypoxia, BMPRII, phosphorylated 
Smad1/5/8 and Id1 expression were strongly reduced in these ECs, which may be of relevance to 
the pathogenesis of hypoxia-induced pulmonary hypertension [46]. BMP9, which interacts with 
ALK1, is reported to be a circulating vascular quiescence factor [15].
Interestingly, there are ECs that express betaglycan and those that express endoglin. ECs 
expressing betaglycan respond to all three isoforms of TGF-β, whereas ECs that express endoglin 
(and not betaglycan) respond with high potency to TGF-β1 and -β3, but not -β2 [47]. In ECs that 
co-express betaglycan and endoglin, both proteins were shown to be part of a common TGF-β 
receptor complex [48]. The co-receptor endoglin is predominantly expressed in highly proliferating 
vascular ECs, but is also reported to be detected on hematopoietic cells, syncytiotrophoblasts 
of term placenta, stromal cells and mesenchymal cells. Ectopic expression of endoglin inhibits 
TGF-β-induced growth inhibition in ECs, monocytes and myoblasts [12, 49] and extracellular 
matrix deposition [50]. Endoglin regulates the fine-tuning between the ALK1 and ALK5 signalling 
pathways. It is required for TGF-β/ALK1 signalling and indirectly inhibits TGF-β/ ALK5 signalling 
[49, 51]. Suppression of endoglin gene expression using siRNA resulted in impaired TGF-β/ 
ALK1 signalling responses [49]. ECs derived from Eng–/– embryos were unable to proliferate in 
culture, displayed reduced migration, VEGF secretion and eNOS expression [49, 52]. Interestingly, 
up-regulation of endoglin protects ECs from the apoptotic action of TGF-β1 [53]. Endoglin was 
recently shown to interact via its C- terminal PDZ binding motif with the scaffolding protein GIPC, 
which promotes endoglin cell surface retention [54]. Elevated endoglin expression levels are used 
as a marker of tumor angiogenesis and endoglin antibodies coupled with toxin or radioactivity 
have been successfully used to target ECs in anti-angiogenic therapy [55, 56]. Two endoglin splice 
forms have been reported, termed long (L) and short (S)-endoglin with pro- and anti-angiogenic 
activity, respectively [57]. While the L-form is most abundantly expressed and promotes TGF-β/ALK1 
signalling, S-endoglin expression was recently shown to be specifically high in senescent ECs and it 
preferentially promotes TGF-β/ALK5 signalling [58,59]. Transgenic mice overexpressing S-endoglin 
in ECs showed hypertension. Taken together, whereas L-endoglin contributes to the activation 
phase of angiogenesis and contributes to pathological neovascularization, S-endoglin is induced 
during EC senescence and may lead to age-associated pathologies such as hypertension [59].
Role of TGF-β signalling in vascular SMCs
Vascular SMCs express multiple type I and type II receptors for TGF-β family members [60]. 
TGF-β is a potent stimulator of vascular SMC differentiation by activating the genetic program that 
TGF-β signalling in vascular biology and dysfunction
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includes a large set of SMC differentiation marker genes [61]. Myocardin, an important coactivator 
of serum response factor, was shown to potently enhance TGF-β/Smad3-mediated activation of 
SM22α actin transcription [62]. The zinc finger E-box binding transcription factor DeltaEF1 was 
also shown to have an important effector role in this respect by forming a complex with serum 
response factor and Smad3 [63]. TGF-β-induced growth inhibition of vascular SMCs was found to 
be ALK5-mediated via both Smad3-dependent and p38 MAP kinase-dependent signalling pathways 
[64]. TGF-β was also shown to inhibit SMC migration in a non-Smad3-dependent pathway via up-
regulation of cysteine rich protein 2 expression [65, 66]. Interestingly, Smad3-deficient vascular 
SMCs demonstrated reduced growth inhibition by TGF-β, but did not show any attenuated TGF-β-
mediated migratory response [64, 67].
Endoglin is also important for the formation of vascular SMCs. Ectopic endoglin expression 
in neural crest stem cells causes pericardial hemorrhage associated with altered vascular 
SMC investment in the walls of major vessels, suggesting a direct role of endoglin in myogenic 
differentiation [68].
Vascular SMC differentiation and function are also influenced by BMPs. The effect of BMPs 
depends on the source of SMCs studied as well as the local environment. While BMP2 stimulates 
vascular SMC migration, it prevents platelet-derived growth factor induced vascular SMC 
proliferation via induction of the PPARγ/apoE axis [69, 70]. BMP7 also inhibits the growth of vascular 
SMCs and helps maintain the vascular SMC phenotype in culture [71]. In pulmonary SMCs both 
BMP7 and BMP4 induce apoptosis via a caspase 8- and 9-dependent mechanism [72]. Interestingly, 
BMP4 induces micoRNA- 21, leading to the repression of PDCD4, an inhibitor of smooth muscle cell 
gene expression; SMC differentiation is thereby stimulated [73].
Interaction between ECs and vascular SMCs
Tight regulation and close coordination between ECs and vascular SMCs are needed to form a 
mature vascular network. Vascular SMCs form abundant gap junctions with ECs and upon receiving 
signals from SMCs, ECs line up and recruit more SMCs [74].
TGF-β is an important regulator of the EC-SMC interaction. ECs produce latent TGF-β that upon 
EC-SMC interaction can be activated and induce SMC differentiation and function [75]. Targeted 
deletions of several TGF-β signalling components have revealed the importance of TGF-β signalling 
in vSMC-EC contact. ALK1- and Endoglin-deficient mice display defective remodeling of the primary 
capillary plexus of the yolk sac and aberrant development of SMCs [4, 5, 22, 76]. Mice lacking TβRII, 
Smad5, Smad1 and TGF-β1 show defects in vasculature structure or blood vessel organization [22] 
indicative of a defect in EC lining and impaired SMC development.
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TGF-β can also stimulate SMCs to produce VEGF partly in a p38 MAP kinase [77], and a reactive 
oxygen species generation-dependent manner [78]. The produced VEGF can influence both the 
ECs as well as SMCs, by inducing their growth and differentiation. Interestingly, VEGF was found 
to inhibit TGF-β release by ECs [79].
Besides influencing their growth, TGF-β and BMP are also potent SMC differentiation factors 
and crucial regulators to switch SMCs from an undifferentiated phenotype to a contractile 
phenotype [61]. Furthermore, TGF-β can also induce trans-differentiation of ECs (Endo-MT) into 
smooth muscle-like cells. TGF-β induces the expression of α-smooth muscle actin and smooth 
muscle myosin in ECs in a Snail-dependent manner [80] and blocking TGF-β signalling with 
neutralizing antibodies abrogates the induction of smooth muscle markers in ECs [75].
Vascular disorders and TGF-β signalling
In recent years multiple cardiovascular disorders have been linked to alterations in TGF-β/
BMP signalling pathways, several of which will be discussed below. Increased understanding of 
the molecular mechanisms has been achieved by studying mouse models that mimic these human 
diseases. Importantly, these mouse models also allow for testing of therapeutic strategies that aim 
to normalize the perturbed signalling balance.
Hereditary hemorrhagic telangiectasia (HHT)
Hereditary hemorrhagic telangiectasia (HHT), or Osler-Rendu-Weber syndrome, is an autosomal 
dominant vascular dysplasia, characterized by the development of mucocutaneous telangiectasias 
and arteriovenous malformations in the brain, lungs, liver, and gastrointestinal tract (Figure 3). 
There is variability in the organs affected, even between individuals within families [81]. Three 
genes are causally related to HHT, i.e. endoglin mutated in HHT type 1 (HHT-1) [82]; ALK1 mutated in 
HHT-2 [83] and mutation in Smad4 causing a syndrome consist- ing of both juvenile polyposis and an 
HHT phenotype [84]. In vivo, EC-specific deletion of ALK1 caused vascular malformations mimicking 
all pathologic features of HHT-2 vascular lesions [85], while endoglin heterozygous mice have dilated 
and fragile blood vessels which resemble clinical manifestations of HHT-1 patients [76, 86].
 
While circulating levels of TGF-β were reduced in HHT-1 patients compared to control, this was 
not found in HHT-2 patients, suggesting that reduced endoglin levels on HHT-1 ECs might lead to 
reduced TGF-β1 secretion [7]. Since TGF-β is important for SMC differentiation, and recruitment 
of SMCs to new vessels as well as their growth requires TGF-β, this reduced TGF-β secretion might 
explain the formation of fragile and leaky vessels in HHT-1 patients. Multiple clinical trials in HHT 
patients are ongoing with anti-angiogenesis agents, including bevacizumab, a neutralizing antibody 
TGF-β signalling in vascular biology and dysfunction
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against VEGF, thalidomide and interferon α-2b to inhibit bleedings and other vascular malformations 
associated with HHT (http://www.hht.org/).
Marfan syndrome and Loeys-Dietz syndrome (MFS and LDS)
Marfan syndrome (MFS) is a genetic connective tissue disorder caused by mutations in the 
fibrillin gene [87]. Typical MFS can affect the skeletal system, ocular system, cardiovascular system, 
pulmonary system as well as other organs, with defects in aorta and heart valves giving the most severe 
complications. Fibrillin contains several motifs homologous to latent TGF-β binding protein (LTBP), and 
has been shown to interact with LTBP and control TGF-β bioavailability [4]. TGF-β is bound and kept 
inactive by the LTBP-fibrillin complex. In fibrillin-1-deficent mice, a model of MFS, fibrillin-1 deficiency 
was found to diminish the sequestration of latent TGF-β to the extracellular matrix, thereby leading to 
increased TGF-β activation [88]. Marfan syndrome type 2 is caused by mutation in the TβRII gene locus. 
Three prominent features of Marfan’s syndrome in humans, i.e. dilatation of the aortic root, air-space 
widening and skeletal myopathy, can be prevented and even reversed in the mouse model by treatment 
with losartan, which blocks the angiotensin II type 1 receptor and antagonizes TGF-β signalling [89, 90].
The Loeys-Dietz syndrome is a recently described autosomal dominant aortic-aneurysm 
syndrome presenting with cardiovascular and skeletal manifestations consistent with those seen 
in MFS, along with other features not present in MFS. Typical Loeys-Dietz syndrome is characterized 
by a mutation in either TβRI or TβRII [91]. The molecular mechanism of Loeys-Dietz syndrome is 
complex and poorly understood; although mutations in TβR are inactivating its function, they 
lead paradoxically to overactive TGF-β signalling, as measured by accumulation of phosphorylated 
Fig. 3 Clinical symptoms of hereditary 
hemorrhagic telangi- ectasia (HHT) include 
(A) bleedings in tongue and lower lip, (B) 
arteriovenous malformations (pulmonary 
angiogram is shown), and (C) nasal telangiectases 
(courtesy of Dr U Geisthoff). Panels A and B were 
reproduced from [117] with permission.
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Smad2 in the nucleus and expression levels of connective-tissue growth factor [92]. Thus TGF-β 
antagonists may also alleviate manifestations of Loeys-Dietz syndrome. In a recent clinical 
study with 18 MFS patients, losartan decreased the rate of progressive aortic-root dilation [93] 
(http://www.marfan.org/ nmf/index.jsp).
Pre-eclampsia
Pre-eclampsia, which involves a raise in blood pressure, is a major cause of maternal, fetal, and 
neonatal mortality. The clinical manifestations of pre-eclampsia reflect widespread EC dysfunction, 
resulting in vasoconstriction, endo-organ ischemia and increased vascular permeability [94]. Soluble 
endoglin (solEng), a placenta- derived 65 kD soluble form of endoglin and soluble fms-like tyrosine kinase 
1 (sFlt1, an inhibitor of VEGF) are both considered to be clinical indicators for pre-eclampsia [95]. Just 
before the onset of pre-eclampsia circulating levels of solEng are found to be markedly el- evated and it 
cooperates with sFlt in the pathogenesis of pre-eclampsia in rats [96]. SolEng was found to inhibit TGF-
β-mediated activation of eNOS, thereby affecting vascular tone. SolEng disrupts EC function, inhibiting 
EC tube formation and enhancing capillary permeability. SolEng is formed by proteolytic cleavage, but 
the protease involved remains to be identified. Upon identification of this protease involved in endoglin 
shedding, it will be interesting to explore whether its targeting could be beneficial for treatment of 
pre-eclampsia. Circulating solEng levels may be a useful diagnostic marker in pre-eclampsia [4].
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a disease caused by constriction of small pulmonary 
arteries leading to an increase in blood pressure (Figure 4). Aberrant proliferation and dysfunction 
of ECs and SMCs contribute to vascular remodeling [97, 98]. Heterozygous germ line mutations in 
the BMP receptor II gene (BMPRII) have been found in more than 80% of familial PAH patients. In 
addition, about 20% of patients with idiopathic PAH were reported to have mutations in BMPRII [99, 
100]. A recent study has implicated mutations of ALK1 in children with PAH [101]. Over-expression 
of a mutant form of BMPRII in SMCs of transgenic mice causes an increase in pulmonary arterial 
pressure and pulmonary arterial muscularization, resembling some manifestations of PAH patients 
[102]. Mutations in BMPRII also can deregulate Id gene expression [103]. BMPRII signalling was 
found to be essential for BMP-mediated regulation of vascular SMC growth and differentiation 
[104]. Clinical trials with prostanoids, endothelin antagonists and phosphodiesterase inhibitors have 
shown promising results in the treatment of PAH. It will be interesting to examine the interplay 
between the targets of these therapeutics and deregulated BMPRII signalling in PAH [105].
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Fig.4 Photomicrographs of lung sections from patients with primary pulmonary hypertension (PPH). The occlusion of 
small pulmonary arteries that is typical of PPH is shown. Stainings of lung sections from PPH patients are shown using 
anti- bodies against (A) CD31 (also known as platelet endothelial cell adhesion molecule-1), an endothelium-specific 
marker (arrow is pointing to single layer of ECs); and (B) SMC α-actin (arrow is pointing to concentric layers of SMCs). 
Figure was repro- duced from [97], with permission from Dr N Morrell and Lippincott, Williams and Wilkins.
Cardiac remodeling and hypertrophy
Cardiac remodeling describes the alteration in size, shape and function of the left ventricle in 
response to changes in hemodynamic loading conditions, neurohormonal activation, or induction 
of local mediators that alter the structural characteristics of the myocardium. TGF-β is a crucial 
regulator of cardiac remodeling through its direct and potent actions in mediating cardiomyocyte 
growth, fibroblast activation and extracellular matrix deposition [106].
TGF-β levels are markedly induced in the hypertrophic myocardium. Angiotensin II via the 
angiotensin type 1 receptor promotes cardiomyocyte growth and stimulates fibroblast proliferation 
and expression of extracellular matrix components [107, 108]. Angiotensin, a potent vasoconstrictor, 
stimulates TGF-β1 mRNA and protein expression and may through its induction of thrombospondin 
lead to TGF-β activation [109], indicating that TGF-β1 acts downstream of angiotensin signalling [107]. 
In addition, angiotensin has been shown to directly lead to Smad3 activation via a mechanism that is not 
well understood [110]. The renin-angiotensin system (RAS) plays an important role in cardiac remodeling 
and clinical trials have documented the beneficial effects of angiotensin II inhibition in patients with 
myocardial infarction and heart failure [111]. Indeed, losartan has been approved for the reduction of 
cardiovascular events in patients with hypertension and left ventricular hypertrophy [112]. Furthermore 
it has been reported that TGF-β stimulation alters the program of differentiation-related gene expression 
in isolated cardiac myocytes, promoting the synthesis of fetal contractile proteins, characteristic of 
pressure-overload hypertrophy [113]. Over-expression of TGF-β in transgenic mice results in cardiac 
hypertrophy which is characterized by both interstitial fibrosis and hypertrophic growth of cardiac 
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myocytes [114]. The local production of TGF-β in hypertrophic myocardium and the link between the 
RAS system and TGF-β strongly implicate the role of TGF-β in hypertrophic response. All these results 
demonstrate the importance of TGF-β in mediating hypertrophic cardiac remodeling, however, limited 
knowledge is available on the signalling pathways responsible for TGF-β action in hypertrophy.
Concluding remarks
The pivotal importance of TGF-β family members in angiogenesis is underscored by the 
observations that nearly all knock-out mice for specific TGF-β family signalling components die 
during midgestation due to a yolk sac angiogenesis defect and that mutations in the genes encoding 
TGF-β pathway components are linked to an increasing number of human pathologies with vascular 
dysfunction. In concordance with these findings in vitro studies with different TGF-β family members 
have revealed potent effects on the function of ECs and vascular SMCs, affecting e.g., proliferation, 
differentiation, migration and extracellular matrix production. However, results obtained by different 
laboratories are sometimes in apparent conflict, but this can largely be attributed to context-
dependent functions of TGF-β family members. Ligand concentration, cell density, cell type, media 
and matrix coating may determine specific cellular responses to TGF-β family members. TGF-β also 
plays an important role in the interplay between EdCs and vascular SMCs. Recent data indicate that 
TGF-β is capable of mediating EndoMT, a transdifferentiation of ECs into SMC- like cells [115].
With misregulation of TGF-β signalling at the heart of cardiovascular disorders, the cognate 
signalling components represent interesting targets for therapy. The first large-scale clinical trials 
with losartan to treat MFS are underway and results are eagerly awaited. Results from one vascular 
disorder may open opportunities for development of therapies in other vascular pathologies. 
Whereas high levels of circulating solEng may lead to pre-eclampsia by causing an EC dysfunction in 
multiple organs, solEng may be explored for anti-angiogenic activity in curbing tumor angiogenesis.
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Abstract
Vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) are 
potent regulators of angiogenesis. How VEGF and TGF-β signalling pathways crosstalk is not 
well understood. Therefore, we analyzed the effects of the TGF-β type-I-receptor inhibitors (SB-
431542 and LY-2157299) and VEGF on endothelial cell (EC) function and angiogenesis. We show 
that SB-431542 dramatically enhances VEGF-induced formation of EC sheets from fetal mouse 
metatarsals. Sub-optimal doses of VEGF and SB-431542 synergistically induced EC migration and 
sprouting of EC spheroids, whereas overexpression of a constitutively active form of TGF-β type-I 
receptor had opposite effects. Using quantitative PCR, we demonstrated that VEGF and SB-431542 
synergistically upregulated the mRNA expression of genes involved in angiogenesis, including the 
integrins α5 and β3. Specific downregulation of α5-integrin expression or functional blocking of 
α5 integrin with a specific neutralizing antibody inhibited the cooperative effect of VEGF and 
SB-431542 on EC sprouting. In vivo, LY-2157299 induced angiogenesis and enhanced VEGF- and 
basic-fibroblast-growth-factor-induced angiogenesis in a Matrigel-plug assay, whereas adding an 
α5-integrin neutralizing antibody to the Matrigel selectively inhibited this enhanced response. 
Thus, induction of α5-integrin expression is a key determinant by which inhibitors of TGF-β type-I 
receptor kinase and VEGF synergistically promote angiogenesis.
Keywords: Angiogenesis, Endothelial cell, Integrin, Signalling, SB- 431542, TGF-β, VEGF 
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Introduction
During embryogenesis, the formation of new blood vessels depends on vasculogenesis and 
angiogenesis. Angiogenesis refers to the formation of new blood vessels from pre-existing ones (1), 
and consists of an activation phase and a resolution phase (2). The activation phase is associated 
with vessel destabilization and increased permeability, degradation of the extracellular matrix 
(ECM), and endothelial cell (EC) proliferation and migration. During the resolution phase, ECs 
become quiescent and pericytes and vascular smooth muscle cells (VSMCs) are recruited to ensure 
stabilization and maturation of the newly formed vessels (1).
Angiogenesis is tightly regulated by pro- and anti-angiogenic signals, and plays an important 
role in pathophysiological and physiological processes such as wound healing, tissue remodeling, the 
female reproductive cycle, autoimmune diseases and cancer (3). Vascular endothelial growth factor 
(VEGF) is a key regulator of vasculogenesis and angiogenesis. Heterozygous mice lacking a single 
VEGF allele die at embryonic day (E)8.5 with severe vascular defects (4; 5). Overexpression of VEGF 
also results in embryonic lethality (6). VEGF signals through two distinct tyrosine- kinase receptors, 
VEGFR1 (also known as Flt-1) and VEGFR2 (also known as KDR and Flk-1) (7), and exerts multiple effects 
on ECs, including proliferation, survival (8), migration and the formation of capillary-like tubules (9).
Genetic studies in mice and humans have suggested that perturbation of TGF-β signalling 
results in vascular abnormalities (10). TGF-β exerts its biological effects by binding to and activating 
type-I and type-II transmembrane serine/threonine-kinase receptors. Binding of TGF-β to the TGF-β 
type II receptor (TβRII) leads to recruitment and phosphorylation of type I receptor [TβRI, or activin 
receptor like kinase 5 (ALK5)]. Activin and Nodal, which are structurally related to TGF-β, signal via 
ALK4 and ALK7, respectively. Activated ALK5, ALK4 and ALK7 propagate the signal into the cells 
by phosphorylating the downstream effector proteins Smad2 and Smad3 (10). In ECs, TGF-β can 
also activate ALK1, an alternate type-I receptor, which mediates phosphorylation of Smad1 and 
Smad5 (11, 12). The TGF-β-ALK5 pathway results in inhibition of EC proliferation and migration, 
whereas the TGF-β-ALK1 pathway results in the activation of proliferation and the migration of 
ECs. Balance between the TGF-β-ALK1 and TGF-β-ALK5 signalling pathways play an important 
role in angiogenesis (11, 12). In line with those results, the effects of TGF-β on angiogenesis are 
highly context dependent, e.g. at low concentrations, TGF-β promotes angiogenesis, whereas, at 
high concentrations, it inhibits it (13). In addition to its direct effects, TGF-β can exert effects on 
angiogenesis by regulating the expression of angiogenic factors such as VEGF and components of 
the ECM such as matrix metalloproteases (MMPs) and integrins (14; 15; 16).
Integrins are heterodimeric transmembrane proteins consisting of α- and β-subunits mediating 
cell-ECM interactions. Up to date, nine integrin heterodimers have been implicated in blood-vessel 
formation, namely α1β1, α2β1, α4β1, α5β1, αvβ1, αvβ3, αvβ5, αvβ8 and α6β4 (17). Despite the 
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fact that integrins lack intrinsic enzymatic activity, upon ligand-induced integrin clustering specific 
intracellular signals are initiated by the activation of intracellular associated kinases and adaptor 
proteins in focal adhesion complexes. Integrins regulate divergent biological events including cell 
adhesion, migration, proliferation, differentiation, survival and angiogenesis (17).
Several studies have provided evidence suggesting that the interplay of VEGF and TGF-β 
signalling pathways plays an important role in angiogenesis. TGF-β can induce the expression of 
VEGF by various cells in the tumor microenvironment, such as tumor cells, stromal fibroblasts and 
cells of the immune system (18; 19). SB-431542, an ALK5/4/7 kinase inhibitor (20) was shown to 
exert an inhibitory effect on VEGF secretion in human cancer cell lines (21; 22; 23). Moreover, it was 
shown that SB-431542 stimulated the formation of FLK1- positive embryonic stem cell (ESC)-derived 
EC sheets induced by VEGF (24).
However, the molecular mechanisms that regulate the cross-talk between the VEGF and 
TGF-β signalling pathways in angiogenesis have not been determined. To elucidate the interplay 
between VEGF and ALK5, we analyzed the effects of VEGF and SB-431542 alone or in combination 
using different angiogenesis assays. We show that VEGF and SB-431542 synergistically induce 
angiogenesis both in vitro and in vivo. Gene expression profiling and functional validation revealed 
that the upregulation of α5-integrin expression plays a crucial role by which VEGF and TGF-β-type-
I-receptor- kinase inhibitor achieve their synergistic angiogenic response.
Results
VEGF and ALK5-kinase inhibitor synergistically enhance angiogenesis in fetal 
mouse metatarsal assay
To investigate the interplay between VEGF and TGF-β-ALK5 signalling in angiogenesis, we made 
use of an ex vivo fetal mouse metatarsal assay. This model provides a quantitative ex vivo assay 
with the complexity of an in vivo assay to study the formation of capillary-like structures (25; 26). 
Metatarsals of 17-day-old mouse embryos were isolated and cultured in 24-well plates for 72 hours 
to allow adherence, followed by stimulation with VEGF, TGF-β3, SB-431542 or combinations thereof. 
Capillary-like structures were visualized by staining the cultures using an EC-specific anti-CD31 
antibody (Fig. 1A). Similar to what was previously reported for VEGF and TGF-β2 (25), quantitative 
image analysis showed that VEGF strongly stimulated the formation of vessel-like structures, which 
was inhibited by TGF-β3 (Fig. 1). Treatment of bone explants with the ALK4/5/7 inhibitor SB-431542 
had no significant effects on basal outgrowth of tube-like structures. However, the combination 
of VEGF with SB-431542 (VEGF+SB-431542) significantly stimulated EC network formation in a 
synergistic manner. Interestingly, treatment of metatarsals with LY-2157299, another ALK5-
VEGF and inhibitors of TGF-β type-I receptor kinase synergistically promote blood-vessel formation by inducing α5-integrin expression
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kinase inhibitor that is structurally divergent from SB-431542 (27), slightly inhibited endothelial 
sheet formation. However, similar to SB-431542, LY-2157299 strongly promoted VEGF-induced 
angiogenesis (Fig. 2A,C). Our results indicate that activation of VEGF and inhibition of TGF-β (and/or 
Activin and/or Nodal) signalling by the SB-431542 or LY-2157299 inhibitors synergistically stimulates 
angiogenesis in vitro.
Fig. 1. TGF-β inhibits VEGF-induced formation of the endothelial network in mouse metatarsal assays. Metatarsals 
of 17-day-old mouse fetuses were prepared, transferred to cell-culture plates and allowed to adhere, and were then 
stimulated with VEGF (50 ng/ml), TGF-β3 (5 ng/ml) or both. (A) Cultures were fixed and vessel-like structures were 
visualized by anti-CD31 staining. Six bones were stimulated per experimental group and one representative picture of 
each group is shown. Ctrl,control. (B) TGF-β3 did not significantly affect baseline formation of the endothelial network. 
Incubation with VEGF strongly stimulated the formation of vessel-like structures, which was dramatically decreased by 
addition of TGF-β3. **P≤0.01.
ALK5 inhibitor and VEGF synergize in inducing EC sprouts in 3D spheroid culture
To study the effect of combined VEGF and ALK5 inhibitor on EC function, we performed a 
three-dimensional (3D)-culture collagen EC spheroid assay, which is a suitable model for the 
analysis of the early regulation of angiogenesis (28). ECs originating from the embedded spheroids 
invade the gel to form capillary-like structures. Spheroids, generated from human umbilical vein 
ECs (HUVECs), were embedded into type I collagen gels and stimulated with VEGF, SB-431542 
or their combination for 24 hours (Fig. 3). In the absence of stimulation, hardly any EC sprouting 
was observed. Stimulation with different amounts of VEGF (10-50 ng/ml) dramatically increased 
the length and the number of sprouts (Fig. 3A). The addition of SB-431542 (1-10 μM) induced the 
formation of sprouting in a dose-dependent manner, but to a lesser extent compared with VEGF 
(Fig. 3B). 
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Fig. 2. Effects of VEGF and SB-431542 on endothelial network formation in mouse metatarsal assays. (A) Metatarsals of 
17-day-old mouse fetuses were prepared, transferred to cell-culture plates and allowed to adhere for 4 days. Medium 
was refreshed and bones were stimulated for 7 days with VEGF (50 ng/ml), SB-431542 [SB; or LY-2157299 (LY)] (10 μM) or 
both. Cultures were fixed and vessel-like structures were visualized by anti-CD31 staining. Six bones were stimulated per 
experimental group and one representative picture of each group is shown. Ctrl control. (B) Enlargements of the EC-sheet 
formation of the images in A. (C) SB-431542 did not significantly affect baseline formation of the endothelial network. 
LY-2157299 slightly inhibited formation of the endothelial network. Incubation with VEGF strongly stimulated the 
formation of vessel-like structures, which was dramatically promoted by co-stimulation with SB- 431542 or LY-2157299. 
**P≤0.01.
Thus, both VEGF and SB-431542 promote EC sprouting. Interestingly, the addition of a VEGFR2-
kinase inhibitor (PTK787) (29) blocked both VEGF- and SB-431542-induced sprouting (Fig. 3D). 
Because PTK787 can inhibit the stimulatory effect of SB-431542 on EC sprouting, we wondered 
whether SB-431542 enhances VEGFR2 phosphorylation. We observed no effect of SB-431542 on 
basal and VEGF-induced VEGFR2 phosphorylation levels or on the VEGF-induced activation of 
downstream pathways such as ERK and p38 MAP kinases (data not shown). Treatment of HUVECs 
with SB-431542 decreased basal phosphorylated Smad2, indicating the presence of TGF-β-like 
factors in media supplements or active TGFβ secreted by HUVECs. VEGF had no effect on the levels 
of Smad2 phosphorylation (data not shown). Taken together, our results indicate that SB-43152 and 
VEGF do not influence immediate VEGFR2- or ALK5-induced responses, respectively.
VEGF and inhibitors of TGF-β type-I receptor kinase synergistically promote blood-vessel formation by inducing α5-integrin expression
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Fig. 3. Synergistic effect of SB-421542 or TGF-β neutralizing antibody with VEGF on EC sprouting. (A) HUVEC spheroids 
embedded in collagen were stimulated with increasing amounts of VEGF (10, 25 or 50 ng/ml). (A)HUVEC spheroids embedded 
in collagen were stimulated with increasing amounts of SB-431542 (SB; 1, 5 or 10 μM). (C) HUVEC spheroids embedded in 
collagen were stimulated with VEGF (50 ng/ml), SB-431542 (10 μM) or both for 24 hours. (D) EC spheroids were stimulated 
with VEGF or SB-431542 in the presence or absence of the VEGF-receptor-kinase inhibitor PTK787. (A-D) Quantitative analysis 
of the mean total sprout length was performed on at least ten spheroids per experimental group. *P≤0.05.
Although stimulation of the spheroids with VEGF (50 ng/ml) and SB-431542 (10 μM) further 
increased sprouting (Fig. 3C), this effect was additive and not synergistic. Therefore, we hypothesized 
that the concentrations of VEGF and SB-431542 are near-to-plateau levels, and we analyzed the effect 
of sub-optimal concentrations of both VEGF and the ALK5 kinase inhibitor. Stimulation of EC spheroids 
with 1 ng/ml VEGF or 0.2 μM SB-431542 alone resulted in a small induction of sprouting compared with 
control (Fig. 4A,B). Interestingly, the combination of low levels of VEGF and SB-431542 synergistically 
enhanced EC sprouting (Fig. 4A,B). Similar results were obtained when the TGF-β type I receptor kinase 
inhibitor LY-2157299 was used. The combination of sub-optimal concentrations of LY-2157299 and VEGF 
resulted in enhanced sprouting compared with VEGF or the inhibitor alone (Fig. 4C,D).
Because SB-431542 interferes with signalling not only of the TGFβ type I receptor ALK5, but also 
with the activity of the Actvin and Nodal type I receptors ALK4 and ALK7, we investigated whether the 
effects seen are due to inhibition of TGF-β or antagonism of Actvin-Nodal signalling. We therefore 
used the 1D11 TGF-β neutralizing antibody (29 30., 1989). EC spheroids were stimulated with a low 
concentration of VEGF in the presence or absence of the TGF-β neutralizing antibody or an isotype-
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matched control antibody (Fig. 4E). The isotype-matched control antibody had no effect on basal or 
VEGF-induced sprouting. Addition of the TGF-β neutralizing antibody did not induce EC sprouting. 
However, the combination of TGF-β neutralizing antibody with VEGF significantly induced EC sprouting 
compared with VEGF or TGF-β blocking antibody alone (Fig. 4E). As expected, ectopic expression of 
a constitutively active form of ALK5 receptor (caALK5) exerted the opposite response of SB-431542 
treatment and inhibited VEGF-induced HUVEC sprouting in the 3D spheroid system (supplementary 
material Fig. S1A). Moreover, caALK5 overexpression inhibited basal cord formation of mouse embryonic 
endothelial cells (MEECs) (supplementary material Fig. S1B). Taken together, our results suggest that 
inhibition of the TGF-β signalling pathway significantly enhances VEGF-induced EC sprouting in vitro.
Fig. 4. Synergistic effect of SB-421542 or TGF-β neutralizing antibody with VEGF on EC sprouting. (A,B) HUVEC spheroids embedded 
in collagen were stimulated with VEGF (1 ng/ml), SB-431542 (SB; 0.2 μM) or both for 24 hours. One representative picture of each 
group is shown. Quantitative analysis of the mean total sprout length was performed on at least ten spheroids per experimental 
group. (C,D) Spheroids were stimulated with VEGF (1 ng/ml), LY-2157299 (LY; 0.2 μM) or both for 24 hours. One representative 
picture of each group is shown. Quantitative analysis of the mean total sprout length per experimental group is shown. (E) EC 
spheroids were stimulated with VEGF (1 ng/ml), TGFβ-neutralizing antibody (30 μg/ml), isotype control antibody (10 μg/ml) or a 
combination for 24 hours. Quantitative analysis of the mean total sprout length per experimental group is shown. *P≤0.05.
VEGF and inhibitors of TGF-β type-I receptor kinase synergistically promote blood-vessel formation by inducing α5-integrin expression
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VEGF and ALK5 inhibitor promote EC migration
To further investigate the mechanisms by which VEGF and SB-431542 exert their synergistic 
effect on angiogenesis, we analyzed their effects on EC migration. To study the effect of VEGF and SB- 
431542 on migration, serum-starved monolayers of HUVECs were wounded by scratching and were 
stimulated for 6 hours. There was no effect on migration when cells were stimulated by VEGF or 
the ALK5-kinase inhibitor alone. However, the combination of VEGF and SB-431542 significantly 
induced EC migration (Fig. 5A,B). Consistent with these results, over-expression of caALK5 in MEECs 
resulted in reduced migration, using the transwell migration assay, and invasion, using a Transwell 
invasion assay with Matrigel coating (11) (supplementary material Fig. S2A,B).
Fig. 5. Effects of SB-431542 and VEGF on EC migration. VEGF and SB- 431542 (SB) synergistically stimulate HUVEC 
migration. HUVECs were allowed to grow to confluence and serum-starved for 5 hours. Monolayers were wounded and 
stimulated with VEGF (1 ng/ml), SB-431542 (0.2 μM) or both for 6 hours. (A) One representative picture of each group 
is shown. Dashed lines indicate the wound edge. (B) Wound closure was measured after 6 hours using ImageJ software. 
**P≤0.01.
Transcriptional profiling of the VEGF+SB-431542-induced EC response
Trying to unravel the mechanistic basis of the VEGF and SB-431542 synergistic effects on 
angiogenesis (EC sprouting), we analyzed expression of a number of genes essential to EC function 
by quantitative real-time PCR. We used a highly sensitive commercial PCR-based array system 
containing up to 84 genes related to EC function. From the genes analyzed, the expression of 20 
of them was significantly upregulated when cells were stimulated by the combination of VEGF 
and SB-431542, but not by VEGF or SB- 431542 alone (Table 1). In addition, VEGF+SB-431542 
stimulation resulted in the downregulation of 30 genes. Interestingly pro- and anti-apoptotic genes 
were differentially regulated following VEGF+SB-431542 stimulation. There was an upregulation 
in expression of the anti-apoptotic gene Bcl2 and a significant downregulation of pro-apoptotic 
genes, such as annexin A5, Bax and caspase 6 (Table 1), suggesting that VEGF and SB-431542 induce 
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pathways that promote EC survival. VEGF and SB-431542 synergistically induced the expression of 
several other genes implicated in angiogenesis, such as angiotensin receptor I, ACE, CCL5, IL3 and 
IL7 (Table 1). Integrins have been shown to play an important role in EC migration and survival, 
as well as in capillary sprouting during angiogenesis. In line with this notion, VEGF+SB-431542 
stimulation synergistically induced α5 integrin and β3 integrin mRNA expression. To verify these 
results, we performed quantitative PCR analysis using PCR primer sets different from those used in 
the array (supplementary material Fig. S3A). Similar results were obtained when mRNA was isolated 
from EC spheroids embedded in collagen after VEGF and/or SB-431542 stimulation (supplementary 
material Fig. S3B).
Table 1. Summary of genes identified as significantly altered by VEGF/SB-431542 stimulation of ECs, using an EC function 
PCR-based array system.
Fold difference compared to control
Gene VEGF SB VEGF/SB p value*
Apoptosis/survival
Bcl2 2.8 4.0 1 x 10
3
<0.01
Bax 1.1 1.8 0.2 x 10
-3
<0.01
Annexin A5 1.1 2.2 8 x 10
-3
<0.01
CASP6 1.0 1.6 0.1 x 10
-3
<0.01
Angiotensin system
AGT 0.5 0.8 0.5 0.2
AGTR1 0.5 0.8 0.5 x 10
3
<0.01
ACE 1.6 2.7 0.6 x 10
3
<0.01
Chemokines
CCL5 (RANTES) 0.93 2.1 5 x 10
3
<0.01
Interleukins
IL1b 1.0 2.6 21 0.5
IL3 1.0 1.0 2 x 10
2
<0.01
IL6 0.5 0.87 7 <0.05
IL7 0.7 0.99 3 x 10
3
<0.01
IL11 0.9 1.8 45
0.08
Integrins
ITGA5 1.0 1.31 1 x 10
3
<0.01
ITGB3 7.6 14.7 51 <0.01
*p value of VEGF/SB stimulated versus untreated control cells.
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Crucial role of α5 integrin in VEGF+SB-431542-induced angiogenesis
Stimulation of VEGF and inhibition of the TGFβ type I receptor kinase significantly induces 
integrins α5 and β3 mRNA expression. Interestingly, pretreatment of HUVECs with cyclohexamide 
(inhibitor of protein synthesis) diminished the synergistic effect of VEGF+SB-431542 on α5-
integrin expression (supplementary material Fig. S4). Those results indicate that the synergistic 
effect of VEGF and SB-431542 on integrin expression is not direct, but it requires de novo protein 
synthesis.
To investigate whether integrins α5 and β3 have a functional role in the synergistic effects 
of VEGF and SB-431542 on capillary sprouting, we studied the loss-of-function effects using an 
RNA-interference approach. HUVECs were transfected with siRNA oligonucleotides for α5 integrin 
and β3 integrin or with control siRNA and subsequently seeded to form spheroids, which were 
then embedded in collagen. In α5 integrin- and β3 integrin- siRNA-transfected cells, the levels 
of α5-integrin and β3 integrin RNA expression decreased on average 50% (data not shown). 
Quantification of sprouting demonstrated a significant decrease in VEGF+SB-431542-induced 
sprout length in the α5 and β3 integrin siRNA transfected spheroids compared with control siRNA 
(Fig. 6A). It is well recognized that integrin-mediated signalling plays a crucial role in angiogenesis. 
To exclude the possibility that downregulation of α5 integrin or β3 integrin results in a general 
block in angiogenesis, we tested the effect of α5 and β3 integrin siRNA on basic fibroblast growth 
factor (bFGF)- and VEGF (high concentration)-induced sprouting in the spheroid assay. Whereas 
α5-integrin downregulation diminished the VEGF+SB-431542-induced sprouting, it had no effect 
on bFGF- or high dose VEGF-induced capillary formation (Fig. 6A). Interestingly, downregulation 
of β3 integrin by siRNA affected VEGF+SB-431542 as well as bFGF- or high dose VEGF-induced EC 
sprouting (Fig. 5A). Moreover, α5-integrin downregulation had no effect on VEGF- (1 ng/ml) or 
SB-431542- (0.2 μM) induced EC sprouting (Fig. 6B).
To further substantiate the role of α5 integrin in the synergistic effect of VEGF and SB-431542 
on angiogenesis, we made use of an α5 integrin neutralizing antibody. Addition of α5 integrin 
function blocking antibody inhibited the synergistic effect of VEGF+SB-431542 on EC sprouting (Fig. 
6C). However, α5 integrin neutralizing antibody had no effect on high dose VEGF-induced capillary 
formation (Fig. 6D). Our results suggest that α5 integrin is necessary for VEGF+SB-431542-mediated 
synergistic induction of EC sprouting in the 3D EC spheroid assay.
VEGF and ALK5-kinase inhibitor synergistically enhance in vivo angiogenesis in a 
Matrigel-plug assay in mice
In order to characterize the effect of inhibition of the ALK5 receptor in VEGF-induced 
angiogenesis, we analyzed the in vivo angiogenesis response by placing Matrigel plugs without 
and with supplements (LY-2157299 and/or VEGF and bFGF) under the skin of mice. Because VEGF 
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alone did not induce angiogenesis in the in vivo Matrigel-plug assay (data not shown), we used 
a combination of VEGF and bFGF. Vascularization was assayed by CD31 staining of sections from 
the recovered plugs (Fig. 7B,C). Matrigel plugs without any stimulus showed no vascularization. 
Addition of LY- 2157299 or VEGF+bFGF combination significantly induced angiogenesis (Fig. 7 A,B).
Fig. 6. Integrin α5 and β3 mediate the synergistic effects of SB and VEGF induced angiogenesis. (A) Downregulation 
of integrin α5 and β3 inhibits VEGF/SB-431542- induced EC sprouting. HUVECs transiently transfected with control, 
integrin α5 (ITGα5) or β3 (ITGβ3) siRNA were allowed to form spheroids. Spheroids were embedded in collagen and 
stimulated with VEGF (1 ng/ml) and SB-431542 (0.2 μM), VEGF (50 ng/ml) or bFGF (100 ng/ml) for 24hr. Quantitative 
analysis of the mean total sprout length per experimental group is shown. (B) HUVECs were transiently transfected with 
control or ITGα5 siRNA were plated to form spheroids. Spheroids were embedded in collagen and stimulated with VEGF 
(1 ng/ml), SB-431542 (0.2 μM) or their combination for 24hr. Quantitative analysis of the mean total sprout length per 
experimental group is shown. (C) Functional blocking of integrin α5 suppresses VEGF/SB-431542-induced angiogenesis. 
Spheroids were embedded in collagen and stimulated with VEGF (1 ng/ml), SB-431542 (0.2 μM), VEGF (1 ng/ml) and 
SB-431542 (0.2 μM), VEGF/SB-431542 or VEGF/SB-431542 and integrin α5 neutralizing antibody (10 μg/ml).  
Quantitative analysis of the mean total sprout length per experimental group is shown. (D) Functional blocking of α5 
integrin does not affect VEGF (high dose)-inducedangiogenesis. Spheroids were embedded in collagen and stimulated 
with VEGF (50 ng/ml) with or without integrin α5 neutralizing antibody (10 μg/ml). Quantitative analysis of the mean 
total sprout length was performed on at least 10 spheroids per experimental group using the Olympus Analysis software.
VEGF and inhibitors of TGF-β type-I receptor kinase synergistically promote blood-vessel formation by inducing α5-integrin expression
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Addition of LY-2157299 with VEGF+bFGF (VEGF+bFGF+LY) further significantly enhanced the blood-
vessel formation (Fig. 7A). To corroborate the role of α5 integrin in VEGF+bFGF+LY synergistic 
effect on in vivo angiogenesis we examined the effect of the α5 integrin neutralizing antibody in 
the Matrigel plug assay. Whereas addition of α5 integrin neutralizing antibody but not a control 
antibody inhibited VEGF+bFGF+LY-induced angiogenesis, it had no significant effect on VEGF+bFGF-
induced angiogenesis. These results illustrate that inhibition of TGFβ-ALK5 signalling in vivo can 
potentiate the pro-angiogenic effect of VEGF and bFGF, which is critically dependent on the 
induction of α5 integrin signalling.
Fig. 7. LY-2157299 induces angiogenesis in vivo in a Matrigel-plug assay and promotes VEGF+bFGF-induced 
angiogenesis. Matrigel plugs combined with either PBS (control), VEGF (300 ng/ml) and bFGF (700 ng/ml), and/or 
LY-2157299 (LY; 0.1 μM), in the presence or absence of α5-integrin-neutralizing antibody (20 μg/ml) or Fc control protein 
(20 μg/ml), were subcutaneously injected into mice. LY-2157299 induces angiogenesis and enhances VEGF+bFGF-induced 
angiogenesis. The synergistic effect of LY+VEGF+bFGF on angiogenesis is inhibited by an anti-α5-integrin antibody but 
not by Fc. (B) Histological analysis of CD31-stained sections recovered from Matrigel plugs with different stimuli. (C) 
Quantification of the vascular density by CD31 immunostaining as a percentage of the lesional area. *P≤0.05; **P≤0.01.
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Discussion
Here we show that inhibition of TGFβ type-I receptor (ALK5) and VEGF synergistically promotes 
angiogenesis. Treatment with the ALK5 inhibitors SB-43152 or LY-2157299 strongly enhanced VEGF-
induced EC capillary formation and EC sprouting. Similar results were obtained using a TGFβ-neutralizing 
antibody (30), indicating that inhibition of TGFβ, and not of Activin- Nodal signalling, is likely to cooperate 
with VEGF in inducing angiogenesis. Addition of the VEGFR2-kinase inhibitor PTK787 (29) blocked not 
only the VEGF- but also the SB- 431542-induced EC sprouting, suggesting that inhibition of TGFβ signalling 
potentiates autocrine VEGF signalling in ECs. Importantly, the TGFβ receptor kinase inhibitor promoted 
basal and VEGF+bFGF-induced angiogenesis in vivo in a Matrigel-plug assay. Conversely, ectopic 
expression of caALK5 potently inhibited all VEGF-induced pro-angiogenic responses of ECs. 
Recently it was reported that inhibition of TGFβ antagonized the pro-angiogenic response on 
human normal dermal microvascular ECs (MVECs) in vitro (31). There are several explanations for 
the discrepancy with our results. First, the pro-angiogenic effects of TGFβ were inhibited using 
TGFβ antagonistic peptides derived from the TGFβ type III receptor sequence. By contrast, we used 
pharmacological inhibitors of the TGFβ and/or Activin receptors and a pan TGFβ-neutralizing antibody 
in combination with VEGF. TGFβ type III receptor facilitates TGFβ signalling by enhancing the binding of 
ligand to TβRII (32). It was recently shown that the TGFβ type III receptor can bind multiple members 
of the BMP subfamily, including BMP2, BMP4 and BMP7, and thereby potentiate BMP signalling. 
BMP2, BMP4 and BMP7 have been shown to induce angiogenesis (33; 25; 34; 35; 36). Consequently, 
it is possible that the peptide antagonists used by Serrati and co-workers inhibit endogenous BMP 
signalling (30). Second, ECs of different origin were used. Seratti used MVECs, whereas we used 
HUVECs. These ECs might respond differently to TGFβ signalling owing to, e.g. expression of different 
receptors or different levels of TGFβ production. We show that treatment of HUVEC spheroids with 
the TGFβ-receptor-kinase inhibitor (or TGFβ neutralizing antibody) resulted in decreased basal Smad2 
phosphorylation and increased sprouting, suggesting that endogenous TGFβ signalling or TGFβ present 
in media supplements or produced by the cells inhibits VEGF signalling in HUVECs.
Transcriptional profiling revealed that the VEGF+SB-431542 stimulation of HUVECs 
synergistically regulates a number of genes involved in angiogenesis. Our results showed that 
VEGF+SB- 431542 stimulation of ECs resulted in a dramatic decrease in the expression of pro-
apoptotic genes and an increase in that of anti-apoptotic genes. TGFβ was shown to induce 
apoptosis of ECs via autocrine and/or paracrine stimulation of VEGF expression and signalling by 
VEGFR2 via downstream activation of p38 (37). We observed no effects of SB-431542 on VEGF- 
induced ERK and p38 phosphorylation (data not shown). Thus, on the basis of our results, we 
suggest that stimulation of ECs with VEGF and SB-431542 protects ECs from apoptosis and enhances 
their survival and proliferation. This might explain the dramatic induction of EC-sheet formation 
we observed upon VEGF+SB- 431542 challenge in the ex vivo metatarsal assay.
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α5 integrin, a cell-surface receptor for fibronectin, is one of the genes that is synergistically 
upregulated by VEGF+SB-431542 co-stimulation. We confirm the importance of this upregulation 
in VEGF+SB-431542-induced EC sprouting because genetic ablation and function neutralizing 
antibodies of α5 integrin inhibit VEGF+SB-431542-induced EC sprouting in vitro and in vivo. 
Our results underline the important role of α5 integrin demonstrated before in blood vessel 
development; α5 integrin null embryos exhibit abnormal blood vessel formation and a lower 
complexity vascular network (38). Furthermore, α5β1 integrin function blocking antibody was 
shown to inhibit HUVEC tube formation in vitro (39), and to inhibit tumor neovascularization and 
growth in animal models (40).
VEGF and TGFβ signalling play a central role in tumor angiogenesis and thus in tumor 
development and metastasis. Several therapeutic strategies targeting TGFβ signalling have been 
shown to prevent the growth and metastasis of certain cancers (41). Interestingly, a recent study 
using low doses of the TβRI kinase inhibitor (LY364947) in experimental tumors decreased VSMC 
coverage of the tumor endothelium and promoted the accumulation of anticancer drugs in the 
tumor tissue (42). Our results suggest that inhibition of TGFβ signalling renders the ECs more 
sensitive to VEGF-induced sprouting in vitro and in vivo. Therefore, anti-TGFβ-based therapeutic 
strategies must be carefully considered before administration of TGFβ antagonists because there 
might be adverse effects, including the induction of tumor angiogenesis. A better treatment 
modality, as suggested by this study, is combining VEGF and TGFβ pathway inhibitors to inhibit 
tumor cell metastasis and angiogenesis.
In conclusion, we investigated the effect of TGFβ type I receptor inhibitor(s) or TGF-β 
neutralizing antibody on VEGF-induced EC sprouting. Our results suggest that combining VEGF 
and inhibition of TGFβ-ALK5 signalling synergistically promotes angiogenesis in vitro and in 
vivo by inducing a cascade of expression of genes that play important roles in EC survival and in 
angiogenesis. Functional studies revealed that the induction and function of α5 integrin is a key 
determinant in VEGF+SB-431542-induced angiogenesis.
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Materials and Methods
Recombinant proteins, inhibitors and antibodies
The VEGF165 isoform was purchased from R&D Systems and bFGF from Peprotech. SB-431542 
was purchased from Tocris Biotrend, LY-2157299 from Calbiochem and PTK787 from Novartis. 
α5-integrin neutralizing antibody was purchased from BD Biosciences, the TGFβ-neutralizing 
antibody and isotype control obtained from Genzyme, and the Fc domain of IgG1 (MOPC-21) from 
Bio Express, West Lebanon, NH. 
Ex vivo metatarsal angiogenic assay
All animal experiments were approved by the local animal ethics committee. Metatarsals from 
17-day-old mouse fetuses were dissected as described earlier (26). Six bones per experimental 
group were transferred to 24-well tissue culture plates containing α-MEM (Gibco), 10% FBS and 
penicillin/streptomycin (PS), and allowed to adhere for 4 days. Then, medium was replaced by fresh 
medium containing the stimuli. Cultures were fixed 7 days after stimulation and vessel formation 
was visualized by anti-CD31 staining (Deckers 25, 2001). 
Cell culture
HUVECs cells were cultured in Medium 199 with Earle’s salt and L-glutamine (Gibco), 10% FCS, 
heparin (LEO pharma), bovine pituitary extract (Gibco) and PS on plates coated with 1% gelatin, 
at 37°C, 5% CO2. HUVECs were used up to passage 4. Experiments were confirmed with HUVECs 
from different donors. MEECs were cultured in DMEM (Gibco) supplemented with 10% FCS and PS 
on 0.1% gelatin- coated plates, at 37°C, 5% CO2. 
3D-culture spheroid assay
HUVECs (400 cells per spheroid) were suspended in Medium M199 containing Earle’s salt and 
L-glutamine, 10% FBS, heparin, bovine pituitary extract, PS and seeded in non-adherent round-
bottom 96-well plates. After 24 hours, spheroids were embedded into collagen and stimulated 
with corresponding stimuli in the presence or absence of inhibitors or neutralizing antibodies for 
another 24 hours. EC sprouts were measured by Olympus Analysis software. 
Migration scratch assay
HUVECs were seeded in six-well plates coated with 1% gelatin and allowed to grow to 
confluence. After serum starvation, monolayers were wounded with three scratches and medium 
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was replaced by fresh medium containing stimuli. Cell migration was measured in five areas per 
well directly after wounding and 6 hours later by automated image analysis using ImageJ software. 
Matrigel plugs
Male 7- to 8-week-old C57BL/6 mice (Charles River Laboratories, Sulzfeld, Germany) were injected 
subcutaneously near their abdominal midline with 0.4 ml of Matrigel basement membrane, high 
concentration (BD Biosciences, San Jose, CA) combined with either PBS, VEGF (300 ng/ml) and bFGF 
(700 ng/ml), and/or LY- 2157299 (0.1 μM), in the presence or absence of α5-integrin-neutralizing 
antibody (20 μg/ml) or Fc control protein (20 μg/ml). Groups of four plugs were injected for each 
treatment and the experiment was repeated twice. Seven days later Matrigel plugs were removed, 
fixed in formalin and embedded in paraffin. Sections were subjected to histological analysis with eosin. 
Sections were deparaffinized. Quenching of endogenous peroxidase activity was done using 0.3% 
H2O2 in methanol for 20 minutes at room temperature (RT), followed by antigen retrieval using citrate 
buffer and blocking with 1% BSA in PBS for 1 hour at RT. The primary antibody against CD31 (1:1000, 
Santa Cruz Biotechnologies, Santa Cruz, CA) was incubated in 1% BSA in PBS overnight at RT. Biotin-
conjugated secondary antibodies were applied followed by amplification using the strep-AB-complex/
HRP (DAKO, Hamburg, Germany). Finally, diaminobenzidine substrate (Sigma) was added to visualize 
peroxidase activity. The area covered by CD31-positive staining was quantified with image analysis. 
Cell transfection and RNA interference
Cells were seeded in six-well plates and the following day were transiently transfected with 
control siRNA or siRNA against α5 integrin and β3 integrin, purchased from Dharmacon, according 
to the manufacturer’s instructions. One day after transfection, cells were trypsinized and seeded 
for spheroid formation or used for RNA isolation. 
RNA isolation and EC PCR array
Total DNA-free cellular RNA was extracted with RNeasy kit (Macherery-Nagel) according to the 
manufacturer’s instruction. RNA from HUVECs grown in monolayers that were either non-treated or 
treated with VEGF, SB-431542 or VEGF+SB-431542 for 24 hours was isolated from three independent 
biological experiments and separately analyzed on the array. A commercial EC PCR-array (purchased 
from Superarray) was used to investigate gene expression profiling of selected angiogenesis- related 
genes involved in EC function (http://www.sabiosciences.com/rt_pcr) product/HTML/PAHS-015A.html). 
The experiment was performed in triplicate. The manufacturer’s instructions were strictly followed 
(http://www.sabiosciences.com/). Gene expression levels were determined by using data analyzer 
template provided by Superarray (http://www.sabiosciences.com/pcrarraydataanalysis.php), using 
GAPDH, β-actin and ribosomal protein L13a as reference. The non-stimulated condition was set to 1.
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Adenoviral infection
HUVECs or MEECs growing in 70-80% confluent monolayers were infected with an adenovirus 
expressing either caALK5 or lacZ with an MOI of 500. At 48 hours after infection, cells were 
trypsinized and re-seeded to be used in different assays.
EC cord formation
Matrigel Basement Membrane Matrix Growth Factor Reduced (Becton Dickinson) was added 
at 50 μl to each well of a 96-well plate and allowed to polymerize for 1 hour at 37°C. Cells were 
removed from culture by trypsinization and resuspended at 30,000 cells/ml. 100 µl cell suspension 
were plated in each well in triplicates and plates incubated for 48 hours. Pictures were acquired 
with a phase-contrast microscope in four different fields. The length of branches was quantified 
using automated image analysis using the Olympus Analysis software.
Transwell migration and invasion assays
Transwell migration was performed in 24-well plates with filter inserts of a pore size of 0.8 
µm (Costar). For the Transwell invasion assay, filters were coated with Matrigel. 30,000 cells were 
seeded in the upper chamber. Experiments were done in triplicates. Cells were fixed after 20 hours 
with 4% paraformaldehyde and stained with 0.1% crystal violet. Pictures of the filters were acquired 
with phase-contrast microscopy at 10x magnification. Three fixed positions were imaged of each 
membrane and the number of cells was counted.
RNA isolation and quantitative PCR analysis
RNA from HUVECs growing in monolayers or EC spheroids embedded in collagen [non-treated, 
or VEGF- (1 ng/ml), SB-431542- (0.2 μM) or VEGF+SB-431542-treated for 24 hours) was isolated 
from three independent biological experiments with RNeasy kit (Macherery-Nagel) and subjected 
to cDNA synthesis with RevertAid H Minus first strand cDNA synthesis kit (Fermentas) according to 
the manufacturer’s instruction. Expression of α5 integrin (ITGα5) and house-keeping gene acidic 
ribosomal phosphoprotein (ARP) were analyzed using the following primers: 
ITGα5 forward: 5-ATACTCTGTGGCTGTTGGTGAATTC-3; 
ITGα5 reverse: 5-ATTAAGGATGGTGACATAGCCGTAA-3; 
ARP forward: 5-CACCATTGAAATCCTGAGTGATGT-3; 
ARP reverse: 5-TGACCAGCCGAAAGGAGAAG-3. 
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Taqman PCR reactions were performed using the ABI prism HT7900 sequence-detection 
system (Applied Biosystem). All samples were plated in duplicates. Gene expression levels were 
determined with the comparative ΔCt method using ARP as reference and the non-stimulated 
condition was set to 1.
Cyclohexamide experiments
HUVECs growing in monolayers were either untreated or pretreated with 5 µg/ml 
cyclohexamide for 1 hour, and subsequently unstimulated or treated with 1 ng/ml VEGF, 0.2 µM 
SB-431542 or a combination of both VEGF and SB-431542 for 24 hours. RNA was isolated and 
subjected to cDNA synthesis followed by quantitative real-time PCR analysis. 
Statistical analysis
All results are expressed as the mean ± s.d. Statistical differences were examined by two-tailed 
Student’s t-test and P≤0.05 was considered to be statistically significant (in the figures, *P≤0.05 
and **P≤0.01). 
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Supplementary Information
Supplemental Fig. 1 Overexpression of constitutively active (ca)ALK5 inhibits EC sprouting and cord formation. (A) 
HUVECs infected with adenoviruses expressing caALK5 or lacZ were plated to form spheroids and embedded in collagen 
were stimulated with VEGF (50 ng/ml) for 24 hours. One representative picture of each group is shown. Quantitative 
analysis of the mean total sprout length was performed on at least ten spheroids per experimental group. (B) MEECs 
infected with adenoviruses expressing caALK5 or lacZ were plated on Matrigel-coated plates for cord formation for 
48 hours. One representative picture of each group is shown. Quantitative analysis of the mean total cord length per 
experimental group is shown.
Supplemental Fig. 2 Overexpression of caALK5 inhibits EC Transwell migration and invasion. MEECs infected with 
adenoviruses expressing caALK5 or lacZwere plated on the upper chamber of 24-well plates with filter inserts. (A) Cells 
were fixed after 20 hours with 4% paraformaldehyde, stained with 0.1% crystal violet and the number of migrating cells 
was counted in three different fields. (B) For the Transwell invasion assay filters were coated with Matrigel. After 20 
hours, cells were fixed, stained and the number of invaded cells was counted in three different fields 
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Supplemental Fig 3 SB-431542 and VEGF synergistically induce expression of integrin α5 in 2D and 3D EC cultures. 
HUVECs growing in monolayers (A) or in EC spheroids treated (B) with VEGF (1 ng/ml), SB-431542 (0.2 µM) or their 
combination for 24 hours. Extracted mRNA was reverse transcribed and used in a quantitative PCR array to determine 
relative integrin α5 mRNA expression patterns. The mRNA levels of integrin α5 in each sample was first normalized to 
the expression of ARP in that sample and then normalized to the expression of that gene in untreated HUVECs.
Supplemental Fig 4 VEGF+SB-431542-induced α5-integrin expression depends on new protein synthesis. HUVECs 
growing in monolayers were pretreated with 5 µg/ml cyclohexamide (CHX), followed by VEGF (1 ng/ml), SB-431542 (0.2 
µM) stimulation or their combination for 24 hours. Extracted mRNA was reverse transcribed and used in a quantitative 
PCR array to determine relative α5-integrin mRNA expression patterns.
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Abstract
Genetic studies in mice and humans have shown that the transforming growth factor-β (TGF- β) 
type-I receptor activin receptor like kinase 1 (ALK1) and its co-receptor endoglin play an important 
role in vascular development and angiogenesis. Here, we demonstrate that ALK1 is a signalling 
receptor for bone morphogenetic protein-9 (BMP-9) in endothelial cells (ECs). BMP-9 bound 
with high affinity to ALK1 and endoglin, and weakly to the type-I receptor ALK2 and to the BMP 
type II receptor (BMPRII) and activin type II receptor (ActRII) in transfected COS cells. Binding of 
BMP-9 to ALK2 was greatly facilitated when BMPRII or ActRII were co-expressed. Whereas BMP-9 
predominantly bound to ALK1 and BMPRII in ECs, it bounds to ALK2 and BMPRII in myoblasts. In 
addition, we observed binding of BMP-9 to ALK1 and endoglin in glioblastoma cells. BMP-9 activated 
Smad1 and/or Smad5, and induced ID1 protein and endoglin mRNA expression in ECs. Furthermore, 
BMP-9 was found to inhibit basic fibroblast growth factor (bFGF) stimulated proliferation and 
migration of bovine aortic ECs (BAECs) and to block vascular endothelial growth factor (VEGF)-
induced angiogenesis. Taken together, these results suggest that BMP-9 is a physiological ALK1 
ligand that plays an important role in the regulation of angiogenesis.
Keywords: ALK1, Angiogenesis, bFGF, BMP, Endoglin, Signalling, Smad, VEGF 
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Introduction
Bone morphogenetic proteins (BMPs) belong to the TGF-β_superfamily and were originally 
identified for their ability to induce ectopic bone growth and cartilage formation (1, 2). Since 
then, substantial knowledge has been obtained about the multiple functions of these growth 
factors. BMPs regulate cell growth, differentiation andapoptosis of various cell types, and they 
are critically involved in the morphogenesis and differentiation of tissues and organs. In addition, 
they play an important role in adult tissue homeostasis (3, 4). BMP-9 is a secreted protein (5) 
that is expressed in the liver (6, 7). It has been associated with the regulation of genes involved 
in glucose and fatty acid metabolism (6), and it induces expression of hepcidin, which plays a key 
role in iron homeostasis (8). BMP-9 stimulates proliferation of non-endothelial cells (non-ECs) 
such as liver tumour cells, pre-adipocytes or myoblasts (6, 7). In addition, BMP-9 induces ectopic 
bone growth and hypertrophic chondrocyte formation and supports the differentiation of 
mesenchymal cells into cartilage (9). BMP-9 is also expressed in the septum and spinal cord of 
mouse embryos, and it is a differentiation factor for cholinergic neurons of the central nervous 
system (10).
In a recent study, BMP-9 was shown to bind with high affinity to the immobilised extracellular 
domain of activin receptor like kinase 1 (ACVL1, also known as, and hereafter referred to, as 
ALK1) in a BIAcore assay (5). The ALK1 receptor is mainly expressed in ECs (11), regulating EC 
proliferation and migration in vitro (12), and angiogenesis in vivo (13, 14). ALK1-deficient 
mice display impaired vessel remodelling, dilated blood vessels and defective recruitment of 
smooth muscle cells (13, 14). In vitro studies have shown that the co-receptor endoglin (ENG) 
is able to form complexes with ALK1 and to promote the effects of ALK1 on ECs (15, 12, 16). 
The phenotype of endoglin deficient mice is highly reminiscent of ALK1-deficient mice, thereby 
suggesting that endoglin also plays a role in ALK1 signalling in angiogenesis (17). Further evidence 
for the importance of ALK1 and endoglin in vessel formation and maintenance is derived from 
the vascular disorder hereditary haemorrhagic telangiectasia (HHT or Osler-Weber-Rendu 
disease). HHT is an autosomal-dominant vascular dysplasia that is characterised by recurrent 
epistaxis, telangiectases in mucosa and skin, gastrointestinal haemorrhage and arteriovenous 
malformations in brain, lung and liver. Mutations in the genes encoding ALK1 (responsible for 
HHT2) or endoglin (responsible for HHT1) have been identified to be the cause for the observed 
phenotype in most of the cases (18,19).
So far, TGF-β1 is the only described functional ALK1 ligand (20, 12, 13). Yet, ALK1 alone is 
not sufficient to transduce the TGF-β signal across the plasma membrane. TGF-β and also BMP 
signalling require a specific heteromeric complex of type I and type II serine/threonine kinase 
receptors (21, 22). Whereas TGF-β1 first binds to the type II receptor and subsequently recruits 
the type-I receptor, this order is reversed for some members of the BMP family (23, 24). Ligand-
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induced receptor complex formation results in phosphorylation of the type-I receptor by the 
type II receptor kinase and in subsequent phosphorylation of downstream receptor-regulated 
Smads (R-Smads, i.e. Smad1, Smad2, Smad3, Smad5 and Smad8). Activated R-Smads then form 
heteromeric complexes with the common mediator (Co)-Smad4, which then translocate into the 
nucleus where they regulate specific gene transcriptional responses (21 - 23). In mammals, three 
BMP type II receptors (BMPRII, ActRIIA, ActRIIB) and three BMP type I receptors (ALK2, ALK3, 
ALK6) have been identified. Activation of BMP receptors leads to phosphorylation of Smad1, 
Smad5 and Smad8. In most cell types, TGF-β signals via the broadly expressed receptor type I 
receptor ALK5 thereby inducing phosphorylation of Smad2 and/or Smad3. The type I receptor 
ALK1 transduces TGF- β signals in ECs, which then leads to activation of Smad1, Smad5 and Smad8 
(12, 13, 20).
The reported interaction of BMP-9 with ALK1 tempted us to investigate whether ALK1 is 
also a receptor for BMP-9 in ECs and how BMP-9 signalling influences EC function. Our results 
demonstrate that BMP-9 binds with high affinity to ALK1 and endoglin in ECs. In non-ECs, BMP-9 
strongly bound to ALK2, thereby providing an explanation for the potent effects of BMP-9 in 
these cell types. BMP-9 was found to induce phosphorylation of Smad1 and/or Smad5 and 
to stimulate the expression of ALK1 target genes. Moreover, BMP-9 stimulated activation of 
a Smad1- and/or Smad5-responsive transcriptional reporter, which was blocked using small 
interference RNA (siRNA) targeting ALK1. The importance of BMP-9 signalling in ECs was shown 
by the inhibiting effect of BMP-9 on basic fibroblast growth factor (bFGF)-induced EC proliferation 
and by the abrogation of vascular endothelial growth factor (VEGF)-induced angiogenesis. Taken 
together these results show that BMP-9 signals via ALK1 and functions as a potent regulator of 
angiogenesis. 
Results
BMP-9 binds with high affinity to ALK1 and endoglin in transfected COS-7 cells
To study BMP-9 receptor binding, we transfected COS-7 cells with cDNAs for ALK1 or 
ALK2 in combination with the type II receptors BMPRII or ActRIIB that have been shown to 
bind ALK1 in the cell-free BIAcore assay (5). Transfected cells were first affinity-labelled with 
[125I] BMP-9 and then ligand-receptor complexes were chemically crosslinked and subsequently 
immunoprecipitated with specific type I or type II antisera. Expression of ALK1, ALK2, BMPR-II 
and ActR-IIB after transfection was checked in parallel by western blotting (data not shown). 
Resolution of immunoprecipitated complexes by SDS-PAGE and detection of the radioactive 
signal on a phosphorimager screen showed that BMP-9 strongly binds to ALK1, but not to 
ALK2 when expressed without a type II receptor (Fig. 1A; lanes 1, 2). The two bands seen after 
BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis
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immunoprecipitation of ALK1 are probably caused by monomeric or dimeric BMP-9 crosslinked 
to the receptor. BMP-9 binding to the type II receptors BMPRII and ActRIIB alone was weak 
(Fig. 1A; lanes 3, 4). Binding of BMP-9 to ALK1 was slightly increased when ALK1 and BMPRII or 
ActRIIB were co-expressed (Fig. 1A; lanes 5, 6). By contrast, BMP-9 binding to ALK2 was greatly 
enhanced when the receptor was co-expressed with either BMPRII or ActRIIB (Fig. 1A; lanes 7, 
8). Thus, whereas BMP-9 can bind to ALK1 alone, it can only interact with ALK2 in combination 
with BMPRII or ActRII.
Fig. 1. BMP-9 binds to ALK1 and endoglin in the absence of type II receptors. COS-7 cells were transiently transfected 
with cDNAs for ALK1, ALK2, BMPRII, ActRIIB or endoglin and affinity-labelled with [125I]BMP-9. Crosslinked complexes 
were immunoprecipitated with specific antisera (marked with a circle) and subjected to SDS-PAGE and autoradiography. 
(A) [125I]BMP-9 binds with high affinity to ALK1, but not to ALK2 in the absence of type II receptors. BMP-9 binding to 
ALK2 is strongly enhanced when BMPRII or ActRIIB are co-expressed. (B) [125I]BMP-9 binds to endoglin in the absence of 
type I or type II receptors.
The accessory receptor endoglin has been described to form complexes with ALK1 and to 
promote ALK1 signalling (15, 16). To investigate whether BMP-9 binds to endoglin, we transiently 
transfected COS-7 cells with cDNAs encoding ALK1, ALK2, BMPRII or endoglin and incubated them 
with [125I]BMP-9. Fig. 1B shows that BMP-9 binds endoglin and ALK1 in the absence of type I or 
type II receptors.
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BMP-9 binds to ALK1, ALK2, BMPRII, ActRII and endoglin in ECs
We then analysed the ability of BMP-9 to bind to endogenous endoglin, type I and type II 
receptors in primary ECs. Bovine aortic ECs (BAECs), human umbilical vein ECs (HUVECs) and 
human dermal microvascular ECs (HDMVECs) were incubated with [125I]BMP-9, and crosslinked 
receptor-ligand complexes were immunoprecipitated with antisera against endoglin, type II 
receptors and type-I receptors known to be involved in BMP signalling. BMP-9 strongly bound 
to ALK1 in all EC types investigated and it weakly bound to ALK2 in BAECs and HDMVECs (Fig. 2A, B 
and data not shown). In addition, in all EC types, BMP-9 bound to BMPR-II, ActR-IIA and endoglin. 
In HUVECs, BMP-9 was also found to bind ActRIIB. The observed co-immunoprecipitation of type 
I with type-II receptors (and vice versa) and of type I and type II receptors with endoglin (and 
vice versa) indicates that these receptors form heteromeric complexes with each other on the 
cell surface.
To verify that BMP-9 binding to ALK1 is specific, we competed [125I]BMP-9 binding to ALK1 in 
HUVECs with excess of unlabelled ‘cold’ BMP-9, activin, BMP-7 or TGF-β and immunoprecipitated 
receptor-ligand complexes with ALK1 antiserum (Fig. 2C). Only excess of cold BMP-9 competed with 
[125I]BMP-9-receptor binding, demonstrating the specificity of the BMP-9-receptor interactions. 
Moreover, incubation of BAECs with [125I]BMP-6 showed that BMP-6 does not bind to ALK1, but 
only to ALK2 and BMPRII (data not shown).
BMP-9 can bind ALK1 and ALK2 in non-ECs
We subsequently investigated BMP-9 binding to non-ECs. In C2C12 myoblasts, BMP-9 was 
found to bind to ALK2 and the type II receptors BMPRII and ActRIIA, but not to ALK1 (Fig. 3A). 
In XTH-1 breast cancer cells, BMP-9 bound to ALK2 and also to endoglin (Fig. 3B). By contrast, 
BMP-9 strongly bound to ALK1 and endoglin, and only weakly to ALK2 in T98G glioblastoma 
cells (Fig. 3C). These results suggest that BMP-9 signalling in non-ECs occurs via ALK1 and/or 
ALK2 and, thus, provides an explanation for the potent effects of BMP-9 on non-ECs described 
in the literature.
BMP-9 induces phosphorylation of Smad1 and/or Smad5, and stimulates 
expression of ID1 protein and endoglin mRNA in ECs
We then went on to investigate whether Smad1 and Smad5, which are downstream in the 
ALK1 signalling pathway, are activated by BMP-9. BAECs, HUVECs, and HDMVECs were stimulated 
for 45 minutes with different doses of BMP-9, lysed and subjected to SDS-PAGE and subsequent 
western blotting. 
BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis
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Fig. 2. BMP-9 binds to endogenous receptors in endothelial cells. (A,B) BAEC (A) or HUVECs (B) were affinity-labelled with 
[125I]BMP-9 and crosslinked ligand-receptor complexes were immunoprecipitated with specific antisera as indicated. 
BMP-9 predominantly binds to ALK1 and BMPR-II, but also to ALK2, ActR-IIA, ActR-IIB and endoglin. (C) Competition of 
[125I]BMP-9 binding to ALK1 in HUVECs with either excess unlabelled (cold) BMP-9, activin, BMP-7 or TGF-β. Only cold 
BMP-9 can compete with [125I]BMP-9 binding to ALK1.
Probing of membranes with an antibody that detects phosphorylated Smad1 and Smad5 
demonstrated that BMP-9 dose-dependently induces phosphorylation of Smad1 and Smad5 
in all cell types investigated (Fig. 4A-C). BMP-6, which is known to activate Smad1 and Smad5, 
was used as positive control. Equal loading was demonstrated by probing membranes with an 
anti-β-actin antibody. We also stimulated cells with BMP-6 and BMP-9, and analysed the expression 
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of ID1, described to be a direct target gene of Smad1 and/or Smad5 signalling (25). In HUVECs 
and HDMVECs, ID1 protein levels increased at the lowest BMP-9 concentration tested (Fig. 4B,C). 
In BAECs, upregulation of ID1 protein levels was seen at a concentration of 1 ng/ml BMP-9 (Fig. 4A).
Fig. 3. BMP-9 binds to endogenous receptors in non-endothelial cells. (A-C) Autoradiography of crosslinked complexes 
of [125I]BMP-9 with cell surface receptors in C2C12 myoblasts (A), XTH-1 breast cancer cells (B), and T98G glioblastoma 
cells (C). Ligand-receptor complexes were immunoprecipitated with specific antisera as indicated in the figure and 
subjected to SDS-PAGE. BMP-9 binds to ALK2 in all cell lines, to ALK1 in glioblastoma cells and to endoglin in breast 
cancer and glioblastoma cells.
Endoglin has been shown to be induced by TGF-β (26) and by overexpression of constitutively 
active ALK1 (27, 28). Using quantitative PCR, we found that, similar to TGF-β, BMP-9 induces 
endoglin mRNA expression in BAECs (Fig. 4D). This suggests that BMP-9 regulates its own signalling 
pathway by inducing the expression of its co-receptor endoglin.
BMP-9 activates the Smad1- and Smad5-responsive BRE reporter via ALK1
The ID1-promoter-derived BMP reporter element (BRE)-luciferase reporter construct is a 
readout system transcriptional responses induced by Smad1 and/or Smad5. BAECs were transiently 
transfected with the BRE reporter and stimulated with TGF-β, BMP-6 or BMP-9 overnight. BMP-9 
and BMP-6 but not TGF-β induced BRE activation (Fig. 5A). We then investigated whether addition 
of the Fc-ccoupled extracellular domain of ALK1 inhibits BMP-9-induced BRE activation. Incubation 
of BAECs with ALK1-Fc efficiently blocked BMP-9-induced BRE activity (Fig. 5B). 
BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis
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Fig. 4. BMP-9 activates Smad1 and Smad5, and upregulates ID1 and endoglin in endothelial cells. (A-C) BAECs (A), 
HUVECs (B) or HDMVECs (C) were incubated with increasing doses of BMP-9 and BMP-6 as indicated in the figure. After 
45 minutes, cells were lysed and samples subjected to SDS-PAGE and subsequent western blotting. Membranes were 
either probed with an antibody that specifically recognises phosphorylated Smad1 and Smad5 or with an antibody 
directed against ID1. An anti-β-actin antibody was used to confirm equal loading. (D) Effect of BMP-9 and TGF-β on 
endoglin mRNA expression in BAECs as measured by quantitative real-time PCR.
To analyse whether BMP-9-mediated BRE activation occurs via ALK1 or ALK2, we designed short 
hairpin RNA (shRNA) expression constructs targeting ALK1 or ALK2. Transient transfection with 
ALK1 shRNA but not ALK2 shRNA inhibited BMP-9-induced reporter activity (Fig. 5C). By contrast, 
BMP-6-stimulated reporter activation was only affected by downregulation of ALK2 but not of ALK1 
(Fig. 5D). To control the specificity of the shRNA constructs, we cotransfected BAECs with the ALK1 
shRNA construct and with expression vectors for human ALK1 or ALK2. Inhibition of BMP-9-induced 
BRE activity by ALK1 shRNA was rescued by the ectopic expression of ALK1 but not of ALK2 (Fig. 
5E). These experiments show that BMP-9 specifically activates the Smad1- and Smad5-responsive 
BRE reporter via ALK1 inBAECs.
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Fig. 5. BMP-9 activates the Smad1- and Smad5-responsive BRE luciferase reporter through ALK1. (A-B) BAECs 
were transiently transfected with an ID1-promoter-derived luciferase reporter construct (BRE) and a construct for 
β-galactosidase as internal expression control. Before stimulation, cells were serum-starved for 8 hours and then 
incubated with the respective ligands overnight. (A) BRE activity is induced by BMP-9 (100 ng/ml) and BMP-6 (100 ng/ml) 
but not by TGF-β (5 ng/ml). (B) BMP-9 (5 ng/ml) stimulated BRE-induction can be inhibited by a 15-fold molar excess of 
ALK1-Fc. (C,D) shRNA constructs against ALK1 or ALK2 were cloned into the pSuper vector and co-transfected into BAECs. 
ALK1 shRNA blocks BMP-9 stimulated (5 ng/ml) (C), but not BMP-6-induced (25 ng/ml) BRE activation (D). (E) ALK1 
shRNA-mediated reduction of BRE activity is rescued by overexpression of human ALK1, but not by human ALK2. *P<0.01 
compared with BMP-9 stimulated control; #P<0.01 compared with ALK1 RNAi after BMP-9 stimulation.
BMP-9 inhibits migration and proliferation of ECs
We next investigated the effect of BMP-9 on EC function. To study the effect of BMP-9 on 
migration, serum-starved monolayers of BAECs were wounded by scratching and stimulated with 
the ligands for 24 hours. BMP-9 weakly, albeit significantly, inhibited EC migration at a dose of 10 
ng/ml (Fig. 6A; P<0.01). 
BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis
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Fig. 6. BMP-9 attenuates migration and inhibits proliferation of ECs. (A) BAECs were allowed to grow to confluence and 
serum-starved overnight. Monolayers were wounded and stimulated with either 30 ng/ml bFGF or 10 ng/ml BMP-9. 
Wound closure was measured after 24 hours using the Olympus Analysis software. (B) Scratched BAEC monolayers were 
incubated with 10 ng/ml BMP-9 and different concentrations of bFGF as indicated in the figure and cell migration was 
measured after 24 hours. (C, D) 3000 BAECs were seeded in 96-well plates and stimulated with different concentrations 
of BMP-9, 30 ng/ml bFGF or combinations of bFGF and BMP-9. Cell proliferation was determined after 2 and 3 days 
by adding the MTS reagent and measuring the absorbance at 490 nm. B9, BMP-9. ##P<0.001 compared with bFGF 
treatment; #P<0.01 compared with control; **P< 0.005 and *P<0.05 compared with the respective bFGF treatment 
without BMP-9
We also studied the influence of BMP-9 on migration induced by bFGF and found that, in 
the presence of BMP-9, inhibition of bFGF-stimulated migration decreased with increasing 
concentrations (0-30 ng/ml) of bFGF (Fig. 6B). Furthermore, we analysed the effect of BMP-9 on 
cell growth and found that it potently inhibited bFGF-stimulated cell growth when applied at 10 
and 100 ng/ml (Fig. 6D). However, BMP-9 alone had no effect on proliferation of BAECs (Fig. 6C).
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BMP-9 inhibits vessel formation in vitro
Considering the data obtained from our functional studies and the established role for ALK1 in 
angiogenesis, we sought to elucidate the effect of BMP-9 on angiogenesis. Metatarsals of 17-day-
old mouse embryos were used to study the effect of BMP-9 on EC outgrowth and vessel formation. 
Culturing of explanted bones leads to formation of a feeder layer of fibroblast-like cells, on which 
a tubular network of ECs is formed (29). Staining of the EC network using an anti-CD31 antibody 
showed that BMP-9 inhibits baseline sprouting of ECs and completely abolishes VEGF- induced 
formation of tube-like structures (Fig. 7). Of note, BMP-9 increased the size of the bone ends, which 
may reflect the reported stimulatory effect of BMP-9 on chondrogenesis (9). These results show 
that BMP-9 is a powerful inhibitor of angiogenesis in vitro.
Fig. 7. BMP-9 blocks endothelial network formation. Metatarsals of 17-day-old mouse foetuses were prepared, 
transferred to cell culture plates and allowed to adhere for 4 days. Medium was refreshed and bones were stimulated for 
7 days with BMP-9 (100 ng/ml), VEGF (50 ng/ml) or both. Cultures were fixed and vessel-like structures were visualised 
by anti-CD31 staining. BMP-9 inhibits baseline formation of the endothelial network. Incubation with VEGF strongly 
stimulated the formation of vessel-like structures, which was completely abrogated by co-stimulation with BMP-9. Six 
bones were stimulated per experimental group and one representative picture of each group is shown.
Discussion
The functional consequences of Alk1 gene disruption in mice and loss-of-function mutations 
in humans have clearly demonstrated that ALK1 is crucial for angiogenesis. (13, 14, 18, 19,). The 
reminiscent phenotypes of TGF-β1-deficient and ALK1 deficient mice, together with the in vitro 
finding that TGF-β1 signals via ALK1, have suggested that TGF- β1 is the ALK1 ligand in vivo (30). In 
the present study, we demonstrate that BMP-9 is also a functional ligand of ALK1 in ECs. Moreover, 
BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis
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we show that BMP-9 inhibits bFGF-induced proliferation and VEGF- induced angiogenesis in vitro, 
suggesting that BMP-9 also plays a role in ALK1 signalling and vascular morphogenesis in vivo.
To study the binding pattern of BMP-9 in ECs, we performed crosslinking studies with 
125I-labelled BMP-9 and found that BMP-9 binds to the type I receptors ALK1 and ALK2, and to 
the type-II receptors BMPRII, ActRIIA and ActRIIB. Compared with ALK2 binding, BMP-9 binding to 
ALK1 was strong even in the absence of a type II receptor. This finding is consistent with a study, in 
which BMP-9 was shown to bind with high affinity to immobilised Fc-coupled ALK1 in the cell-free 
BIAcore assay (5). However, BMP- 9 binding to ALK2 was enhanced when co- expressed with either 
BMPRII or ActRIIB. The affinity of TGF-β superfamily members for the type I receptor is low or 
absent, but is strongly increased after heteromeric complex formation with the type II receptor. 
BMP-9 binding to ALK2 resembles the binding pattern of BMP-6 and BMP-7 that bind only efficiently 
when both ALK2 and ActRII are present (24, 31). The high affinity of BMP-9 for ALK1 resembles more 
the binding pattern of BMP-2 and BMP-4 (24, 31). BMP-2 and BMP-4 strongly bind to the type I 
receptors ALK3 and ALK6, respectively, and show only low affinity for their type II receptor BMPRII.
In primary ECs, we identified ALK1 and BMPRII as the predominant BMP-9 receptors. Moreover, 
BMP-9 also bound to endoglin even in the absence of type II and type I receptors. So far, BMP-2, 
BMP-7, activin A, TGF-β1 and TGF-β3 have been described to bind endoglin. However, these 
molecules can only bind endoglin in the presence of either type I or type II receptors (33, 34). 
Together with our finding that BMP-9 potently induces endoglin mRNA expression; these results 
suggest an important role for endoglin in BMP-9 signalling.
BMP-9 has been described to have strong effects on non-ECs (6, 9, 35). We identified the type-I 
receptor ALK2 and the type II receptor BMPR-II as predominant BMP-9 receptors in myoblasts. In 
addition, BMP-9 bound to ALK2 and endoglin in XTH-1 breast cancer cells and to ALK1 and endoglin 
in T98G glioblastoma cells. These results indicate that BMP-9 elicits its broad effects on non-ECs by 
signalling via ALK2 and/or ALK1. In a recent study, BMP-9 has been shown to signal via ALK1 and the 
type II receptors BMPRII and ActRIIA in HDMVECs (36). We further extend these findings by showing 
that BMP-9 binds to these receptors in other EC types as well, that BMP-9 also binds to endoglin, 
ALK2 and ActRII-B in ECs, and that ALK1 and ALK2 are both receptors for BMP-9 in non-ECs.
We then sought to elucidate whether BMP-9 activates the signalling pathway downstream 
of ALK1. BMP-9 strongly induced phosphorylation of Smad1 and/or Smad5, and activated the 
Smad1- and Smad5-responsive BRE luciferase reporter in ECs. BMP-9-induced BRE activation was 
inhibited by ALK1-Fc. However, we were unable to inhibit BMP-9- stimulated BRE activity with a 
500-fold higher concentration of the monomeric extracellular domain of ALK1 (data not shown). 
As proteins with Fc-fusion are artificially dimerised this suggests that ALK1 dimers are needed 
for high-affinity binding of BMP-9. Conclusive evidence for a role of ALK1 in BMP-9 signalling was 
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obtained by shRNA-mediated down-regulation of ALK1 or ALK2 in ECs. Decreased ALK1, but not 
ALK2 expression abrogated the BMP-9-induced BRE signal. By contrast, BMP-6 stimulated reporter 
activity was completely blocked by ALK2 shRNA but not by ALK1 shRNA, thereby proving the 
functionality of the shRNA constructs. Future studies will reveal whether ALK2 plays a role in BMP-9 
signalling in ECs. Consistent with the BMP-9- induced activation of the ID1-promoter-derived BRE-
luciferase reporter, we found an upregulation of ID1 protein after BMP-9 stimulation in all EC types 
investigated. ID1 is one of the most important BMP target genes and has also been characterised 
as ALK1 target gene (27, 28). BMP-9 was also found to activate a Smad3- and Smad4-responsive 
transcriptional reporter, which could be blocked by ALK1 shRNA (P.t.D., unpublished observation). 
We are currently analysing the significance of this finding.
We further investigated the effect of BMP-9 on EC function. BMP-9 inhibited EC migration and 
significantly delayed bFGF-induced migration. Moreover, BMP-9 was found to inhibit proliferation 
of ECs stimulated with bFGF. Importantly, BMP-9 completely abrogated VEGF-induced formation 
of tubular EC structures in a bone-explant angiogenesis assay. The mechanism by which BMP-9 
negatively interferes with bFGF- and/or VEGF-induced cellular responses remains to be elucidated. 
It is probable that BMP-9 exerts its anti-angiogenic activities by decreasing the expression of 
angiogenic factors and/or their receptors.
The observed negative effects of BMP-9 on angiogenesis are in contrast with other studies 
showing that several other BMP family members promote angiogenesis (37 - 41). BMP-9, however, is 
the first BMP family member described to signal through ALK1 and this may explain the discrepancy. 
As mentioned earlier, ALK1 and its accessory receptor endoglin are established as crucial regulators 
of angiogenesis in vivo. However, the question whether ALK1 plays a role in the activation or 
resolution phase of angiogenesis remains open. In vitro data show that expression of constitutive 
active ALK1 in ECs leads to positive as well as negative effects on EC migration and proliferation (21, 
41). The lack of vessel sprouting in ALK1- or endoglin-deficient mice suggests that these receptors 
play a role in the activation phase of angiogenesis. However, these mice also have dilated, unstable 
vessels that lack smooth muscle cell coverage, which would point to a role in the resolution phase 
of angiogenesis. An explanation for all these contradictory findings could be that ALK1 and endoglin 
are involved in both the activation and in the resolution phase, and that a fine balance of receptor 
levels, receptor types (TβRII or BMPRII) and ligands (TGF-β or BMP-9) determines the effect on 
angiogenesis in the respective vascular bed.
BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis
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Materials and Methods
Cell culture
BAECs were grown in low glucose Dulbecco’s modified Eagle’s medium (DMEM, Gibco) with 
10% foetal calf serum (FCS) and penicillin-streptomycin (PS). HUVECs were cultured in Medium 199 
with Earle’s salts and L-glutamine (Gibco), 10% FCS, heparin (LEO pharma), bovine pituitary extract 
(Gibco), and PS. HDMVECs were grown in EGM-2 MV (Clonetics). C2C12 mouse myoblast cells were 
grown in DMEM, 10% FCS, L-glutamine and PS. XTH-1 breast cancer cells (kind gift from Hartmut 
Beug, IMP, Vienna, Austria) were cultured in RPMI medium supplemented with 15% FCS, PS and 
2.5 ng/ml TGF-β. T98G glioblastoma cells (42) were grown in DMEM with 10% FCS. All cells were 
cultured at 5% CO2, apart from BAECs which were cultured at 10% CO2.
RNA isolation and quantitative real-time PCR
Total DNA-free cellular RNA was extracted with the RNeasy kit (Macherery-Nagel). The 
oligonucleotide primers for PCR were designed using the Primer Express Software (Applied 
Biosystems). Expression of bovine endoglin and bovine hypoxanthine phosphoribosyltransferase 
(HPRT) were analysed using the following primers: endoglin forward, 5’-tcctcaactgggcgaatacg-3’; 
endoglin reverse, 5’ gatgctttgcggcttgct-3’; HPRT forward, 5’-acgacagcactttgaggcatt-3’; HPRT 
reverse, 5’-agttaatactaccgaaacctactgaaacac-3’. Taqman PCR reactions were performed using the 
ABI prism HT7900 sequence-detection system (Applied Biosystems). All samples were plated in 
triplicate. Gene expression levels were determined with the comparative ΔCt method using HPRT 
as reference and the non-stimulated condition was set to 1.
Expression plasmids and shRNA constructs
Expression constructs for full-length human ALK1 and ALK2 have been cloned into the pcDNA3 
vector as described previously (43). Vectors expressing short hairpin RNA (shRNA) targeting ALK1 
and ALK2 were made by cloning bovine ALK1- and ALK2-derived constructs and complementary 
oligonucleotides into the pSuper vector (44). Experiments were performed with different shRNA 
constructs: 
 bovineALK1(5’-3’) construct1, 
gatccccGTGAGAGCGTAGCCGTCAAttcaagagaTTGACGGCTACGCTCTCACttttg gaaa;
bovine ALK1 (5’-3’) construct 2 
gatccccGACTTATTGTGAC- ATGAAAttcaagagaTTTCATGTCACAATAAGTCttttggaaa; 
bovine ALK2 (5’-3’) construct 1, 
gatccccGATGAGAAGTCGTGGTTTAttcaagagaTAAACCACG- ACTTCTCATCttttggaaa. 
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The shRNA sequence (uppercase letters) was linked to its reverse complementary antisense 
shRNA sequence by a short spacer (lowercase letters). The shRNA sequence is flanked at the 3’ 
end by a string of T residues that serve as a transcription termination site. Representative results 
of bovine ALK1 construct 1 and bovine ALK2 construct 1 were shown.
Recombinant proteins
Recombinant BMP-9 was obtained from Human Genome Sciences. The purity and specific 
activity of the preparation was accessed as previously described (5). Recombinant BMP-6 and BMP-7 
were obtained from K. Sampath (Creative Biomolecules, Inc., Hoptinton, MA) and recombinant 
activin from Y. Eto (Ajinomoto Co, Kawasaki, Japan). Recombinant TGF-β3 was obtained from K. 
Iwata (OSI Pharmaceuticals, Inc., Boulder, CO). The VEGF165 isoform and ALK1- Fc were purchased 
from R&D systems and bFGF from Peprotech.
[125I]BMP-9 binding assay
Iodination of BMP-9 was performed according to the chloramine T method and cells were 
subsequently affinity-labelled with the radioactive ligand as described before (31, 45). In brief, 
cells were incubated on ice for 3 hours with the radioactive ligand. After incubation, cells were 
washed and crosslinking was performed using 54 mM disuccinimidyl suberate (DSS) and 3 mM 
bis(sulfosuccinimidyl)suberate (BS3, Pierce) for 15 minutes. Cells were washed, scraped and lysed. 
Lysates were incubated with the respective antisera overnight and immune complexes were 
precipitated by adding proteinA Sepharose (Amersham). Samples were washed, boiled in SDS 
sample buffer and subjected to SDS-PAGE. Gels were dried and scanned with the STORM imaging 
system (Amersham).
Transcriptional reporter assay
BAECs were seeded in 24-well plates and transiently transfected for 4 hours with the BRE-
luciferase reporter construct (25) using Lipofectamine reagent (Invitrogen) according to the 
manufacturer’s protocol. Expression vectors for human ALK1 or human ALK2 and shRNA expression 
constructs for bovine ALK1 or bovine ALK2 were co-transfected where indicated. An expression 
plasmid for β-galactosidase was co-transfected and used to correct for transfection efficiency. Cells 
were serum-starved the following the day (or two days after transfection for RNAi experiments) 
and stimulated overnight with the respective ligands. Cells were washed, lysed and luciferase 
and β-galactosidase activity were determined. Each transfection was carried out in triplicate and 
representative experiments are shown.
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Western blot analysis
Cells were seeded in six-well plates and allowed to grow to 90% confluence. Cells were washed 
with PBS and serum-starved for 6 hours (HUVECs, HDMVECs) or overnight (BAECs). Cells were 
stimulated with different concentrations of BMP-6 and BMP-9 for 45 minutes, washed with PBS 
and lysed in SDS sample buffer. Samples were boiled for 10 minutes and subjected to SDS-PAGE 
and western blotting. Smad phosphorylation was detected with an antibody specifically recognising 
phosphorylated Smad1 and Smad5, which has been described previously (46). The anti-ID1 antibody 
was from Santa Cruz. Equal loading was shown with an anti-β-actin antibody (Sigma).
Cell growth and migration assay
BAECs were seeded at a density of 3000 cells/well in 96-well plates. The next day, medium 
was aspirated and replaced by fresh medium containing the respective ligands. Proliferation of 
cells was determined after 2 and 3 days by adding MTS solution (Promega), and by measuring 
the absorbance at 490 nm. To determine cell migration, BAECs were seeded in six-well plates and 
allowed to grow to confluence. After serum starvation, monolayers were wounded with three 
scratches and medium was replaced by fresh medium containing the ligands. Cell migration was 
measured in four areas per well directly after wounding and 24 hours later by automated image 
analysis using the Olympus Analysis software.
Metatarsal angiogenesis assay
Metatarsals from 17-day-old mouse foetuses were dissected as described earlier (47). Six 
bones per experimental group were transferred to 24-well tissue culture plates containing a.-MEM 
(Gibco), 10% FCS and PS and allowed to adhere for 4 days. Then, medium was replaced by fresh 
medium containing the ligands. Cultures were fixed 7 days after stimulation and vessel formation 
was visualised by anti-CD31 staining (29).
Statistical analysis
All results are expressed as the mean ± s.d. Statistical differences were examined by one-way 
ANOVA followed by Bonferroni’s multiple comparison test. For statistical comparison of two 
samples, a two-tailed Student’s t-test was used where applicable. P<0.05 was considered as 
statistically significant.
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Abstract
Endoglin is a co-receptor for transforming growth factor-β (TGF-β) family members that is 
highly expressed in endothelial cells and has a critical function in the development of the vascular 
system. Mutations in endoglin are associated with the vascular disease known as hereditary 
hemorrhagic telangiectasia type l (HHTl). Using mouse embryonic stem cells we observed that 
angiogenic factors, including vascular endothelial growth factor (VEGF), induce vasculogenesis in 
embryoid bodies even when endoglin deficient cells or cells depleted of endoglin using shRNA 
are used. However, endoglin is required for the stem cell-derived endothelial cells to organize 
effectively into tubular structures. Consistent with this finding, fetal metatarsals isolated from 
E17.5 endoglin heterozygous mouse embryos showed reduced VEGF-induced vascular network 
formation. Moreover, shRNA-mediated depletion and pharmacological inhibition of endoglin 
in human umbilical vein cells (HUVECs) mitigated VEGF-induced angiogenesis. In summary, we 
demonstrate that endoglin is required for efficient VEGF-induced angiogenesis. 
Key words: embryonic stem cell; embryoid body; endoglin; TRC105; angiogenesis; VEGF
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Introduction
During development of the embryo, blood vessels evolve de novo from hemangioblasts that 
differentiate into endothelial cells and form a primary vascular plexus. This process is defined 
as vasculogenesis [1]. Angiogenesis refers to the remodeling and maturation of this primitive 
vascular network into a branched vascular network [2]. Angiogenesis is a dynamic and carefully 
balanced process involving an activation phase associated with increased vascular permeability, 
basement membrane degradation, endothelial proliferation and migration, and a resolution phase 
accompanied by inhibition of endothelial cell proliferation and migration, in parallel with basement 
membrane reconstitution [3]. In the maturation phase the recruitment of pericytes and vascular 
smooth muscle cells is needed to maintain vessel stability and protect endothelial cells from 
apoptosis [4], [5]. 
Vascular endothelial growth factor (VEGF) plays a very prominent role in vasculogenesis and 
angiogenesis. VEGF represents a family of related cytokines, of which the VEGF-A isoform is a 
potent endothelial mitogen strongly induced by hypoxia [6]. Mice lacking one Vegfa allele die at 
embryonic day (E)8.5 as a result of vascular malformations [2], [7]. VEGF-A signalling occurs via 
the high affinity tyrosine kinase receptors VEGFR1 (Flt-1), and VEGFR2 (Flk-1) [8], [9]; VEGFR2 is the 
important endothelial VEGF receptor during angiogenesis. Vegfr2 knockout mice die at E8.5 from 
impaired development of hematopoietic and endothelial cells [10] and closely resemble VEGF-A 
deficient embryos.
Endoglin (CD105) is a transmembrane glycoprotein essential for angiogenesis and vascular 
development, which is predominantly expressed in vascular endothelial cells [11]. Mice lacking 
Endoglin die at El0.5-E11.5 from angiogenic and cardiovascular defects. The early steps of 
vasculogenesis appear to be normal but the primary endothelial network fails to remodel into a 
mature circulatory system [12]-[14]. Endoglin functions as a co-receptor for transforming growth 
factor-β (TGF-β) family members, and interacts with their signalling serine/threonine kinase 
receptors [15], [16]. TGF-β relays its signal via Type I receptors (TβRI), also termed as activin 
receptor-like kinases (ALKs). TβRI acts downstream of type II receptors (TβRII) [17] and mediates 
the activation of intracellular Smad effector transcription factors [18]. In endothelial cells, TGF-β 
can signal via two different TβRIs, ALK1 and ALK5 [3], [19]. Activation of ALK1 induces Smad1 or -5 
phosphorylation and mediates endothelial cell proliferation and migration, whereas ALK5 induces 
Smad2 and -3 activation leading to vascular quiescence [3], [20]. Endoglin promotes ALK1/Smad1/5 
signalling and inhibits ALK5/Smad2/3 signalling [21] - [23]. Endoglin and ALK1 have also been shown 
to bind other TGF-β family members. Bone morphogenetic protein (BMP) 9, in particular, can bind 
directly and with high affinity to endoglin and ALK1 [24], [25]. 
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In humans, mutations in endoglin lead to hereditary haemorrhagic telangiectasia type I (HHT1, 
also known as Rendu-Osler-Weber syndrome), while HHT2 is associated with mutations in the type 
I receptor, ALK1 [26], [27]. HHT is an inherited autosomal-dominant vascular disorder that affects 
the blood vessels of many organs. Characteristic symptoms include epistaxis (nosebleeds), skin and 
mucosal telangiectases associated with hemorrhage, as well as pulmonary, cerebral and hepatic 
arteriovenous malformations [28], [29]. 
During the differentiation of mouse embryonic stem cells (ESCs) in vitro, hematopoietic 
commitment within Vegfr2+ precursor populations are characterized by endoglin expression [30]. 
In particular, endoglin is expressed during the progression from the Vegfr2+Cd45- to Vegfr2-Cd45+ 
stage, marking the hemangioblast [31]. In endoglin deficient ESCs, the number of hemangioblast 
precursors were reduced and myelopoiesis and deﬁnitive erythropoiesis were severely impaired, 
suggesting that the regulated expression of endoglin functions to support lineage-speciﬁc 
hematopoietic development from Vegfr2+ precursors [30], [31]. Additional studies with forced 
expression of endoglin in ESCs and transcriptional profiling studies on Eng+Vegfr2+ from E7.5 
embryos further supported an important role for endoglin in hematopoietic development [32], [33].
In the present study, we examined the role of endoglin in vasculogenesis and angiogenesis 
using aggregates of ESCs known as embryoid bodies (EBs). We found that endothelial cell 
differentiation was not affected by a lack of endoglin, but that VEGF-induced angiogenesis was 
severely impaired. The effects were dependent on the level of endoglin: heterozygotes exhibited 
an intermediate phenotype, reminiscent of features in HHT1 patients. These results were validated 
and consolidated by shRNA-mediated endoglin depletion and pharmacological endoglin inhibition 
studies in endothelial cells. The impaired VEGF-induced endothelial cell sprouting in the absence 
of endoglin might provide a suitable cell model to screen for drugs that can rescue this phenotype, 
which might lead to novel treatment modalities. 
Endoglin is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis
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Results
Absence of endoglin impairs organization of vascular structures in 15-day-old 
embryoid bodies
To elucidate the role of endoglin in blood vessel morphogenesis we examined the effect of 
endoglin gene dosage using the established assay of differentiation of ESCs into EBs [34]. When 
induced to differentiate, Eng+/- or Eng-/- ESC lines [13] were found to form EBs of similar size and 
compactness to those of wild type EBs (Fig. 1A). Next, the assembly of vascular structures was 
analyzed by platelet endothelial cell adhesion molecule (PECAM)-1 staining of sections of ESC-
derived EBs with different endoglin gene dosage (Eng+/+, Eng+/- or Eng-/-) obtained after 15 days of 
differentiation embedded in plastic and sectioned (Fig. lB). Morphology of the vasculature formed 
in wild type ESC-derived EBs was very similar to that of the yolk sac in wild type mouse embryos 
(Fig. 1B). Multiple blood islands, lined with a single layer of thin elongated endothelial cells, were 
found between the outer endoderm and the inner ectoderm layers (Fig. 1B), as reported previously 
by Wang et al. [35]. The number of blood islands in Eng-/- ESC-derived EBs appeared less numerous 
than in the wild type ESC-derived EBs and endothelial cells were found in clusters rather than in 
elongated single cell layers, confirming the defective formation of vessel-like structures in Eng-/- 
ESC-derived EBs (Fig. 1B). Vascular structures also developed in Eng+/- ESC-derived EBs, but their 
frequency and organization were markedly reduced compared to those in wild type ESC-derived 
EBs, indicating a dose dependent effect of endoglin on vascular organization (Fig. 1B). 
Endoglin does not affect endothelial cell differentiation
Two processes are responsible for the formation of blood vessels during embryonic 
development: (i) vasculogenesis, the primary in situ differentiation of endothelial precursors from 
mesoderm, and their organization into a primary capillary plexus and (ii) angiogenesis, the formation 
of new vessels by a process of sprouting from pre-existing vessels [1], [36]. RT-PCR analysis of 
endothelial cell speciﬁc markers on ESC-derived EBs collected from days 0 to 20 were used to define 
the role of endoglin during endothelial cell differentiation. Distinct gene expression patterns were 
induced as differentiation proceeded. VEGFR1 was rapidly up-regulated at day 3 and VEGFR2, Tie-1 
and Tie-2 more prominently at day 5 (Fig. 2A). The expression patterns of the different EC markers 
were similar in Eng-/- ESC-derived EBs. In addition, we determined the number of PECAM-1 positive 
cells in dissociated 11-day-old EBs by FACS analysis and found no differences between wild type, 
Eng+/- or Eng-/- ESC-derived EBs (Fig. 2B). Analysis of the expression of multiple pericyte-vascular 
smooth muscle markers by RT-PCR also did not reveal striking differences between ESC-derived 
EBs with different endoglin gene dosage (Fig. 2C). Taken together, our results show that endoglin 
is not required for endothelial and mural cell differentiation.
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Fig 1. Impaired vasculature in Eng null mutation ESC-derived 11-day-old EBs. (A) Eng+/- or Eng-/- ESC lines form EBs with 
no difference when compared to EBs derived from wild type ESCs (B) PECAM-1 whole mount immunohistochemistry 
of representative wild type, Eng+/-, and Eng-/- ESC-derived 11-day-old EBs. Wild type ESC-derived EBs form a primitive 
vascular plexus. In contrast, Eng-/- ESC-derived EBs form irregular vascular structures with endothelial cell clusters. Light 
microscopy of serial plastic sections of wild type, Eng+/-; and Eng-/- ESC-derived 11-day-old EBs stained as whole mount 
for PECAM-1. Black arrowhead indicates vessel like structures. Asterisk indicates endothelial cell clusters.
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Fig 2. Expression of endothelial-specific markers during vascular development in EBs. (A) RT-PCR analysis of endothelial 
cell markers was performed on ESC and EBs cultured for the indicated number of days. Abbreviations: PECAM, platelet 
endothelial cell adhesion molecule; tie, tyrosine kinase with immunoglobulin-like loop and epidermal growth factor 
homology domain; VEGF, vascular endothelial growth factor receptor (B) The number of PECAM-1 positive cells was 
quantified by FACS analysis of the cell suspension of wild type, Eng+/-, and Eng-/- ESC-derived 11-day-old EBs. (C) RT-PCR 
analysis of pericyte-smooth muscle cell markers was performed on ESC and EBs cultured for the indicated number of 
days. Abbreviations: aebp, adipocyte enhancer binding protein; axl, a receptor tyrosine kinase; cspr, cysteine- and 
glycine-rich protein; cspg, chondroitin sulfate proteoglycan; cnn, calpoin; pdgf, platelet-derived growth factor, rgs, 
regulator of G protein signalling.
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Endothelial cell organization is disrupted in Eng-/- ESC-derived EBs plated 
on gelatin
EBs plated on a gelatin-coated substrate can develop branching vascular structures indicative 
of vascular morphogenesis [37]. Endothelial cells are initially aggregated in dense clusters but when 
plated, rapidly form thin branching tubes, in a process resembling angiogenesis. To determine 
the role of endoglin in this process, we plated 11-day-old EBs derived from Eng+/+, Eng+/- and 
Eng-/- ESCs and maintained them in culture for four additional days before staining them with an 
antibody to PECAM-1 and hematoxylin to reveal the vascular network. Three different phenotypes 
could be identiﬁed in the EBs: (i) those with an extensively branched vascular network without 
endothelial cell clusters categorized as “organized”, (ii) those forming some vessels and still 
containing endothelial cell clusters referred to as “intermediate”, (iii) those with endothelial cells 
clusters only; these were designated as “dispersed” (Fig. 3A). Of around 90 EBs scored in each 
case in two independent experiments, on average about 63% of Eng+/+ EBs showed an organized 
phenotype, ~26% an intermediate phenotype and only ~ 11% a dispersed phenotype (Fig. 3B). By 
contrast, in the Eng-/- EBs, ~39% lacked cord-like structures entirely and were classified as dispersed, 
whereas ~59% had an intermediate phenotype. Furthermore, the length of the vessel sprouts that 
did form was greatly reduced compared to those of the Eng+/+ EBs and vessels appeared often 
wider. Quantitative analysis also showed that an intermediate vascular phenotype predominated 
in the Eng+/- EBs with ~20% dispersed and ~60% intermediate phenotypes (Fig. 3B). When EBs were 
embedded into a collagen gel and allowed to form vascular sprouts in 3D, we observed a reduction 
in both number of sprouts and sprout length in the Eng-/- EBs (Supplementary Fig. 1).
To validate the data obtained with the Eng-/- ES cell line we depleted endoglin by shRNAs 
targeting endoglin in ESCs. Essentially we obtained the same results as for ESCs in which gene 
dosage was reduced (Fig. 4). Partial knock down of endoglin in ESC in differentiated EBs (Fig. 4B) 
interfered with efficient VEGF-induced sprouting (Fig. 4D), whereas expression of endothelial 
markers PECAM-1 and VE-Cadherin was not significantly affected (Fig. 4A and 4C). 
Endoglin is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis
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Fig 3. Eng-/- ESC-derived EBs plated on gelatin coated plates lack organized vessel structures. (A) PECAM-1 
immunohistochemical staining of ESC-derived 11-day-old EBs plated on gelatin for 4 days displayed “organized”, 
“intermediate” or “dispersed” phenotype. (B) Quantification of wild type, Eng+/-, and Eng-/- ESC-derived 15-day-old EBs 
vascular phenotypes as they were defined in A.
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Fig 4. shRNA-mediated knock down of endoglin inhibits VEGF-induced endothelial cell sprouting of EBs. ES cells were transduced 
with either scrambled or endoglin targeting shRNA. ES cells formed EBs during 4 days of hanging drop culture before embedding 
in collagen and stimulation with VEGF (30ng/ml). Sprouting EBs were analyzed after 8 days of VEGF stimulation. A) Control EBs 
and EBs with incomplete endoglin knockdown stained for endothelial marker PECAM-1 (green) and DAPI (blue). Control EBs 
have large and many outgrowing sprouts of endothelial cells, which form extensive networks. EBs with incomplete endoglin 
knockdown show less sprouts, which do not seem to form as extensive networks as control EBs. Sheets of cells that are mostly 
PECAM-1 negative have formed between the sprouts. B) Control EBs and EBs with incomplete endoglin knockdown stained for 
endoglin (green) and DAPI (blue). Endoglin is present in the entire sprout in the control EBs, with the highest expression towards 
the tip of the sprout. In the EBs with incomplete knockdown showed expression of endoglin mainly in the tips of the outgrowing 
sprouts. The cellular sheets hardly had endoglin expression. C) qPCR analysis of endoglin, PECAM-1 and VE-cadherin expression 
during differentiation of the control and endoglin knockdown ES cells. Endoglin expression is reduced by approximately 85% in the 
ES cells, but during differentiation, at day 7 and 9, expression is restored to half of the normal levels. Expression of PECAM-1 and 
VE-cadherin did not differ between control and endoglin knockdown EBs at the ES cell state or at day 7 and 9 of differentiation. D) 
Analysis of number of tips per EB. Endoglin knockdown EBs exhibit significantly less sprouts than the control EBs.
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VEGF-induced angiogenesis is reduced in fetal metatarsals from Eng+/- mice
In the studies above, VEGF was provided as the angiogenic stimulus. VEGF is a potent mitogen 
for endothelial cells and elevated endoglin expression has been associated with activated 
endothelial cells in tumor stroma [38]. To investigate a possible interplay between VEGF and 
endoglin in angiogenesis, we compared the VEGF-induced angiogenic response in fetal mouse 
metatarsals derived from wild type and Eng+/- mice. After adherence of the fetal bones to the 
culture dish, fibroblast-like cells migrate from the bones to form a monolayer, on which a tubular 
network of endothelial cells is formed [38], [39]. Staining of this endothelial cell network with an 
antibody to PECAM-1 showed that the VEGF-induced angiogenic responses, as measured by the 
number and the length of capillary sprouts were significantly reduced in the Eng+/- metatarsals 
(Fig. 5). This result suggests that endoglin is required for efficient VEGF-induced angiogenesis. 
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Fig 5. VEGF-induced angiogenesis is impaired in Eng+/- fetal metatarsal bones. Metatarsals of 17-day-old mouse fetuses 
were prepared from wild type and Eng+/- mice, transferred to cell-culture plates, allowed to adhere, and then stimulated 
with VEGF (50 ng/ml). (A) Cultures were fixed and vessel-like structures were visualized by anti-PECAM-1 staining. Six 
bones were stimulated per experimental group and one representative picture of each group is shown. (B) VEGF addition 
stimulated the formation of vessel-like structures. No significant difference in the baseline vascular network formation 
was observed between wild type and Eng+/- metatarsals. The induction of the vascular network of wild type metatarsals 
is significantly stronger than the network of Eng+/- metatarsals. P≤0.05.
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Inhibition of endoglin expression or function mitigates VEGF-induced sprouting 
of HUVECs 
To elucidate the role of endoglin in VEGF-induced endothelial sprouting, we used a 
3D-endothelial cell spheroid-sprouting assay, an established model for studying early in vitro 
angiogenic responses [40]. Non-stimulated spheroids of human umbilical vein endothelial cells 
(HUVECs) in collagen remain quiescent, and mimic the quiescent endothelial cells in the vessel wall. 
When stimulated with VEGF, tube-like protrusions emerge from the HUVEC spheroid within one 
day. We observed that shRNA-mediated depletion of endoglin in HUVECs significantly reduced the 
VEGF-induced response in this assay (Fig. 6A, B). In addition, treatment of HUVECs with the endoglin 
neutralizing antibody TRC105 also mitigated this response (Fig. 6C), confirming that inhibition of 
endoglin function attenuates the VEGF-induced angiogenic response. 
Direct VEGF-induced signalling is not affected in endoglin-deficient cells
The data above suggest an involvement of endoglin in the VEGF signalling pathway or crosstalk 
between endoglin and the VEGF pathway. We therefore further investigated the effect of endoglin 
on VEGF signalling. The first event in the VEGF signalling cascade is binding of VEGF to its receptor, 
VEGFR2. However, specific depletion of endoglin in HUVECs using shRNA did not affect VEGF binding 
to VEGFR2 as measured by affinity crosslinking with radiolabeled VEGF (data not shown). After 
VEGF-VEGFR2 interaction, VEGFR2 autophosphorylates itself at amino acid 1175, and thereafter 
initiates activation of the ERK kinase pathways. However, analysis of VEGF-induced VEGFR2, 
phospho-ERK pathways did not reveal any significant changes upon endoglin knock down (Fig. 6D) 
These data indicate that endoglin deficiency does not affect VEGF-induced ERK signalling directly. 
Discussion
In the present study, we examined the role of endoglin in vasculogenesis and angiogenesis 
using aggregates of mouse ESCs known as EBs that were challenged with angiogenic supporting 
factors, including VEGF. Under appropriate conditions, both vasculogenesis and angiogenesis take 
place in EBs [41] - [45]. We compared EBs from wild type mouse ESCs with those from mouse ESCs 
with heterozygous or homozygous deletions in endoglin (Eng+/- and Eng-/-, respectively). We found 
that the endothelial cell differentiation program in ESC-derived EBs is not affected by homozygous 
deletion of endoglin. However, homozygous mutant endothelial cells were severely inhibited in 
their ability to form organized vascular structures either following plating of EBs on gelatin in 2D 
or in 3D collagen gels, supporting evidence for an essential role of endoglin in VEGF-mediated 
angiogenesis. This is consistent with reports by Bourdeau et al. [13], Li et al. [14] and Arthur et al. 
[12], and more recently by Park et al. [46].
Endoglin is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis
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Fig 6 Endoglin deficiency inhibits VEGF-induced sprouting of HUVEC spheroids. (A) Effect of shRNA-mediated depletion of 
endoglin on VEGF-induced endothelial cell sprouting. HUVECs were transduced with lentivirus expressing endoglin shRNA 
overnight. HUVEC spheroids with deficient endoglin expression were embedded in collagen and stimulated with VEGF 
(50ng/ml). (B) Quantitation of effects seen in (A). A representative experiment is shown. (C) Effect of TRC105 endoglin 
antibody on VEGF-induced endothelial cell sprouting. HUVEC spheroids were embedded in collagen and stimulated 
with VEGF (50ng/ml), TRC105 (10µg/ml), or both overnight. As control antibody for experiments using TRC105, the Fc 
domain (MOPC-21) from Bio Express, West Lebanon, NH, was used. Pictures were taken by phase-contrast microscopy. 
Quantitative analysis of the mean total sprout length was performed on 10 spheroids per experimental group. P≤0.05. 
(D) VEGF-induced VEGFR2 phosphorylation at site 1175 and extracellular regulated kinase (ERK) mitogen activated 
protein (MAP) kinase phosphorylation was examined in shRNA-mediated endoglin knockdown cells. Two bands were 
detected with the phosphor ERK MAPK antibodies with a molecular weight of 44 and 42 kDa; they represent ERK1 
and ERK2 isoforms, respectively. Number sign (#) represents a background band, indicating the even loading for the 
experiment. Asterisks indicate the protein bands with expected size.
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However these data are different from earlier reports on the Eng-/- ESCs claiming no effect on 
endothelial cell organization in differentiating embryoid bodies. However, different methods 
were used, which might have contributed to the different outcomes [47]. To validate the defect in 
sprouting of Eng-/- ESC lines compared with control Eng+/+ ESC, we depleted endoglin by shRNA. 
Essentially we were able to confirm the results obtained using the knock out cells in that they are 
also defective in VEGF-induced endothelial cell sprouting, albeit not as dramatically as knock out 
cells. shRNA-mediated depletion has the advantage of looking at the effects of endoglin depletion 
at an early stage, before any long term adaptation responses occur. Thus, we conclude that endoglin 
is responsible for the lack of VEGF-induced endothelial vascular organization.
We observed interdependence for endoglin in VEGF-induced angiogenic responses. Genetic 
depletion of endoglin from endothelial cells and pharmacological inhibition using TRC105 endoglin 
antibody severely affected VEGF-induced endothelial cell sprouting. These results are in line with 
previous studies, which demonstrated that endoglin is essential for normal growth, migration 
and cord formation of endothelial cells [21], [48], [49]. In addition, our results are consistent with 
a recent report that showed that TRC105 inhibited VEGF and FGF-induced HUVEC endothelial 
tube formation when co-cultured with dermal fibroblasts [50]. Moreover, soluble endoglin 
has been shown to inhibit tumor angiogenesis [51], [52], and elevated placental expression of 
endoglin results in high serum levels of soluble endoglin that contribute to vascular dysfunction 
in pre-eclampsia [53]. 
Remarkably, mouse embryonic endothelial cells (MEECs) isolated from Eng-/- embryos have 
been described as exhibiting enhanced proliferation [54]. The basis for the differences between 
our findings here and these studies is not clear. One explanation may be adaptive mechanisms 
that take place in endothelial cells in order to compensate for reduced endoglin expression 
in vivo [21], [54-56]. 
Analysis of yolk sac vasculature in endoglin mutant mice has shown previously that vascular 
smooth muscle cells are sparse in the vicinity of vessels lacking endoglin and it was striking that 
immunodetectable TGF-β l was reduced in the smooth muscle cells although TGF-β l mRNA levels 
in the adjacent endothelial cells were unaffected [55]. The impaired ability of endothelial cells 
to secrete or activate TGF-β1 was believed to explain the lack of phosphorylated Smad2 in the 
adjacent mesothelium and the subsequent failure of these cells to differentiate into vascular 
smooth muscle cells. In the EB vasculogenesis assay used here, vascular smooth muscle cells did 
form and organize to some extent, albeit abnormally, in the absence of endoglin in contrast to the 
observations in vivo. However, the culture conditions used included the use of fetal bovine serum 
as a medium supplement, which could provide active TGF-β and facilitate partial rescue. Since the 
EB vasculogenesis assay closely models aspects of vascular development and includes both the 
differentiation and organizational aspects of EC and vascular smooth muscle cell components, 
Endoglin is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis
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it is potentially useful in screening anti- or pro-angiogenic drugs as well as in understanding the 
underlying molecular mechanisms. 
In conclusion, our results provide insights into the molecular mechanisms that underlie vascular 
defects reminiscent of those in HHT1 patients and opens new avenues for inhibition of VEGF 
signalling by interfering with endoglin function. 
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Materials and Methods
Cell culture
HUVECs
Human umbilical vein endothelial cells (HUVECs) cells were cultured in Medium 199 with Earle’s 
salt and L-glutamine (Gibco), 10% FCS, heparin (LEO pharma), bovine pituitary extract (Gibco) and 
penicillin/streptomycin (PS) on plates coated with 1% gelatin, at 37°C and 5% CO2. HUVECs were 
used up to passage 4. Experiments were confirmed with HUVECs from different donors.
Embryonic stem cell lines and culture
Two independent R1 ESC lines were used as controls. Eng+/- mouse embryonic stem cells 
(ESCs) were generated by gene targeting of the parental wild-type 129/Ola-derived E14 ES cell 
lines, deleting 609 base pairs (bp), including Eng exon 1 and its initiation codon and leaving the 
endoglin promoter intact [13]. Eng-/- ESCs were derived in vitro from Eng+/- ESCs by selection 
with high concentrations of G418 [30]. Genomic DNA was isolated from ESC lines using standard 
techniques [57]. Primers MEFI and MERl amplify normal Exon 1 (300 bp) and primers MEFR1 and 
MEZR amplify the recombinant product (476 bp), as previously described [13]. ESC lines were 
cultured in the presence of mouse embryonic ﬁbroblasts (MEFs) in DMEM, supplemented with 
20% heat-inactivated fetal bovine serum (FBS), 0.1 mM [3-Mercaptoethanol, lx non-essential amino 
acids and 1000 U/ml recombinant Leukemia Inhibitory Factor (LIF).
Lentiviral transduction
HUVECs were infected with lentivirus encoding an shRNA sequence against human endoglin 
(TRCN0000003273, TRCN0000003276) selected from the MISSION shRNA library (Sigma) and 
a third lentivirus encoding shRNA was generated in our lab [58]. R1-ES cells were infected with 
lentivirus encoding an shRNA targeting mouse endoglin (TRCN0000094355, MISSION shRNA library 
Sigma). As a control, a non-targeting shRNA sequence (SHC002) (Sigma) or empty vector pRRL was 
used. Virus transduction was performed overnight, and the infected cells were selected using 
culture medium containing puromycin (1 μg/ml) for 48 h. The efficiency of endoglin knockdown 
was verified by qPCR. 
In vitro differentiation of embryonic stem cell clones
Two different methods were used to differentiate ES cells in vitro. 
Method 1: ESC lines were cultured in hanging drops to form EBs, as described previously [59]. 
Brieﬂy, 800 cells were cultured in 20 µl of DMEM, supplemented with 20% FBS, 25 ng/ml VEGF, 
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50 ng/ml bFGF-2, hanging from the lid of the culture dish for 5 days, which allows the formation 
of cell aggregates (EBs). This makes it possible to control the size of the EBs and circumvents 
paracrine stimulation between EBs, and therefore allows a very high degree of reproducibility. 
Subsequently, EBs were either (i) cultured in suspension on bacterial dishes coated with 1% 
agar for 11 or 15 days. EBs were then washed with PBS and ﬁxed in methanol (MeOH)-dimethyl 
sulfoxide (DMSO) in a ratio of 4:1, overnight (o/n) at 4°C before staining; or (ii) 11-day old EBs 
were plated on gelatin coated coverslips for 4 days and then ﬁxed in Zinc ﬁxative o/n at 4°C 
before staining.
Method 2: Mixed Feeder-ES cell cultures were trypsinized and subsequently cultured for 45 
minutes on gelatin-coated plates before the experiment in order to deplete the MEFs, which adhere 
faster to the plate. The ES cells were harvested and plated in suspension as hanging drops of 20µl 
in complete ES-medium, containing 1200 cells/drop, for four days. 
Embryoid body maturation in 2D culture
Four-day old EBs obtained with method 2 were plated in gelatin-coated 6 well-plates with 
15-20 EBs per well. EBs were cultured in ES medium without LIF and supplemented with 50ng/ml 
hVEGF-165 (PeproTech, Rocky Hill, USA). After 7 or 9 days, EBs were washed with PBS and RNA was 
isolated for qPCR analysis.
Embryoid body maturation in 3-D Collagen matrix
Method 1: All the ingredients of the collagen medium (DMEM, 20% FBS, 25 ng/ml VEGF, 50 
ng/ml bFGF-2) with the exception of collagen were mixed and stored on ice before harvest of the 
EBs to avoid prior polymerization of the medium. Prior to use, rat tail type 1 collagen was added 
and mixed to a ﬁnal concentration of 1.25 mg/ml. 11-day-o1d EBs were immediately incorporated 
into the collagen medium at a ﬁnal concentration of 50 EBs/ml. 12 ml was poured into a 35 mm 
bacterial grade Petri dish and cultures incubated for 3 days at 37°C in a 5% CO2 atmosphere [30], 
[42]. For further analysis of sprouting vessels, the 35 mm gel dish was inverted over a 50 mm 
x 75 mm glass slide. The collagen gel was gently laid out on the slide and excess liquid around 
the gel removed by pipetting with a dispenser. The gel was then dehydrated using nylon linen 
and absorbent ﬁlter cards. The slide was air-dried for 12 hours and incubated in zinc ﬁxative o/n 
at 4°C before staining as previously described [42]. The EBs were stained for PECAM-1 (Clone 
MEC13.3, BD Biosciences).
Method 2: Collagen solution was made as following: Purecol (Advanced Biomatrix, 
San Diego, USA) with 34.65% HAM’s F12 (Gibco), 6.25% NaOH (0.1M), 6.25% 10x F12, 1.25% 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (1M), 0.975% Sodium bicarbonate 
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7.5% and 0.625% Glutamax. Four-day old EBs were suspended in 350µl collagen and transferred to 
a 24-well collagen pre-coated plate (one EB per well). EBs were cultured in complete ESC-medium 
without LIF and supplemented with 30ng/ml hVEGF-165. The EBs were cultured for eight days in 
collagen and the medium was changed every four days. Afterwards, EBs in collagen were washed 
with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde in PBS for 30 min at 
room temperature. 
RNA isolation and quantitative PCR
Total DNA-free cellular RNA was extracted with Trizol reagents, according to manufacturer’s 
protocol (Invitrogen). Samples were DNase I treated to eliminate genomic DNA and 1 µg RNA was 
reversed transcribed as described [60]. All PCR analyses of the endothelial cell and SMC specific 
markers were as previously described [61]. RNA from ESCs and EBs from method 2 was isolated with 
the NucleoSpin RNA II kit according to manufacturer’s protocol (Bioké, Leiden, Netherlands). qPCR 
was performed with SYBRGreen reagent (Roche) for endoglin, FLK-1 and VE-cadherin. The ΔΔCt 
method was applied for the expression profiling. Gene expression is normalized to house-keeping 
gene GAPDH and wild type ES cells as the reference sample.
Target Forward primer Reverse primer
Endoglin GGTCATGACTCTGGCACTCA AGGCGCTACTCAGGACAAGA
PECAM-1 ACCAAGGCGACTATGTTTGC GGGCAAGTCACTTCAATGGT
VE-cadherin ATTGAGACAGACCCCAAACG TGTTTTTGCCTGAAGTGCTG
GAPDH AACTTTGGCATTGTGGAAG ACACATTGGGGGTAGGAACA
Immunofluorescence staining 
For cryosections, ESC-derived l5-day-old EBs were processed as previously described
[62] and subsequently sectioned at 7 µm before acetone ﬁxation for 10 minutes at 4°C, 
followed by 30 minutes air drying at RT. Next, slides were permeabilized for 5 minutes with 
0.2% Triton X-100 in PBS, followed by blocking with 2% BSA in PBS at RT for l hour. The slides 
were then incubated with rat anti-mouse PECAM-1 (Clone MEC14.7, Santa Cruz) o/n at 4°C. The 
slides were then washed four times in PBS and incubated for 1 hour with goat anti-rat Cy3 
(Jackson ImmunoResearch Laboratories) at RT. The slides were then washed four times in PBS and 
mounted in Mowiol before confocal laser microscope analysis. Slides containing EBs cultured in 
3D-collagen gel and zinc ﬁxed were permeabilized for 15 minutes with 0.2% Triton X-100 in PBS, 
followed by blocking with TNB blocking solution for 1 hour at RT, as described above. EBs were 
stained with rat anti-mouse PECAM-1 (Clone MEC13.3, BD Biosciences) and mouse anti-smooth 
muscle cell actin (Clone 1A4, Sigma) simultaneously o/n at 4°C. The slides were then washed in 
TBS and incubated 1 hour with donkey anti-rat FITC (Jackson ImmunoResearch Laboratories) and 
goat anti-mouse (Jackson IrnmunoResearch Laboratories) secondary antibodies diluted in TNB. 
Endoglin is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis
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The slides were then washed four times in TBS and mounted in Mowiol before confocal laser 
microscope analysis. EBs matured in 3D according to method 2 were excised from collagen. 
The EBs were blocked in blocking solution (Tris-Buffered Saline Tween (TBST) with 3% BSA) for 
2 hours or overnight at room temperature. Staining with primary and secondary antibodies 
was done overnight. The EBs were stained with Hoechst to visualize the nuclei. The following 
antibodies were used: rat anti-mouse PECAM-1 (BD Pharmingen) and rat anti-mouse endoglin 
(CD105 MJ7/18, BD Pharmingen). Secondary antibodies: donkey anti-rat Alexa 488 (Invitrogen) 
and goat anti-rabbit Alexa 594 (Invitrogen). EBs were stored at 4oC in PBS until analysis with 
fluorescence microscopy. Endothelial cell sprouting from the EBs was quantiﬁed by measuring 
the length of the tubes.
Flow Cytometric analysis
To obtain single cell suspensions for FACS analysis, 15-day-old EBs were collected from 
agar coated-dishes and washed twice with PBS before being incubated for 30 minutes in a 
dissociation solution containing 0.2% collagenase B (Roche Diagnostics). EBs were gently ﬂushed 
every 5 minutes using one ml tip. After centrifugation, the cell pellet was washed twice with 2% 
FBS in PBS and then incubated for one hour at 4°C with a FITC conjugated anti-mouse PECAM-1 
before FACS analysis.
Western blot analysis
Cells were seeded in six-well plates and allowed to grow to 90% confluence. Cells were washed 
with PBS and serum-starved for 5 hours. Cells were stimulated with VEGF 50 ng/ml for 5 minutes, 
washed with PBS and lysed in SDS sample buffer. Samples were boiled for 10 minutes and subjected 
to SDS-PAGE and western blotting. Phospho-VEGFRII, phospho-ERK antibodies were purchased 
from Cell signalling Technology. Endoglin was analyzed with an antiserum recognizing human 
endoglin [63].
3D-culture spheroid assay
HUVECs (400 cells per spheroid) were suspended in Medium M199 containing Earle’s salt and 
L-glutamine, 10% FBS, methylcellulose, heparin, bovine pituitary extract, PS and seeded in non-
adherent round-bottom 96-well plates. After 24 hours, spheroids were embedded into collagen 
and stimulated with corresponding stimuli in the presence or absence of inhibitors or neutralizing 
antibodies for another 24 hours. As control antibody for experiments with endoglin neutralizing 
antibody TRC105, the Fc domain (MOPC-21) from Bio Express, West Lebanon, NH, was used. EC 
sprouts were measured by Olympus Analysis software.
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Ex vivo fetal mouse metatarsal angiogenic assay
Metatarsals from 17-day-old mouse fetuses from Eng+/+ and Eng+/- mice [12] were dissected 
as described previously [64]. Six metatarsals per experimental group were transferred to 24-wells 
tissue-culture plates containing α-MEM (Gibco), 10% FBS and penicillin/streptomycin (PS), and 
allowed to adhere for 4 days. Then, medium was replaced by fresh medium containing 50 ng/ml 
VEGF. Cultures were fixed 7 days after stimulation and vessel formation was visualized by anti-
PECAM-1 staining [39]. Vascular density was quantified by automated image analysis with Image J. 
All animal experiments were approved by the local animal ethics committee
Statistics
All results are expressed as the mean ± s.d. Statistical differences were examined by two-tailed 
Student’s t-test and P≤0.05 was considered to be statistically significant (in the figures, *P≤0.05 
and **P≤0.01).
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Abstract
Endoglin is a transforming growth factor-β coreceptor with a crucial role in angiogenesis. A 
soluble form of endoglin is present in the circulation, but the role of soluble endoglin (sEndoglin) 
is poorly understood. In addition, the endoglin shedding mechanism is not known. Therefore, we 
examined the role of sEndoglin in tumor angiogenesis and the mechanism by which the extracellular 
domain of endoglin is released from the membrane. In colorectal cancer specimens, we observed 
high endothelial endoglin protein expression, accompanied with slightly lower sEndoglin levels in 
the circulation, compared with healthy controls. In vitro analysis using endothelial sprouting assays 
revealed that sEndoglin reduced spontaneous and vascular endothelial growth factor–induced 
endothelial sprouting. Human umbilical vascular endothelial cells were found to secrete high 
levels of sEndoglin. Endoglin shedding was inhibited by matrix metalloproteinase (MMP) inhibitors 
and MMP-14 short hairpin RNA, indicating MMP-14 as the major endoglin shedding protease. 
Coexpression of endoglin and membrane-bound MMP-14 led to a strong increase in sEndoglin 
levels. Endoglin shedding required a direct interaction between endoglin and membrane-localized 
MMP-14. Using cleavage site mutants, we determined that MMP-14 cleaved endoglin at a site in 
close proximity to the transmembrane domain. Taken together, this study shows that MMP-14 
mediates endoglin shedding, which may regulate the angiogenic potential of endothelial cells in 
the (colorectal) tumor microenvironment.
Keywords: MMP14, Angiogenesis, sEndoglin, MMP inhibitors, VEGF 
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Introduction
Endoglin (CD105) is a 180-kDa integral membrane-bound glycoprotein, which serves as a 
high-affinity coreceptor for transforming growth factor (TGF)-β1 and TGF-β3, in the presence 
of the TGF-β type II receptor (1, 2). Mutations in the gene encoding endoglin lead to hereditary 
haemorrhagic telangiectasia type I, a multisystemic vascular disease characterized by bleeding 
from small vascular lesions in the mucocutaneous tissues and the presence of arteriovenous 
malformations (3, 4). Endoglin is highly expressed by activated endothelial cells, in which it has a 
crucial role in angiogenesis, shown by the fact that endoglin knockout animals die in utero because 
of defects in the vascular system (5). Expression of endoglin can be induced by hypoxia (3, 6), 
TGF-β1 (1, 7, 8), and/or TGF-β3 (9). Endoglin expression was shown to be upregulated in various 
cancers (1) and correlated with the development of metastatic disease in colorectal cancer (CRC; 
ref. 6). Together, these data indicate a crucial role for endoglin in tumor angiogenesis. Besides 
membrane-bound endoglin, in the circulation, a soluble form (sEndoglin) exists (3). Elevated levels 
of sEndoglin have been reported in pregnant women suffering from preeclampsia (10, 11) and 
colorectal and breast cancer patients (12–14). However, the studies on sEndoglin in cancer are few 
and not conclusive.
Receptor shedding is important in regulating cellular homeostasis by influencing cytokine 
and growth factor signalling. Ectodomain shedding of receptors is mainly regulated through the 
proteolytic cleavage of the extracellular part of the receptor. The TGF-β type I receptor (TβRI) is 
released through tumor necrosis converting enzyme (TACE)–mediated cleavage, which decreases 
cell surface localized receptors and therefore inhibits TGF-β signalling (15). The TGF-β coreceptor 
betaglycan is released through proteolytic cleavage by membrane-type 1 matrix metalloproteinase 
(MMP-14). Soluble betaglycan can compete with membrane-bound betaglycan for TGF-β binding 
and thereby inhibit TGF-β effects on cells (16). sEndoglin has been shown to contribute to 
endothelial cell dysfunction (11, 17), but the mechanism of shedding and the consecutive effects 
of sEndoglin on tumor angiogenesis remain to be identified.
The aim of this study was to analyze the role of sEndoglin in regulating tumor angiogenesis and 
to identify the mechanism by which the extracellular part of endoglin is cleaved from cells. First, 
endoglin protein expression was determined in CRC tissue and sEndoglin levels in the circulation of 
CRC patients. Next, we evaluated the effect of sEndoglin on angiogenesis and the endoglin shedding 
mechanism in endothelial cells. The data revealed that MMP-14 sheds endoglin at a cleavage site 
close to the transmembrane domain.
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Results
Endoglin expression and sEndoglin levels in CRC patients
We determined the expression and cel lular  local ization of  endogl in in CRC 
specimens, corresponding normal mucosa, and premalignant adenomatous polyps using 
immunohistochemistry. In normal colonic tissue, endoglin protein expression was low and 
only present in submucosal endothelial cells (n = 7; Fig. 1, left). In contrast, in tumors, strongly 
increased endoglin protein expression in angiogenic endothelial cells was observed, confirmed by 
staining for the endothelial marker CD31 and vimentin, and absence of pan-cytokeratin staining 
(n = 7; Fig. 1, right). ELISA analysis (Supplementary Fig. S1A) revealed that endoglin levels were 
significantly increased in carcinoma as compared with normal mucosa, (5.4 ng/mg protein versus 
2.7 ng/mg protein, respectively; n = 191; P < 0.0001) or premalignant adenomas (2.5 ng/mg 
protein; n = 82).
Next, we determined plasma sEndoglin levels in healthy volunteers and CRC patients pre-
operation and 3 months post-operation. Mean preoperative sEndoglin levels in CRC patients 
were slightly but significantly lower (mean, 4.9 ng/ mL; n = 48) compared with healthy controls 
(mean, 7.6 ng/ mL; n = 96) and increased postoperatively (mean, 5.2 ng/mL; n = 25; Supplementary 
Fig. S1B). In this cohort of CRC patients, sEndoglin levels were not related to the Dukes stage of 
the tumor (Supplementary Fig. S1C). Together, these data indicate that endoglin expression is not 
increased in benign adenomas, but strongly increased in CRC with slightly lower sEndoglin levels 
in the circulation of these patients.
Fig. 1. Endoglin expression in CRC. Localization of endoglin 
in normal colonic tissue (left) and in CRC (right). Staining was 
performed for endoglin, the pan-endothelial marker CD31, 
pan-cytokeratin (epithelial marker), and vimentin (mesenchymal 
marker) on sequential sections. Magnification ×200;  
bottom left, ×400.
Matrix Metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumour angiogenesis
107
Ch
ap
te
r 
5
sEndoglin inhibits angiogenesis
Endoglin plays an important role in endothelial cell function and angiogenesis. Therefore, we 
evaluated the role of sEndoglin in angiogenesis. HUVEC cells were subjected to cord formation 
assays on Matrigel and three-dimensional endothelial sprouting assays. HUVEC cells form tubes on 
Matrigel, which was efficiently inhibited (∼65%) by the addition of 1 μg/mL recombinant endoglin-
Fc chimera (Eng-Fc), but not by control Fc protein (Fig. 2A). In addition, endoglin-Fc also inhibited 
VEGF-induced endothelial sprouts in three-dimensional collagen matrices (∼55% inhibition; 
Supplementary Fig. S2). To further investigate the inhibiting role of sEndoglin in angiogenesis, we 
used ECRF (immortalized HUVEC endothelial cells) and HUVEC cells, which were transduced with 
lentiviral vectors expressing endoglin-Fc or Fc only as a control. Expression of the Fc constructs 
was confirmed by Western blot analysis (anti-Fc and anti-endoglin antibodies; data not shown) and 
did not influence the proliferation of the cells (Supplementary Fig. S3A and B). Spheroids of ECRF 
cells formed spontaneous sprouts once embedded in collagen, which were left unaffected by the 
lentiviral-induced expression of the Fc protein. In contrast, sprouting was reduced ∼50% when cells 
were transduced with an endoglin-Fc construct (Fig. 2B). 
Furthermore, endoglin-Fc also efficiently inhibited VEGF-induced and basal sprouting of HUVEC 
spheroids (Fig. 2C). Together, these data indicate that sEndoglin reduces spontaneous sprout 
formation in ECRF cells, cord formation in HUVECs, and VEGF-induced sprouting of HUVEC cells. To 
confirm these data, we used a metatarsal assay. This model provides a combination of a quantitative 
in vitro assay combined with the complexity of a multicellular system. Metatarsals from mice 
were transduced with Fc- or endoglin-Fc expressing adenoviruses and capillary outgrowth was 
determined. The data revealed that endoglin-Fc significantly reduced VEGF- induced capillary 
outgrowth from fetal bones compared with Fc or non-infected cells (Fig. 2D). 
Identification of MMP-14 as the endothelial endoglin shedding protease
MMPs have been identified as important regulators of tumor invasion and metastasis, by 
influencing extracellular matrix remodeling, growth factor activation, and receptor shedding. To 
analyze the potential role of MMPs in regulating endoglin shedding, we used HUVEC endothelial 
cells that secrete high levels of sEndoglin into the medium (∼1 ng/mL, ELISA). Western blot analysis 
revealed that the sEndoglin cleavage product has a similar size as the recombinant endoglin 
extracellular domain (Fig. 3A), which implies a cleavage site close to the transmembrane domain. 
To investigate the role of proteases in mediating endoglin shedding, HUVEC cells were treated with 
various protease inhibitors and sEndoglin levels were determined by ELISA.
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The broad-spectrum MMP inhibitors GM6001 and Marima-stat strongly inhibited sEndoglin 
levels in contrast to inhibitors of cystein proteases (E64) and serine proteases (Aprotinin), including 
cathepsins and plasmin, which had no inhibitory effect. Inhibition of sEndoglin release was 50% by both 
GM6001 and Marimastat (Fig. 3B). Specific inhibitors of gelatinases (MMP-2 and MMP-9), stromelysins 
(MMP-3), had only a mild effect on sEndoglin release, whereas a collagenase inhibitor (MMP-13) did 
not affect sEndoglin levels at all. This indicated that these classes of MMPs were probably not involved 
in the shedding process and suggested membrane-type MMPs to be the primary endoglin shedding 
candidates because they are inhibited by these broad-spectrum inhibitors (29).
Therefore, we analyzed expression of MT-MMPs in HUVEC and ECRF cells by real-time PCR, 
which revealed that MMP- 14 is the most abundantly expressed MT-MMP in endothelial cells 
(Fig. 3C). MMP-15, MMP-16, MMP-17, and MMP-24 are also expressed but to a lower extent, 
whereas MMP-25 was undetectable. MMP-14 plays an important role in cancer progression by 
influencing angiogenesis, invasion, and receptor shedding (30). Therefore, we analyzed the tissue 
distribution of MMP-14 in relation to endoglin in CRC cancer (n = 7). MMP-14 expression was 
observed in malignant epithelial cells and endothelial cells. Interestingly, staining of sequential 
sections for MMP-14 and endoglin revealed that strong MMP-14 staining was accompanied by 
lower or absent endoglin staining (Fig. 3D, top). Accordingly, we observed that strong endoglin 
staining was accompanied by low or absent MMP-14 staining (Fig. 3D, bottom). These data 
indicate MMP-14 as the primary candidate to mediate endothelial endoglin shedding and was 
therefore further analyzed.
Fig.2 Effect of sEndoglin on the angiogenic potential of 
endothelial cells. A, HUVEC cord formation assay. The 
average cord length in the presence of endoglin-Fc (Eng-Fc) 
or a control Fc protein (both 1 μg/mL) was analyzed 
by phase-contrast microscopy. Columns, mean from a 
representative experiment; bars, SD. B and C, ECRF (B) and 
HUVEC (C) endothelial sprouting assay with endoglin-Fc or 
Fc-expressing cells (+V, VEGF stimulated). Data represent 
mean of at least three independent experiment performed 
in quadruplicate. D, metatarsal assay. Endoglin-Fc 
expression reduces vascular density compared with Fc (*, P 
= 0.047) and control (**, P = 0.0005).
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MMP-14 knockdown strongly reduces endoglin shedding 
To confirm the role of MMP-14 on endoglin shedding, we performed shRNA-mediated 
knockdown experiments. MMP-14 shRNA efficiently reduced MMP-14 expression in HUVEC and 
ECRF cells (Fig. 4A). Levels of sEndoglin were reduced up to 75% in the conditioned media of HUVEC 
cells (constructs #2, #3, and #4; Fig. 4B). A milder MMP-14 knockdown (construct #1) resulted 
in a minor decrease of sEndoglin, indicating that MMP-14–mediated endoglin shedding is very 
efficient and low levels of MMP-14 are already sufficient to mediate endoglin shedding. In ECRF 
cells, sEndoglin levels were reduced by 60% to 75% (Fig. 4C). Interestingly, a reduction of MMP-14 
and sEndoglin was accompanied by a higher membrane–bound endoglin expression (Fig. 4D). These 
data Indicate that in endothelial cells, MMP-14 is the main endoglin shedding protease.
 
  
Fig.3 MMP-14–mediated endoglin shedding in endothelial 
cells. A, Western blot analysis HUVEC conditioned medium. 
A band at similar height as recombinant human endoglin 
extracellular domain (Rec Eng) was observed. B, sEndoglin 
levels in HUVEC conditioned medium after additional protease 
inhibitors. GM6001 and Marimastat: broad-spectrum MMP 
inhibitors, Aprotinin and E64, and serine and cystein protease 
inhibitors, respectively. % versus appropriate control, n = 4 to 
6 independent experiments performed in triplicate; columns, 
mean; bars, SEM. C, real-time quantitative PCR for membrane-
type MMPs in HUVEC and ECRF cells. Columns, mean from 
representative experiment performed in duplicate; bars, SD. E, 
Endoglin (Eng; left) and MMP-14 (right) staining on sequential 
colorectal carcinoma sections. Magnification, ×400.
Fig. 4 MMP-14 knockdown in endothelial cells. A, MMP-14 
knockdown efficiency in HUVEC and ECRF cells analyzed by 
Western blot. Rh MMP-14, recombinant human MMP-14. 
sEndoglin levels in HUVEC (B) or ECRF (C) conditioned medium 
after MMP-14 knockdown. D, Western blot analysis of ECRF 
cells revealing increased membrane localized endoglin upon 
MMP-14 knockdown. All experiments were performed at least 
thrice in triplicate. Data shown are from a representative 
experiment.
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Membrane localization of MMP-14 is required for efficient endoglin shedding
To examine the endoglin shedding mechanism, we used COS-7 cells transiently transfected 
with endoglin and MMP-14 expression plasmids. After O/N starvation, sEndoglin levels were 
determined in the conditioned media. Co-expression of endoglin with mem brane localized MMP-14 
led to increased sEndoglin levels in the medium. This increase was not observed with the MMP-14 
mutant lacking the transmembrane domain MMP-14ΔTM (Fig. 5A). Accordingly, treatment with 
recombinant soluble MMP-14 did not increase sEndoglin levels (data not shown). The increase in 
endoglin shedding could be inhibited by the addition of the MMP inhibitor GM6001, but not by the 
addition of the serine protease inhibitor aprotinin. Finally, experiments showed that co-transfection 
with MMP-13, which is activated by MMP-14, did not increase endoglin shedding (data not shown).
  
Next, we studied if the expression of endoglin and MMP-14 on the same cell is required for 
efficient shedding. Cells were transfected with endoglin or MMP-14 plasmids or co-transfected with 
both. After reseeding, the cells in a 1:1 ratio sEndoglin levels were determined in the medium. Figure 
5B shows that only cotransfection of endoglin and MMP-14 leads to endoglin shedding, indicating 
that expression of endoglin and MMP-14 on the same cell is required. To further evaluate if endoglin 
directly interacts with MMP-14, we performed coimmunoprecipitation experiments. Lysates from 
endoglin and MMP-14 co-transfected cells were immunoprecipitated with MMP-14 antibodies and 
subjected to Western blot analysis for endoglin. Figure 5C shows that endoglin coprecipitates with 
MMP-14 and that addition of GM6001 increased interaction between these proteins. Together, these 
data revealed that membrane localization of MMP-14 is required for efficient endoglin shedding and 
that the shedding process involves a direct interaction between endoglin and MMP-14.
Fig .5 Endoglin and MMP-14 transfection in COS cells. A, COS 
cells were transfected with endoglin, and MMP-14 expression 
plasmids and sEndoglin levels were determined in the medium. 
EV, empty vector (pcDNA3.1); MMP-14 ΔTM, MMP-14 lacking 
the transmembrane domain; GM6001, broad-spectrum MMP 
inhibitor; Apr, aprotinin. B, COS cells were transfected with 
endoglin, MMP-14, or cotransfected (coT) expression plasmids 
and were reseeded. sEndoglin levels were determined. 
Columns, mean of three independent experiments performed 
in triplicate; bars, SEM. C, COS cells were cotransfected 
with endoglin and MMP-14. Next, immunoprecipitation 
of MMP-14 followed by endoglin Western blotting (WB) 
was performed. IP, immunoprecipitate; TL, total lysates 
before immunoprecipitation; HA, hemaglutinin tag. Green 
fluorescent protein was used as a transfection control.
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Determination of the MMP-14 cleavage site in endoglin
Because we observed that MMP-14 cleaves endoglin, releasing a fragment close to the size 
of the complete extracellular domain, we evaluated potential cleavage sites in proximity to the 
transmembrane domain. Analysis of 79 MMP-14 substrates with known cleavage site revealed that 
the majority of the cleavage sites have a flanking G-L amino acid sequence (Supplementary Fig. S4A 
and B). The endoglin sequence contains four G-L sequences located in different domains of the protein 
(Fig. 6A). One of these cleavage sites at position 586 to 587 is in close proximity to the transmembrane 
domain and would therefore lead to a cleavage product consisting of the complete extracellular 
domain. Therefore, we hypothesized that MMP-14 cleaves endoglin at position 586-587.
To investigate this possibility, we mutated amino acids 586 and 587 using site-directed 
mutagenesis. Four mutants were created, based on non-occurring amino acids in the natural 
MMP-14 substrates and keeping as much as possible the amino acid characteristics intact. The 
wild-type (WT) endoglin G-L sequence was mutated to V-P, V-H, H-P, and H-H. WT and mutant 
plasmids were cotransfected with MMP-14 in COS cells and sEndoglin levels in the medium were 
determined after O/N starvation. Mutation of these amino acids did not change the membrane 
localization of endoglin, as confirmed by FACS analysis (data not shown). Decreased sEndoglin 
levels were observed especially for the V-H, H-P, and H-H mutants and to a lesser extent with the 
V-P mutant (Fig. 6B). Western blot analysis confirmed the decrease in 80 kDa sEndoglin in the 
medium (data not shown). Taken together, these data indicate that MMP-14 cleaves endoglin at 
the G-L bond at position 586 to 587, releasing nearly full-length endoglin extracellular domain 
into the circulation.
Fig. .6 Mutation of MMP-14 cleavage site in endoglin. A, endoglin contains four 
potential cleavage site located in the extracellular domain at positions 299, 387, 
453, and 586. B, the proposed MMP-14 cleavage site was mutated using site-
directed mutagenesis and sEndoglin levels were determined in the conditioned 
media. EV, empty vector transfected cells; WT, WT endoglin. Columns, mean of 
representative experiment from three independent experiments;  
bars, SD. *, P = 0.02 versus WT; **, P < 0.002 versus WT.
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Discussion
In this study, we identify MMP-14 as the main endoglin shedding protease. We reveal that 
coexpression of endoglin with MMP-14 on the cell membrane leads to the cleavage of endoglin 
at the G-L bond at position 586, releasing the nearly complete endoglin extracellular domain. 
In addition we show that sEndoglin has antiangiogenic properties; it is capable of reducing 
spontaneous and VEGF- induced angiogenesis.
Our work shows that MMP-14 is the most abundantly expressed MT-MMP in endothelial 
cells and that knockdown of MMP-14 strongly reduces sEndoglin levels in the conditioned media 
of these cells. This process is very efficient be- cause milder shRNA-mediated knockdown of 
MMP-14 still results in high sEndoglin levels. MMP-14 belongs to the sub- class of the membrane-
type MMPs and is highly expressed by (malignant) epithelial cells, endothelial cells, and several 
other cell types. MMP-14 can directly degrade extracellular matrix components, but also cleaves 
cell surface molecules such as EMMPRIN (CD147, an inducer of MMP expression), LRP, CD44, 
and cadherins (30–33). In addition, MMP-14 is the major activator of MMP-2 and MMP-13 (34) 
and it has an important role in tube formation during angiogenesis (35). This study shows that 
the coexpression of membrane-localized MMP-14 and endoglin results in increased endoglin 
shedding and this effect depends on a direct interaction between MMP-14 and endoglin. 
Cotransfection with MMP-13, which is downstream of MMP-14 in the MMP activation cascade, 
did not show this increase. Moreover, we identified the cleavage sequence used by MMP-14 to 
shed endoglin. Analysis of natural MMP-14 substrates revealed broad substrate specificity, but 
in the majority (40%) of the cases, the cleavage site was flanked by a glycine and leucine residue. 
Endoglin contains four G-L sequences in the extracellular domain, of which one is very close 
to the transmembrane domain. Mutation of the G-L sequence at position 586 to 587 resulted 
in a dramatic decrease in sEndoglin levels and therefore indicates this site to be the natural 
cleavage site.
In this study, we observed strongly increased tissue endoglin levels in colorectal carcinoma, 
but not in premalignant adenomas, corresponding to what has previously been shown for benign 
gastric lesions (36). High endoglin expression on tumor-associated endothelial cells has been 
associated with poor survival in various types of cancers (1, 6, 13), even being prognostically 
superior to other angiogenic markers such as CD31 or CD34 (13, 36, 37). Disturbance in the 
balance between membrane-localized and soluble receptors can result in pathologic conditions. 
For example, in pregnant women suffering from preeclampsia (a severe complication during 
pregnancies characterized by hypertension and proteinuria), soluble VEGF receptor (sFlt-1) and 
sEndoglin levels are strongly increased (10). Interestingly, gene expression analysis recently 
showed that in preeclampsia patients, both endoglin and MMP-14 gene expression is upregulated 
(38). Soluble receptors are capable of scavenging circulating ligands. VEGF can be bound to sFlt, 
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whereas it has been described that endoglin can bind different TGF-β superfamily members (11, 
39), which could influence angiogenesis. Our data show that sEndoglin inhibits spontaneous cord 
formation in HUVECs, sprout formation in ECRF cells, and VEGF- induced HUVEC sprouting. In 
addition, we show that sEndoglin inhibits capillary outgrowth from fetal mouse metatarsals. Our 
data are consistent with previous findings showing that adenoviral overexpression of sEndoglin 
interferes with vascular function by decreasing perfusion of the vessels and increasing their 
permeability (17). Preliminary data from our group show that endoglin-Fc strongly reduces 
microvessel density in a mouse model of invasive ductal breast carcinoma4. The exact role of 
sEndoglin in malignancies remains unclear. Several studies revealed increased levels in cancer 
patients compared with controls (12, 14, 40), whereas other showed no increased levels (41–44). 
On the other hand, our results from CRC patients support an anti-angiogenic role of sEndoglin 
because we observed lower circulating sEndoglin levels in these patients and would therefore 
suggest higher angiogenic activity in these patients. In line with our results, changes of sEndoglin 
levels in the circulation reported previously are generally low. This indicates that sEndoglin in 
the circulation cannot be used as a powerful marker of angiogenic activity in cancer patients. 
However, local regulation of endoglin shedding could result in dramatic changes in sEndoglin 
levels in the tumour microenvironment and therefore have stronger effects on the angiogenic 
potential of tumor-associated endothelial cells. Local up-regulation of endothelial MMP-14 
expression will increase sEndoglin, decrease membrane localized endoglin, and transform the 
endothelium to a quiescent state. This notion is supported by our immune-staining results, 
showing the absence of endoglin expression with high MMP-14 staining on endothelial cells 
and vice versa.
Recent data showed a cross-talk between the TGF-β signalling pathway and the VEGF-induced 
angiogenesis (45). Furthermore, we have shown that combined TGF-β and BMP-9 treatment 
synergistically induces angiogenesis (46). Although the exact mechanism is subject of ongoing 
research, we speculate that scavenging of ligands such as BMP-9 and/or TGF-β by sEndoglin can 
disturb this delicate balance required for efficient angiogenesis and the normalization of blood 
vessels. Together, these data indicate an important role for sEndoglin in regulating (tumour) 
angiogenesis and highlights the importance of the identification of the endoglin shedding 
protease.
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Materials and Methods
Patient material
Preoperative and 3 months postoperative citrate plasma samples (n = 48 and n = 25, 
respectively) and tissue specimens (n = 191) from patients undergoing resection for primary CRC 
at the Department of Oncologic Surgery, Leiden University Medical Centre, were collected as 
described before (18, 19). In addition, plasma samples were collected from 22 healthy volunteers 
and an additional group of 74 healthy controls previously described (20). Colorectal adenomas 
(n = 82) were removed endoscopically at the Department of Gastroenterology-Hepatology. Tissue 
was homogenized and protein concentrations were determined as previously described (18). 
For immunohistochemistry, tumour tissue and adjacent normal mucosa were collected, fixated, 
dehydrated, and embedded in paraffin. Human samples were used according to guidelines of the 
Medical Ethics Committee of the Leiden University Medical Centre.
Cell culture
COS cells were purchased from the American Type Culture Collection and maintained in DMEM, 
supplemented with 10% fetal bovine serum (FBS) and penicillin/ streptomycin. Human umbilican 
vein endothelial (HUVEC) cells were isolated from umbilical cords as described before (21). Cells 
were maintained in M199 medium supplemented with 20% FBS, penicillin/streptomycin, heparin 
(Leo Pharma), and bovine putitary extract. ECRF cells (an immortalized HUVEC cell line; ref. 22) 
were a gift from Dr. R. Fontijn, Amsterdam Medical Center (Amsterdam, the Netherlands) and were 
cultured in HUVEC medium in fibronectin-coated cell culture flasks.
Endoglin and sEndoglin ELISA
Endoglin levels in tissue homogenates (5 μL) and cell culture media (50 μL) were determined 
essentially according to the DY1097 human endoglin ELISA (R&D Systems). For sEndoglin 
determination in plasma samples, the capture antibody was replaced by mouse monoclonal anti-
endoglin (clone E9, Cell Sciences). Detailed information can be found in Supplementary Materials 
and Methods.
Immunohistochemistry
To determine tissue localization of endoglin, immunohistochemistry was performed as 
previously described (23). Representative photomicrographs were taken with a Nikon Eclipse E900 
microscope equipped with a Nikon DXM1200 digital camera. Detailed information can be found in 
Supplementary Materials and Methods.
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Cord formation assay
HUVEC cells (3 × 103 cells/well) were resuspended in Medium 199 containing 4% FBS, 1 μg/
mL endoglin extracellular domain/Fc chimera (endoglin-Fc), or 1 μg/mL Fc protein and seeded on 
growth factor reduced Matrigel coated (BD Biosciences) 96-well plates. After 16 hours, photographs 
were acquired with a phase contrast microscope in four different fields. The length of branches 
was quantified by automated image analysis using the Olympus analysis software.
Endothelial sprouting assay
Endothelial sprouting assays were performed in the presence or absence of endoglin-Fc (1 
μg/mL; R&D Systems) or Fc protein (1 μg/mL) as described before (24, 25). In addition, ECRF and 
HUVEC cells were infected with lentiviral vectors encoding endoglin-Fc or Fc only. Expression of the 
proteins was examined by Western blot using anti-Fc antibodies (dilution, 1:1,000; R&D Systems). 
Angiogenic activity was analyzed as described above. ECRF spheroids form spontaneous sprouts in 
collagen and were therefore not vascular endothelial growth factor (VEGF) stimulated.
Metatarsal assay
Metatarsals were dissected from 17-day-old albino fetal mice and the assay was performed as 
described before (26). Bones were transduced with endoglin-Fc or endoglin-Fc adenovirus at 1 × 
106 plaque-forming unit at day 4. After stimulation with 50 ng/mL VEGF for 7 days, vessel formation 
was visualized by anti-CD31 staining. Vascular density was quantified by automated image analysis 
with Image J. Animal experiments were approved by the Dutch animal ethics committee.
Protease inhibitor experiments
HUVEC cells were seeded in 24-well plates and treated with 0 to 160 ng/mL recombinant human 
MMP-14 (Chemicon) or with proteinase inhibitors: 20 μmol/L E64 (cystein protease inhibitor), 10 μg/
mL Aprotinin (serine protease inhibitor, both Sigma- Aldrich), 1 μmol/L GM6001 (broad-spectrum 
MMP inhibitor), 10 μmol/L Marimastat (kindly provided by British Biotech Pharmaceuticals), 100 
nmol/L MMP-2/MMP-9 inhibitor, 100 nm MMP-13 inhibitor, or 1 μmol/L specific MMP-3 inhibitor 
(all Calbiochem). Serum-free M199 medium and 0.1% DMSO were included as controls. The 
percentage inhibition versus the appropriate control was calculated.
Quantitative real-time PCR
To analyze the expression of membrane-type MMPs, total RNA was isolated from HUVEC 
and ECRF cells using Nucleospin RNA columns (Macherey-Nagel) followed by cDNA synthesis 
using Revertaid first strand cDNA synthesis kit (Fermentas). Quantitative PCR was performed as 
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previously described (27), according to the manufacturers’ protocol, using MMP-14, MMP-15, 
MMP-16, MMP-17, MMP-24, and MMP-25 primers ordered at the supplier (Applied Biosystems).
Knockdown experiments
Lentiviral constructs expressing short hairpin RNAs (shRNA) targeting human MMP-14 were 
obtained from the Sigma Mission shRNA library. HUVEC and ECRF cells were infected with the 
lentiviral knockdown vectors, and 1 week after infection, the cells were plated in 24-well plates. 
Knockdown was confirmed by MMP-14 Western blot (Abcam; dilution, 1:2,000). After O/N 
starvation, serum-free medium was collected and subjected to sEndoglin ELISA.
Transfections
COS cells were transfected with plasmids encoding HA-tagged endoglin (28), full-length 
MMP-14, MMP-14 lacking the transmembrane domain (MMP- 14ΔTM, both kindly provided by 
Dr. R. Hanemaaijer, TNO Quality of life BioSciences, Leiden, the Netherlands), or empty vector 
in triplicate. DNA (0.4 μg) was transfected using Lipofectamin, according to the manufacturers’ 
protocol (Invitrogen). Twenty-four hours after transfection, cells were serum starved for 16 hours 
and sEndoglin levels were determined by ELISA. To examine the interaction between endoglin and 
MMP-14, COS cells were transfected with endoglin and MMP-14 plasmids as described above in 
six-well plates. After 48 hours, cells were lysed and incubated with rabbit monoclonal MMP-14 
antibodies (Abcam; 1:100) for 3 hours at 4°C, followed by protein-A Sepharose beads for another 
30 minutes at 4°C. After extensive washing, samples were subjected to SDS-PAGE and Western blot 
detection with MMP-14 (Abcam; dilution, 1:2,000) and endoglin (R&D; dilution, 1:500) antibodies.
Mutation of MMP-14 cleavage sequence in endoglin
The predicted MMP-14 cleavage site in endoglin [glycine-leucine (G-L) amino acid 586-7] was 
mutated into V-P, V-H, H-P, and H-H variants. PCR-mediated overlap extension method was used 
for site-directed mutagenesis using the pDisplay-endoglin plasmid as a template (28). Detailed 
information can be found in Supplementary Materials and Methods. The obtained constructs 
were sequenced and transfected into COS cells. Transmembrane localization of endoglin mutants 
was confirmed by fluorescence-activated cell sorting (FACS). After O/N starvation, medium was 
collected and subjected to sEndoglin ELISA.
Statistical analysis
Differences were calculated using the t test, Mann-Whitney U test, or the Wilcoxon signed-rank 
test using the SPSS 14.0 statistical package. P values of <0.05 were considered statistically significant.
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Supplementary Information
Supplementary materials and methods
Endoglin and sEndoglin ELISA
96 well plates (MaxiSorp, Nunc, Glostrup, Denmark) were coated with mouse monoclonal ant 
human endoglin antibodies (R&D Systems, 2 μg/ml in PBS) overnight at 4°C. Plates were washed 
with PBS containing 0.05% Tween-20 (Merck, Darmstadt, Germany) after each step. Nonspecific 
binding was blocked with PBS containing 5% Tween-20, 0.05% NaN3 for 2 h at room temperature 
(RT). Samples (5 μl tissue homogenates or 50 μl cell culture media) or standard (0-4 ng/ml 
recombinant human endoglin, R&D Systems) diluted in PBS with 1% bovine serum albumin (BSA, 
Sigma, Germany) were incubated for 2h at RT. Immunodetection was performed with biotinylated 
goat anti-human endoglin antibodies (2 μg/ml in PBS/1% BSA, R&D systems) for 2h at RT, and 
a substrate reagent pack according to the manufacturers’ protocol (R&D Systems). Values were 
calculated in ng/ml for cell-culture media and in ng/mg total protein for tissue samples. The ELISA 
was validated by western blot analysis and spiking with a fixed amount of recombinant human 
endoglin. For determination of endoglin levels in citrate plasma samples the capture antibody 
was replaced by mouse monoclonal anti-endoglin (clone E9, Cell Sciences, Canton, MA, USA). The 
standard curve was diluted in PBS containing 40 mg/ml human serum albumin (Sigma) to correct for 
background absorption. The ELISA was validated using a serially diluted plasma samples and spiking 
of these samples with a fixed amount recombinant human endoglin, which accordingly increased 
the ELISA signal (data not shown). The ELISA was performed and validated as described above. 
Immunohistochemistry
For immunohistochemical staining slides were deparaffinized, rehydrated and antigen retrieval was 
performed by boiling in 0.01M sodium citrate buffer pH 6.0. Slides were incubated overnight (O/N) at RT with 
unlabeled primary antibodies: mouse monoclonal anti-pan-cytokeratin (1:1000), mouse monoclonal anti-
vimentin (1:400, both Santa Cruz Biotechnologies, Santa Cruz, USA), mouse monoclonal anti-CD31 (1:400, 
Dako, Glostrup, Denmark), mouse monoclonal anti-MMP-14 (1:1600), or biotinylated goat-anti human 
endoglin (1:200, both R&D systems). Immunodetection was performed with goat anti-mouse antibodies 
and streptavidin-biotin complex (all Dako). Staining was visualized with diaminobenzidine and H2O2. 
Endothelial sprouting assays 
To analyze the angiogenic potential, endothelial sprouting assays were performed. In short, 
endothelial spheroids were prepared (750 cells/spheroid) and after overnight incubation embedded 
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in a collagen type-1 matrix. HUVEC spheroids were stimulated with 50 ng/ml vascular endothelial 
growth factor (VEGF, R&D systems), which stimulates endothelial sprouting, in the presence or 
absence of endoglin-Fc (1 μg/ml, R&D systems) or Fc protein (1 μg/ml) as a control. After overnight 
incubation sprout length was determined as described before (1, 2). In addition ECRF and HUVEC 
cells were infected with lentiviral vectors encoding Endoglin-Fc or Fc only. Expression of the 
constructs was examined by western blot using anti-Fc antibodies (dilution 1:1000, R&D systems). 
Angiogenic activity was analyzed as described above. ECRF spheroids form spontaneous sprouts 
once embedded in collagen, and were therefore not VEGF stimulated.
Mutation of of MMP-14 cleavage sequence in endoglin
The predicted MMP-14 cleavage site in endoglin sequence G-L (aa 586-7) was mutated 
into V-P, V-H, H-P and H-H variants. PCR-mediated overlap extension method was used for 
site-directed-mutagenesis. 
In brief, two flanking primers: for 5’-cccaaggacacttgtagcccg-3’, rev 5’-acgtggcttcttctgccaaagc-3’ 
and two mutagenic primers per construct: 
V-P: for 5’-aagcaaagtccccgtcctgccc-3’, rev 5’-caggacggggactttgcttgtg-3’; 
V-H: for 5’-aagcaaagtccacgtcctgccc-3’, rev 5’-caggacgtggactttgcttgtg-3’; 
H-P: for 5’-aagcaaacaccccgtcctgcccg-3’, rev 5’-caggacggggtgtttgcttgtgc-3’;
H-H: for 5’-aagcaaacaccacgtcctgcccgc-3’, rev 5’-gcaggacgtggtgtttgcttgtgc-3’ were used for 
generation of intermediate PCR products (two per construct) with overlapping regions containing 
the desired mutations (mutations introduced into nucleotide sequence are underlined). pDisplay-
endoglin plasmid was used as a template (3). The two PCR fragments per construct were mixed 
and used for a second round of PCR with flanking primers. Subsequently the obtained products 
were digested and cloned into SacI/SalI site in pDisplay-endoglin vector leading to an exchange 
of wildtype G-L site with the desired mutations. All PCR reactions were performed using Phusion 
High-Fidelity PCR Master Mix (Finnzymes, Espoo, Finland) and 98°C-30”, (98°C-5”, 60°C-20”, 
72°C-15”) x 35, 72°C-5’ conditions. The obtained constructs were sequenced and used for 
transfection experiments. Wild type or endoglin mutants were transfected into COS cells in 6 
well plates (250.000 cells/well). Transmembrane localization of endoglin mutants was confirmed 
by flow cytometry (FACS). After O/N starvation medium was collected and sEndoglin levels were 
determined by ELISA as described above.
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Supplemental Fig 1. Endoglin levels in colorectal cancer A, Endoglin levels in colon tissue homogenates determined 
by ELISA. Levels are increased in carcinomas, compared to normal tissue and premalignant adenomas. B, Box-whisker 
plots showing levels of soluble endoglin in citrate plasma samples in colorectal cancer patients pre- and 3 months 
post-operation, and healthy controls. Levels were determined by ELISA. Soluble endoglin levels are lower in CRC patients 
before operation compared to healthy volunteers. (Healthy versus pre-operation, P<0.0001). C, Soluble endoglin levels in 
CRC patients show no relation with Dukes stage. 
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Supplemental Fig 2.HUVEC endothelial sprouting assay with Endoglin-Fc HUVEC spheroids were prepared, embedded in 
collagen and stimulated with 50 ng/ml VEGF in the presence of control Fc protein or Endoglin-Fc (both 1 μg/ml). Sprout 
length was determined from at least 10 spheroids per experimental condition after O/N incubation. Data represent 
average sprout length ± SD from a representative experiment.
Supplemental Fig 3. Influence endoglin-Fc on proliferation endothelial cells. HUVEC and ECRF cells were transduced with 
Fc- or Endoglin Fc expressing lentivirusses. Proliferation was determined using the MTS assay. Data show no effect of 
Endoglin-Fc on proliferation of HUVEC (A) or ECRF cells (B). 
Matrix Metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumour angiogenesis
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5Supplemental Fig.4 . Determination MMP-14 cleavage sequence in endoglin A, Analysis of amino acids flanking the 
MMP-14 cleavage site in natural substrates. 79 natural MMP-14 substrates with known cleavage sites were analyzed. 
Occurrence of the amino acids flanking the cleavage site is shown in % of total. B, Endoglin amino acid sequence 
with potential MMP-14 cleavage sites based on the consensus G—L sequence indicated by arrows (G-L sequences). 
Transmembrane domain is indicated in bold
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Abstract
Pre-eclampsia, characterized by hypertension and proteinuria, affects approximately 3–5% 
of all pregnancies worldwide and is a major cause of maternal and fetal morbidity and mortality. 
Maternal endothelial dysfunction is associated with disease pathogenesis. Recently, reports have 
shown that elevated levels of circulating soluble fms-like tyrosine kinase 1 [sFlt1] and soluble 
endoglin [sEng] are associated with pre-eclampsia. Flt1 is a receptor for vascular endothelial 
growth factor receptor [VEGF], whereas endoglin [Eng] is an auxiliary receptor for transforming 
growth factor-β [TGF-β] super-family members. Both signalling pathways modulate angiogenesis 
and are involved in vascular homeostasis. Increased levels of sFlt1 and sEng dysregulate VEGF and 
TGF-β signalling respectively, resulting in endothelial dysfunction of maternal blood vessels. This 
review summarizes our current knowledge of Flt1 and endoglin and soluble forms in pre-eclampsia. 
Furthermore, it highlights the predictive and early-screening value of circulating levels of sFlt1 and 
sEng for the risk of developing pre-eclampsia
Keywords: Angiogenesis, Endothelial dysfunction, Pre-eclampsia, sFlt1, Soluble endoglin, 
TGF-β, VEGF
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Introduction
Pre-eclampsia is a pregnancy-speciﬁc syndrome that develops after mid-gestation and 
is characterized by de novo hypertension [systolic blood pressure P140 mm Hg or diastolic 
blood pressure P90 mm Hg] accompanied by new onset proteinuria deﬁned as 300 mg of 
protein/24 h or more after 20 weeks of gestation [1]. To date, the clinical incidence of pre-eclampsia 
is 3–5% of pregnancies, which in some instances can lead to complications such as maternal renal 
failure, hemolysis, elevated liver enzymes and low platelets [HELLP], seizures, liver failure, stroke 
or death [2–4]. For the fetus, pre-eclampsia can result in intrauterine growth restriction [IUGR], 
preterm delivery and death [2–4]. Pre-eclampsia resolves after placental delivery; however, women 
with a history of pre-eclampsia are at higher risk of developing cardiovascular complications later 
in life [5,6].
The etiology of pre-eclampsia remains incompletely understood. Its origin lies in defective 
placentation resulting in the release of placenta-derived angiogenic modulators into the maternal 
circulation. Studies have shown that levels of soluble fms-like tyrosine kinase 1 (sFlt1) and soluble 
endoglin (sEng) are elevated in the blood of pregnant women suffering from pre-eclampsia [7–9]. 
Flt1 is a vascular endothelial growth factor [VEGF] receptor and also known as VEGF receptor 1 
(VEGFR1), while endoglin is a co-receptor for transforming growth factor (TGF)-β super-family 
members. Both receptors are highly expressed on endothelial cells and are involved in maintaining 
vascular homeostasis. The aberrantly large quantities of these placenta-derived soluble receptors 
in pre-eclamptic women can cause maternal endothelial cell dysfunction and thereby the resulting 
clinical symptoms of pre-eclampsia.
Besides the contribution of these anti-angiogenic factors, inﬂammatory responses and 
metabolic syndromes are also considered to be associated with the etiology of pre-eclampsia [1,10]. 
In this review we focus on discussing the roles of placenta-derived sFlt1 and sEng in endothelial 
dysfunction and their potential as biomarkers to assess the risk of developing pre-eclampsia.
The biology of sFlt1 and sEng
The biology of sFlt1
VEGF is a multifunctional molecule that is involved in numerous biological processes during 
postnatal development and in both physiological and pathological conditions. The mammalian 
VEGF family is composed of VEGF- A, VEGF-B, VEGF-C VEGF-D and placenta growth factor (PlGF). 
The predominant form, VEGF-A, is alternatively spliced in different isoforms which have pro- and 
anti- angiogenic properties [11]. Three types of VEGF receptors are activated upon ligand binding, 
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namely Flt1, Flk1 (VEG- FR2) and Flt4 (VEGFR3). Co-receptors, such as neuropilins and heparan 
sulfate proteoglycans modify VEGFR activities in diverse fashions [12–16]. Flt1 binds VEGF-A, -B 
and PlGF, whereas Flk1 binds to VEGF-A and -C and Flt4 binds VEGF-C and -D [17].
VEGFs and their receptors are crucial for vascular development and lymphatic vessel formation. 
VEGFRs consist of an extracellular domain, a trans-membrane domain and an intracellular protein 
tyrosine kinase domain. Ligand binding leads to VEGFR dimerization and activation of the tyrosine 
kinase activity, upon which diverse intracellular signalling pathways are initiated that modulate 
vascular biological functions. Flt1 and Flk1 mediated signalling events regulate endothelial cell 
function, such as endothelial cell proliferation, migration, tube formation and branching [18]. 
VEGFR3 signalling is mainly important for lymphatic vessel development [19].
The importance of Flk1 and Flt1 in vascular function became apparent from the analysis of 
knockout mice. Depletion of either Flt1 or Flk1 in mice resulted in embryonic lethality due to 
vascular malfunction, but with distinct differences in the phenotypes. Flt1 knockout mice showed 
irregular vascular organization due to endothelial cell overgrowth, whereas Flk1 knockout embryos 
had an absence of blood vessels and blood islands [20,21]. The extracellular domain of both 
Flk1 and Flt1 consists of seven extracellular immunoglobulin (Ig) homology domains. The 2nd Ig 
homology domain is sufﬁcient for VEGF binding to Flt1, while Flk1 requires both the 2nd and 3rd Ig 
homology domains for adequate VEGF binding [22–25]. VEGF-A has a higher afﬁnity for Flt1 than 
Flk1, which may be explained by the difference in ligand-binding domains. Yet the kinase activity of 
Flt1 in response to VEGF-A binding is weak [26–28], possibly because the juxtamembrane domain 
of the intracellular domain represses kinase activation [29]. Interestingly, mice deﬁcient in the 
kinase domain of membrane-anchored Flt1, but with an intact ligand binding domain, revealed 
no defects in vascular development, suggesting the kinase activity of Flt1 is dispensable for its 
role in vasculature formation [30]. Taken together, these data suggest that Flt1 may function as 
a decoy receptor for VEGF-A, thereby regulating VEGF-A bio-availability for Flk1 [18]. PlGF binds 
directly to Flt1 and ampliﬁes VEGF-driven angiogenesis through Flk1 [31]. PlGF can outcompete 
VEGF-A for the binding of Flt1, indirectly promoting VEGF-A/Flk1 signalling by increasing the bio-
availability of VEGF-A for Flk1 [32,33]. Nonetheless, other experimental evidence indicates that Flt1 
not only serves to ﬁne-tune the VEGF-Flk1 axis, but is also directly involved in signal transduction. 
VEGF-A and PlGF induce Flt1 receptor phosphorylation and downstream signalling [31]. Loss of Flt1 
kinase activity shows deﬁcient inﬂammation and angiogenesis in various disease models such as 
atherosclerosis, choroidal neovascularization, lung metastasis and rheumatoid arthritis [34–37]. 
In addition, Flt1 can act as a negative regulator for endothelial tip cell sprouting and branching 
morphogenesis in zebra ﬁsh system [38]. Up to date, the apparent function of Flt1 in angiogenesis 
is evident, but the exact signalling of Flt1 remains to be elucidated.
Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia
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The transmembrane Flt1 protein is encoded by 30 exons; sFlt1 is generated through alternative 
splicing (Fig. 1A) and consists of exons 1 through 13 with an intron 13 derived encoded carboxy 
tail [39–41]. sFlt1 and Flt1 share the ﬁrst six Ig-homology domains, which are essential for ligand 
binding [42,43]. The splicing of sFlt1 is possibly regulated by hypoxia and histone jumonji domain-
containing demethylases [44–46]. Recent studies have described additional splice variants of sFlt1, 
(termed as sFlt1-v2,-v3,-v4). While all share an extracellular domain followed by a short C-terminal 
tail, they differ in composition [47,48]. Different from the other variants, sFlt1-v2 has been reported 
to be highly expressed in placental tissues as a non-endothelial cell form of sFlt1 [48,49]. However 
the relevance of this secreted sFlt1 on placenta function in vivo has not yet been investigated. In 
addition to alternative splicing, a ligand-induced proteolytically cleaved version of soluble Flt1 has 
been found to be expressed by leukemic cells [50]. Whether proteolytic shedding also contributes 
to sFlt1 in pre-eclampsia is not known.
Fig.1A. Different transcripts of sFlt1 and the generation of sFlt. The transmembrane VEGF receptor, including the 
extracellular domain, transmembrane domain (TM), and intracellular catalytic domain (IntrD), is encoded by all 30 
exons of the FLT1 gene. The sFLT1 proteins are the result of alternative splicing, generating a secreted form of FLT1 with 
a unique 31 amino acid (sFLT1-v1) or 28 amino acid (sFLT1-v2) c-terminal tail. In human placenta, 80% of FLT1 expression 
corresponds to transcript sFLT1-v2, 15% to sFLT1-v1, and 5% to the transmembrane version.
The transmembrane Flt1 protein is encoded by 30 exons; sFlt1 is generated through alternative 
splicing (Fig. 1A) and consists of exons 1 through 13 with an intron 13 derived encoded carboxy 
tail [39–41]. sFlt1 and Flt1 share the ﬁrst six Ig-homology domains, which are essential for ligand 
binding [42,43]. The splicing of sFlt1 is possibly regulated by hypoxia and histone jumonji domain-
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containing demethylases [44–46]. Recent studies have described additional splice variants of sFlt1, 
(termed as sFlt1-v2,-v3,-v4). While all share an extracellular domain followed by a short C-terminal 
tail, they differ in composition [47,48]. Different from the other variants, sFlt1-v2 has been reported 
to be highly expressed in placental tissues as a non-endothelial cell form of sFlt1 [48,49]. However 
the relevance of this secreted sFlt1 on placenta function in vivo has not yet been investigated. In 
addition to alternative splicing, a ligand-induced proteolytically cleaved version of soluble Flt1 has 
been found to be expressed by leukemic cells [50]. Whether proteolytic shedding also contributes 
to sFlt1 in pre-eclampsia is not known. 
sFlt1 sequesters circulating VEGF-A, VEGF-B and PlGF [31,42] (Fig.1B). In addition, it can form 
a stable receptor complex with the extracellular domain of Flk1, thereby interfering with Flk1 
dimerization and subsequent intracellular signalling [43]. Due to the neutralizing function of sFlt1 
for its natural ligands, sFlt1-based trap has been developed for preclinical purpose, which contains 
the ﬁrst three Ig-homology domains of Flt1 [51]. sFlt1 and the sFlt-based trap have been shown 
to act as negative regulators for endothelial function [52] and angiogenesis in several pre-clinical 
studies [53–56]. Notably, Flt1 and sFlt1 are highly expressed in placental tissues, particularly in the 
trophoblast [49,57–59] and can be released into the maternal circulation [60].
Fig.1B. VEGF/Flt1 signalling and effect of sFlt1 thereon. VEGF induces Flt1 receptor dimerization. As a result of Flt1 
receptor activation, downstream signalling pathways are indirectly or directly activated, such as p38 mitogen-activated 
protein kinases (p38 MAPK), focal adhesion kinase (FAK), phosphoinositide 3-kinase (PI3K), endothelial nitric oxide 
synthase (eNOS). The VEGF/Flt1 system regulates endothelial cell migration, proliferation and permeabilization. 
Increased sFlt1 levels in the circulation can sequester VEGF locally and thereby interfere with VEGF-induced endothelial 
function.
Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia
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The biology of sEng
Endoglin (CD105) is a membrane-bound glycoprotein which functions as an auxiliary/co-
receptor for TGF-β super-family members [61]. The TGF-β superfamily includes TGF-βs, activins 
and bone morphogenetic proteins (BMPs); they affect not only vascular cells, but also many other 
cell types. The TGF-β superfamily signals via complexes of type I and type II serine/threonine kinase 
receptors [62].
Endoglin contains an extracellular domain, a single transmembrane domain and a short 
cytoplasmic domain [63] (Fig. 2A). The extracellular domain of endoglin harbors a signal peptide, 
an orphan domain and a zona pellucida (ZP) domain. The ZP domain is involved in endoglin 
oligomerization; the extracellular and intracellular domains mediate heteromeric interactions 
with TGF-β receptors I and II (TβRI/II) [64]. TGF-β only binds to endoglin in complex with TβRII, 
whereas BMP-9 directly binds to the orphan domain of endoglin [65,66]. Endoglin is closely related 
to the TGF-β co-receptor betaglycan. Endoglin binds to TGF-β1 and β3, while betaglycan interacts 
with all three TGF-β isoforms [67]. In part, the cell type-speciﬁc effects of TGF-β are mediated 
by the auxiliary receptors that demonstrate differential expression patterns and interact with 
different afﬁnity to TGF-β isoforms. Due to differential mRNA splicing, two membrane-bound 
forms of endoglin have been described: long-form endoglin (L-endoglin) and short-form endoglin 
(S-endoglin). L-endoglin is the most abundantly expressed isoform [68,69]. Apart from the 
membrane-bound forms, endoglin can exist as a soluble form (sEng) (Fig. 2A).
Endoglin is expressed at low levels in quiescent endothelial cells, but is highly expressed in 
proliferating endothelial cells [70]. In addition to endothelial cells, endoglin is also expressed 
in syncytiotrophoblasts [70,71], stromal cells [71,72] and hematopoietic cells [73] of full term 
placentas. Endoglin expression can be induced and regulated by hypoxia, TGF-β1, TGF-β3 and 
BMP-9 [66,75,76]. Mouse aortic endothelial cells (MAEC) isolated from endoglin null mice display 
reduced proliferation, migration, VEGF secretion and decreased endothelial nitric oxide synthase 
(eNOS) expression [77–79]. Lebrin et al. also found that endothelial cells derived from endoglin 
null embryos demonstrated impaired proliferation in culture [61]. Up-regulation of endoglin has 
been shown to protect endothelial cells from TGF-β1-induced apoptosis [79]. The importance of 
endoglin in vascular biology was demonstrated by the embryonic lethality of mice deﬁcient in 
endoglin due to defective angiogenesis in vivo [80,81]. Mutations in endoglin cause the autosomal 
dominant disease hereditary hemorrhagic telangiectasia [HHT] type I. HHT is a vascular dysplasia 
disease characterized by the development of mucocutaneous telangiectasias and arteriovenous 
malformations in the brain, lungs, liver and gastrointestinal tract. Endoglin heterozygous mice 
exhibit vascular lesions due to capillary malformation, resembling HHT type 1 [81–83]. Thus, 
endoglin has a pivotal role in endothelial cell function [74,84].
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Levels of sEng are elevated in the sera of pre-eclamptic patients [7,9] as well as in colorectal 
and breast cancer patients [85,86], which results in abnormal angiogenic responses. It has been 
reported that sEng is generated via metalloproteinase (MMP)-14 (MT1-MMP) mediated shed- ding 
of membrane bound endoglin in colorectal cancer, at the site close to the transmembrane domain 
of endoglin [86] (Fig.2A). This cleaved sEng contains the entire extracellular domain, retaining the 
ability of binding to TGF-β and BMP-9 [9,66]. Thus, local shedding of endoglin is a potential source of 
sEng, which subsequently can affect tumor angiogenesis in the tumor microenvironment. MMP14 
was recently shown to be involved in the generation of sEng in pre-eclampsia patients. MMP14 
was expressed by syncytiotrophoblasts and interacted with endoglin within the pre-eclamptic 
placenta. Challenging trophoblasts with MMP14 inhibitors attenuated the production of sEng [87].
Fig. 2A. Different forms of endoglin and the generation of sEng. Endoglin is a 90kDa protein that contains a large 
extracellular domain and short intracellular domain that lacks an enzymatic motif. Endoglin is a dimeric protein and 
monomers are connected by a disulphide bridge. Several sub-domains have been identiﬁed, including orphan domain 
and TGF-β/BMP binding domains, receptor interacting domains. The long form (L; yellow) and the soluble form (S; gray) 
forms differ in the size of their intracellular domain. At its carboxy terminus endoglin has a PDZ interaction motif. sEng 
consists of part of the extracellular domain of endoglin; it lacks a transmembrane and intracellular domain. sEng can be 
generated by shedding of membrane bound endoglin possibly via MMP14 activity. It is not excluded that endoglin can be 
cleaved by any other unknown enzymes because it contains multiple potential proteolytic cleavage site.
Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia
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It has been shown that sEng inhibits angiogenesis in ex vivo assays, such as the fetal mouse 
metatarsal [86] and chick chorioallantoic membrane assay [88]. sEng can exert anti-angiogenic 
effects on endothelial cells by modulating TGF-β/BMP signalling [9,86,88,89] (Fig. 2B); Studies in 
vitro have shown that sEng interferes with TGF-β signalling and eNOS activity [9]. The explanation 
for these ﬁndings could be that sEng functions as a scavenger for circulating ligands such as 
TGF-β1/3 and BMP-9 [88], and thereby affects the vascular balance maintained by TGF-β/BMP 
signalling. It is also possible that by binding to TGF-β receptors, sEng interferes with the availability 
of TGF-β receptors for membrane-bound endoglin [88].
Endothelial cell dysfunction with increased levels of sFlt1 and 
sEng in pre-eclampsia
Angiogenesis is tightly controlled by pro- and anti-angiogenic factors. An imbalance in this process can 
lead to excessive or insufﬁcient angiogenic responses, which has been associated with different diseases. 
Studies in humans and animal models have demonstrated that TGF-β and VEGF signalling play crucial 
roles in maintaining physiological vascular homeostasis by modulating endothelial cell function [90–92].
Initial insights from human studies
In 2003, the ﬁrst studies were published that clearly demonstrated increased sFlt1 levels in 
the circulation of pre-eclamptic women as to compared normotensive pregnant women [8,92]. 
Also, free VEGF and PlGF levels were lower in the blood of pre-eclamptic patients compared to 
Fig.2B. TGF-β/BMP/endoglin signalling and the effect 
of sEng thereon. TGF-β and BMP bind to heteromeric 
type II/type I serine/threonine kinase receptor 
complexes. Endoglin is an auxillary receptor and can 
interact with, and modulate ligand binding to type 
II/type I receptor complexes. The active receptor 
complex can activate intracellular Smad pathways 
and non-Smad pathways: early response kinase 
(ERK); phosphoinositide 3-kinase (PI3K); p38 mitogen-
activated protein kinases (p38 MAPK), endothelial 
nitric oxide synthase (eNOS). In the endothelial cell, 
TGF-β/ BMP signalling modulates cell migration and 
proliferation. sEng functions as a negative regulator 
for TGF-β/BMP signalling in endothelial cells.
136
Chapter 6
normotensive pregnancies [8,93], conﬁrming the antagonistic effects of sFlt1 on the VEGF system. 
Subsequently, many other studies have conﬁrmed these ﬁndings with the agreement that sFlt1 
holds predictive value reviewed by Lapaire [94]. Most importantly, the increase in sFlt1 was 
detected before the onset of pre-eclampsia. A human study performed by Levine and colleagues 
has shown the signiﬁcant predictive value for sFlt1 [7]. Sera were analyzed for sFlt1 by ELISA from 
a total number of 120 women with pre-eclampsia and matched healthy pregnant women during 
their pregnancy. Women who developed pre-eclampsia showed higher levels of sFlt1 compared 
with the control group. An increase in sFlt level was detected 5 weeks before the clinical onset 
of pre-eclampsia. Meanwhile, PlGF concentration was signiﬁcantly lower in women who later 
developed pre-eclampsia compared to controls [95]. Because the increase of sFlt1 is accompanied 
with a decrease in PlGF levels, the angiogenic balance was most likely shifted toward inhibition in 
women with a high risk of developing pre-eclampsia. This subverted anti-angiogenic status in pre-
eclampsia patients is further supported by a renal biopsy study, which illustrated mild glomerular 
endotheliosis in normal pregnancy, but severe lesions in pre-eclampsia [96].
A landmark study, performed by Venkatesha et al., showed that the expression of sEng is 
elevated both in placenta tissues as well as serum of pre-eclamptic patient compared to controls. 
The high levels of sEng in pre-eclamptic patients were dramatically reduced after placental delivery, 
indicating that the increase in sEng is pregnancy-associated. Similar to the role of excessive sFlt1 in 
kidney dysfunction, elevated sEng levels induce glomerular endotheliosis [9,97].
Insights from rodent studies
Many of the clinical symptoms of pre-elampsia can be recapitulated in animal models. As the 
mouse placenta shares molecular and structural similarities with the human placenta reviewed 
by Rossant [98], a variety of rodent models have been proposed for pre-eclampsia studies. These 
models include the sFlt1/sEng induction model, the reduced uterine perfusion pressure (RUPP) 
model and the renin angiotensin abnormalities (AT-AAs) model.
Rats administered with adenoviral sFlt1 showed a clear increase in blood pressure and 
proteinuria recapitulating major features observed in human patients [8]. Similar responses were 
observed after intravenous injection of sFlt1 protein into mice [99]. Introduction of adenoviral 
sEng into pregnant rats also resulted in a signiﬁcant increase in mean arterial pressure, mild renal 
endotheliosis and vascular damage in the placenta [9,100]. Furthermore, the combination of 
adenoviral induction of sEng and sFlt1 in pregnant rats increased complications of pre-eclampsia, 
including infarction at the maternal-fetal interface, fetal growth restriction, hepatic ischemia and 
necrosis [9]. Reversely, neutralization of free sFlt1 in pre-eclamptic mice by the increase of VEGF 
or PlGF ameliorated the pre-eclampsia syndrome [99,101].
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In the RUPP model, the bilateral utero-ovarian arteries are ligated in pregnant animals. This 
results in the development of pre-eclampsia-like symptoms such as hypertension, proteinuria 
and glomerular endotheliosis [102]. This technique has been applied in different animals 
including rabbits [103], dogs [104,105], monkeys [106], baboons [107] and sheep [109] to 
study hypertension in relation to blood pressure changes during pregnancy. In a recent study, 
using the RUPP model to induce pre-eclamptic hypertension in rats, it was shown that both 
the sFlt1 and the sEng levels [99,108] in serum were signiﬁcantly increased compared to the 
control group, again conﬁrming the association of elevated sFlt1/sEng levels with pre-eclamptic 
hypertension.
Another mouse model to induce pre-eclampsia is achieved by the injection of angiotensin 
receptor activating autoantibodies (AT1-AAs), which are obtained from women with pre-eclampsia, 
into healthy pregnant mice. When mice were co-treated with an AT1 receptor antagonist [losartan], 
pre-eclampsia did not develop [9,110] validating the importance of AT1-AAs for pre-eclampsia 
onset. The injection of AT1-AAs resulted in elevated levels of sFlt1 and sEng in pregnant mice, 
whereas these levels were not affected in non-pregnant AT1-AA treated control mice [110,111], 
further suggesting the relevance of sFlt and sEng in pre-eclampsia. Similar to human studies, 
increased levels of sFlt1 and sEng are associated with pre-eclampsia in rodent models. These 
models provide researchers with great opportunities to investigate the intervention value of sFlt1 
and sEng as potential therapeutic targets.
sFlt1 and sEng as circulating biomarkers for pre- eclampsia
As hypertension and proteinuria are not speciﬁc symptoms for pre-eclampsia, a speciﬁc 
diagnostic marker is greatly needed for pre-eclamptic patients for early diagnosis and 
prevention. For this purpose a number of biomarkers have been under investigation [112]. The 
expression of sFlt1 and sEng is increased in pre-eclamptic patients prior to the occurrence of 
the pre-eclamptic syndrome, indicating their predictive value for the onset of pre-eclampsia. 
Nevertheless, the level of sFlt1 during pregnancy is variable between individuals, so it is 
difﬁcult to interpret its accuracy as a circulating biomarker. Therefore, recent studies have 
analyzed the sFlt1/PlGF ratio to enhance the sensitivity of this marker as an indicator for the 
onset of pre-eclampsia [7]. This ratio increases before the onset of pre-eclampsia, but it does 
not distinguish between women with subsequent gestational hypertension and the control 
group [7]. Using an automated sFlt1/PlGF assay [Elecsys® sFlt1 and PlGF assay developed by 
Roche] the sFlt1/PlGF ratio was shown to be a valuable tool in the assessment of pre-elampsia 
[112,113].
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Besides increased sFlt1 levels, sEng levels are also elevated in pre-eclamptic patients with an 
increased sFlt1/ PlGF ratio [7]. Increased sEng has been shown to be associated with pre-eclampsia 
development in a cohort study [114] and supported by another independent study in a Korean 
cohort [115]. In addition, sEng is reported to be informative to discriminate pre-eclampsia from 
gestational hypertension and chronic hypertension [116]. Of note, its increase also occurred in 
normotensive pregnancies with IUGR [117]. However, the association between IUGR and increased 
sEng levels was challenged by other studies in which no association between IUGR with sEng levels 
could be demonstrated [118].
The currently available enzyme-linked immunosorbent assay (ELISA) kits for the detection 
of sFlt1 are comprised of antibodies that do not distinguish the different isoforms of sFlt1. sFlt1 
variants are expressed at different levels in the placenta [49]. Use of antibodies which discriminate 
between the different subtypes could more speciﬁcally evaluate the potential roles of different 
isoforms in the pathogenesis of pre-eclampsia. With regard to sEng detection, different molecular 
weights of sEng have been reported. A study by Hawinkels et al. reported sEng to be around 80 
kDa in endothelial cells, whereas Venkatesha et al. detected a 65 kDa form of sEng in placental 
tissue. The size of sEng appears to be variable in different experimental settings. To validate the 
prediction value of sEng, more studies are needed to understand the source of different sEng forms.
Concluding remarks and future perspectives
Pre-eclampsia is a complex pregnancy-related syndrome. Deﬁcient placental function has been 
recognized as the major cause, but the pathological mechanism that underlies this disease remains 
less understood. Concerning the high incidence among pregnant women globally, an effective 
diagnostic tool for pre-eclampsia is urgently needed. Notably, the predictive potential of sFlt1 and 
sEng has drawn great attention in the research ﬁeld of pre-eclampsia in recent years, as substantial 
evidence implies that aberrant sFlt1 and sEng levels are involved in the angiogenic imbalance in pre-
eclampsia patients. Whereas the application of combining sFlt1/PlGF ratio together with the sEng 
concentration as diagnostic markers may contribute to better prediction and early identiﬁcation 
of pre-eclamptic patients, further studies regarding sFlt1 and sEng as predictive biomarkers for 
pre-eclampsia are required. Furthermore, it would not be surprising if aberrant sEng or sFlt1 levels 
are associated with other diseases, such as vascular complications in hypertension, diabetes and 
gestational proteinuria patients [119,120].
To explore potential therapeutic approaches for suppressing of pre-eclampsia progression 
the perturbed VEGF-sFlt1 balance was restored in mice by the administration of VEGF. This 
indeed alleviated the pre-eclampsia-like symptoms [101]. Targeting endoglin shedding may be 
an option to suppress sEng levels in the circulation. Alternatively, pharmalogically targeting of 
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the signalling upstream of sFlt1 and sEng expression might be more effective. Increasing levels of 
Heme-oxygenase-1 [HO-1] may be beneﬁcial for ameliorating pre-eclampsia HO-1 is a negative 
regulator for both sFlt1 and sEng expression in human placenta explants at the transcriptional level 
[121,122]. This strategy has been pursued n the ongoing trial StAmP [Statin to Ameliorate Early 
Onset Pre-eclampsia] to validate the use of statins in early-onset pre- eclampsia [123]; statins, a 
class of anti-oxidant agents, induce HO-1 expression [121,124]. However, an issue which should 
not be neglected is that all aforementioned angiogenic-based therapeutic approaches may affect 
the systemic endothelial homeostasis.
Recent ﬁndings have provided evidence suggesting that levels of sFlt1 and sEng associate 
with pathology of pre-eclampsia. Yet understanding the exact function of sFlt1 and sEng in pre-
eclampsia remains incomplete. Future advances in understanding the biology of sFlt1 and sEng in 
vascular biology could possibly reveal the etiology of pre-eclampsia and potentially be beneﬁcial 
in diagnosing patients at risk for the development of pre-eclampsia.
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The TGF-β family signalling pathways are highly fine-tuned cellular signalling networks 
and their biological effects dependent on the local microenvironment and context. Signalling 
cascades of TGF-β family members have been shown to be important in vascular development 
and angiogenesis. Mutations in TGF-β family receptors or Smads have been linked to vascular 
disorders such as HHT, PAH and Marfan Syndrome, as described in the introduction of this thesis. 
Mice deficient in specific TGF-β family signalling components, i.e. ligands, receptors or Smad 
transcription factors, frequently develop embryonic lethality due to vascular defects. The exact 
mechanism by which signalling of TGF-β family members, and perturbations therein, affects 
vascular function remains largely unknown. Therefore, this discussion will focus on our current 
perspectives of mechanisms underlying the crosstalk between TGF-β and VEGF, the perspective of 
BMP9 and endoglin in endothelial cell biology and the emerging role of TGF-β family signalling in 
angiogenic sprout remodeling. 
The interplay between TGF-β and VEGF signalling pathways in 
endothelial cell function
TGF-β signalling in endothelial cells
In endothelial cells (ECs), after the binding to type II receptor (TβRII), TGF-β signals via two 
opposing type I receptors (TβRI) and thereby activate distinct Smad signalling pathways: (i) the 
ALK5/Smad2/3 signalling pathway leading to inhibition of EC migration and proliferation, and (ii) 
the ALK1/Smad1/5 cascade that resulting in the induction EC migration (1). In addition, endoglin, 
a co-receptor for TGF-β ligands, promotes ALK1- but inhibits ALK5-induced signalling (2). Although 
the TGF-β/ALK1 pathway appears to directly antagonize TGF-β/ALK5 signalling, the presence of 
ALK5 is a requirement for efficient TGF-β/ALK1 signalling (3). Interestingly, when ECs are plated on 
fibronectin the requirement of ALK5 for TGF-β/ALK1 signalling is bypassed (4). To intervene with 
the pro-angiogenic effects of the TGF-β superfamily, tools have been generated to specifically 
inhibit the function of ALK1 and endoglin. Soluble chimeric forms of ALK1 (ALK1-Fc) or endoglin 
(endoglin-Fc) fused to an antibody Fc domain can attenuate the ALK1 signalling pathway possibly by 
scavenging pro-angiogenic ligands of the TGF-β superfamily. As a result, the fine-balance between 
TGF-β family and VEGF signalling is disturbed resulting in impaired VEGF-induced EC sprouting in 
vitro and in vivo (5 - 6). 
TGF- β regulates VEGF expression
Besides the direct effects that TGF-β has on EC behavior, TGF-β also regulates EC function 
indirectly by regulating the expression of angiogenic factors in non-endothelial cell types, such 
as smooth muscle cells, macrophages and tumor cells. Notably, in macrophages TGF-β induces 
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vascular endothelial growth factor (VEGF) production in a Smad-dependent manner to mediate 
angiogenic responses (8). In addition, TGF-β induces the expression of VEGF in tumor cells and 
tumor associated-stromal fibroblasts via the ALK5/TβRII complex (9, 10). SB-431542, an ALK4/5/7 
kinase inhibitor (11), has been shown to exert an inhibitory effect on VEGF secretion in human 
cancer cell lines (12 - 14). Moreover, TGF-β synergizes with hypoxia, a potent stimulator of 
angiogenesis, in stimulation of VEGF promoter activity in a Smad3-dependent manner (9, 15). 
In contrast, the activation of the ALK1/BMPRII complex upon BMP9 binding has been shown to 
suppress VEGF expression both in cells in vitro and in mouse aorta, lungs, liver, and intestine (16), 
indicating distinct regulatory effects of ALK1 and ALK5 on VEGF expression by different TGF-β 
family members.
Thus the regulation of VEGF production is mediated by different TGF-β superfamily members 
via distinct signalling transduction routes in diverse cell types. Therefore, the effect of TGF-β family 
members on local angiogenesis is mediated in part through modulation of VEGF signalling (17 - 19). 
This cross-talk between VEGF and TGF-β signalling orchestrates in an intricately regulated manner 
the vascular balance, and interfering with either one will result in vascular malformations
VEGF and TGF-β intracellular crosstalk
VEGF and TGF-β family members play prominent roles in angiogenesis, and the interaction 
between the two signalling pathways modulates EC behavior. While VEGF controls endothelial 
cell functions in angiogenesis such as migration, proliferation, sprouting and permeability, TGF-β 
family members are prerequisite for vascular network modeling via the regulation of EC migration, 
death and survival (20). In vitro TGF-β/ALK5 signalling can induce apoptotic effects and inhibit EC 
proliferation, migration and sprouting (Chapter 2, 1, 3). Interestingly, treatment with a sub-optimal 
dose of the ALK5 kinase inhibitors SB-43152 or LY-364947 synergistically enhanced EC capillary 
formation and EC sprouting in response to VEGF, suggesting that crosstalk between TGF-β and VEGF 
signalling regulates endothelial cell behavior (Chapter 2, 21). This synergistic effect in EC sprouting 
is also observed when using TGF-β neutralizing antibodies in combination with VEGF (Chapter 
2, 21). Transcriptional analysis revealed that inhibition of ALK5 signalling in combination with 
VEGF stimulation promotes the expression of anti-apoptotic factors and angiogenesis-associated 
integrins and down-regulates pro-apoptotic genes (Chapter 2). In the similar research line, Watabe 
et al. reported that the inhibition of TGF-β improves stem cell derived EC survival and endothelial 
sheet formation (22). Furthermore, TGF-β was shown to be able to convert VEGF activity from 
being anti-apoptotic to pro-apoptotic in EC by shifting the activation of p38 MAP kinase from 
the pro-survival p38β to the pro-apoptotic p38α MAP kinase (23, 24,). Remarkably the activation 
of p38α by TGF-β is transient and the ECs become refractory to TGF-β induced apoptosis due to 
reduced levels of p38α and increased levels of p38β MAP kinase (24), showing that the crosstalk 
between TGF-β and VEGF signalling dynamically regulates EC biology.
150
Chapter 7
Since modulation of a signal transduction pathway can occur at different levels, e.g. at the 
level of the receptor or downstream modulators, we made attempts to identify at what level the 
crosstalk between VEGF and TGF-β occurred. Unfortunately, we did not observe any significant 
changes in either Smad signalling, p38 or ERK MAP kinase activity after treatment with ALK5 kinase 
inhibitor or co-stimulation with TGF-β and VEGF (unpublished data). VEGR2 triggers different 
and diverse signalling pathways to regulate EC function. Yet we cannot exclude the possibility of 
involvement of other downstream signalling events such as endothelial cell permeability-related 
nitric oxide synthase (eNOS/NOS3) activation, cell migration related focal adhesion kinase (FAK) 
activity or PI3 Kinase activity. In addition, our studies (Chapter 2) have only addressed the role of 
TGF-β in EC angiogenic property both in vitro and in vivo. A more extensive investigation on the 
effect of the other TGF-β super family members such as BMPs and their receptors on EC function 
will improve the current understanding of the TGF-β/VEGF crosstalk.
In summary, TGF-β and VEGF signalling intimately intertwine and crosstalk with each other 
to regulate EC function. Inhibition of TGF-β signalling potentiated the VEGF-induced angiogenesis 
(22, Chapter 2). However the fine-tune of this crosstalk in EC is also dependent on various factors: 
ligand gradient, time windows and local vascular bed condition. The interpretation of TGF-β/VEGF 
crosstalk can not only be based on any particular specific biological setting, but requires the local 
EC status and its interaction with neighboring other cell types in the local microenvironment.
Crosstalk between VEGF and TGF-β at the receptor level
Although our experiments did not provide evidence for direct interaction of the downstream 
intracellular VEGF and TGF-β signalling cascades, other studies offered alternative clues pointing 
to possible crosstalk at the receptor levels. Glinka and co-workers showed that in cancer cells the 
co-receptors of VEGF, neuropillin-1 and 2 have affinity for ALK5 and TβRII, and over-expressing of 
neuropillin-1 and 2 increased the levels of phosphorylated Smad2/3 (25) indicating neuropillins 
potentiates ALK5/Smad2/3 pathway. Furthermore, neuropillin-1 and -2 capture and activate latent 
TGF-β to be accessible by changing the conformation of the bound form of latent TGF-β. Given that 
neuropillin-1 and -2 are required for efficient VEGF signalling and enhance ALK5/Smad2/3 pathway 
(22, 26), it is possible that neuropillins may be a modulator for the interplay between TGF-β and 
VEGF signalling in endothelial function.
VE-cadherin is another interesting potential mediator for TGF-β and VEGF interplay. 
Clustered VE-cadherin improved the sensitivity of Smad activation upon TGF-β stimulation by 
enhancement of TβRI/TβRII assembly; disruption of VE-cadherin clustering results in reduction 
of TGF-β-induced inhibition of EC growth and migration (27). In addition, TGF-β induces assembly 
of the adherens junction complex by separating VEGF receptor 2 (VEGFR2) from VE-cadherin but 
increasing β-catenin association with both VEGFR2 and VE-cadherin (28). These studies suggest 
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that the interplay between TGF-β and VEGF pathways may be regulated by the formation of 
complexes containing TGF-β receptors and VEGF receptors with VE-cadherin as the core. It is 
plausible that the affinity of VE-cadherin for VEGFR2 and TGF-β receptor determines the TGF-β 
and VEGF crosstalk.
BMP9: both inhibit and stimulate angiogenesis
Out of more than 30 TGF-β superfamily ligands, there are over 20 BMP subfamily members. 
BMPs signal through both BMP receptors and activin type II receptors to relay their signals to 
the downstream cascades via different BMP type I receptors such as ALK1,-2,-3, and -6, while 
they are also regulated by intrinsic antagonists (e.g. noggin) (29). BMPs exert broad functions 
as a result of great complexity between combinations of ligands, type I and II receptors. BMP9 
is a secreted circulating protein (30) that is highly expressed in the damaged liver (31) and binds 
to the extracellular domain of ALK1 and endoglin (30, 32). BMP9 signals via ALK1 to modulate 
endothelial cell function (Chapter 3; 33). Mutations in ALK1 are associated with the vascular 
disease HHT2. Mutations found in the extracellular domain of ALK1 interfere with the binding of 
BMP9, whilst HHT2 mutations in the intracellular domain are shown to reduce ALK1 activation 
upon BMP9 stimulation (34, 35), suggesting that there might be a role of BMP9 in the vascular 
disease HHT2.
BMP9 has an important role in angiogenesis (33, 36, 37). However, its effect on EC function 
and the mechanism of action remain unclear. Chapter 3 demonstrates an inhibitory effect of 
BMP9 on VEGF-induced angiogenesis. This result is supported by observations by David et al., 
who reported that BMP9 functions as a circulating vascular quiescence factor (38). A recent in vivo 
study has confirmed that activation of ALK1 by BMP9 inhibits retina angiogenesis and blockade 
of the BMP9/ALK1 signalling by ALK1-Fc induced hypervascularization of retina (39). Interestingly, 
BMP9 has also been shown to stimulate EC proliferation and to be a pro-angiogenic factor in 
Matrigel plug vascularization and tumor angiogenesis in a xenograft model (40, 41). In addition, 
BMP9 has been shown to stimulate endothelial tube formation in vitro (43). Moreover, anti-hALK1 
and anti-BMP9 antibodies can inhibit endothelial cell sprouting (37). These different results can 
in part be ascribed to differences in experimental setup: a low dose of BMP9 was found to have 
a pro-angiogenic effect, while a high concentration exerts an inhibitory effect on EC function (41; 
Chapter 3). However other factors can also contribute to the different results obtained. Differential 
receptor usage and/or different levels of activation of intracellular effectors of BMP9 may underlie 
its complex effects in different types of ECs. 
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The role of endoglin in endothelial cell function
Endoglin is expressed at the cell surface as a disulfide-linked homodimer, especially in active 
ECs (42, 44 45). It exists as long-form (L-endoglin) and short-form (S-endoglin) based on the different 
length of the cytoplasmic domain (46, Chapter 7). Apart from the membrane-bound forms, endoglin 
can be shedded by Matrix Metalloproteinase-14 (MMP14) existing as a soluble form (sol-Eng) 
(Chapter 3), which will be discussed later in detail.
In Chapter 4 we demonstrate that the lack of endoglin decreases the potential of VEGF 
signalling and VEGF-induced sprouting, resulting in defective endothelial cell sprouting. Mutations 
in endoglin are associated with the human vascular disease HHT1 (47). Endoglin heterozygous 
mice exhibit vascular lesions due to capillary malformation, resembling HHT1 syndromes (48 - 50). 
EC-specific deletion of endoglin in adult mice caused severe cerebrovascular dysplasia with the 
injection of adeno associated virus carrying VEGF; while one copy loss of endoglin only develops 
minimal irregular vascular formation (51). Our in vitro observations together with in vivo findings 
in the literature underscore the importance of endoglin in VEGF-induced vascular physiology. Yet 
the requirement of endoglin for efficient VEGF responses is likely not only restricted to ECs since 
endoglin is also expressed by fibroblasts, smooth muscle cells, and macrophages. Therefore, it is 
worthwhile to investigate the role of endoglin in VEGF-induced angiogenesis also by addressing 
other modulators of EC sprouting and the angiogenic microenvironment in order to achieve more 
insights. 
Different forms of endoglin through differential splicing and membrane shedding
It remains very difficult to clarify the role of endoglin in EC function. Up to now, most of the 
studies about endoglin have focused on the characterization of the functional role of L-endoglin, 
which is usually referred to endoglin. A few studies have tried to elucidate the role of S-endoglin 
in EC function. Surprisingly S-endoglin has binding preference for ALK5 rather than ALK1, which 
provides a possible explanation for the different effects of L-endoglin on EC function (52, 53). 
Endoglin has been reported to impose opposing effects on EC. While endoglin was shown to be pro-
angiogenic and required for EC function (2, Chapter 4), another study demonstrates that endoglin 
inhibits EC migration (54). The discrepancies among studies are not only due to differences in the 
experimental setup, such as the source of ECs model system, cell density, or even the expression 
ratio of S-endoglin/L-endoglin; but also the engagement of endoglin in distinct TGF-β/BMP receptor 
complexes in response to diverse TGF-β superfamily ligands. Endoglin is a pivotal modulater for 
ALK1 and ALK5 signalling in ECs. Yet further studies are required to elucidate the precise role of 
different forms of endoglin in EC function regulation upon TGF-β treatment in different biological 
environments. 
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Endoglin with its interactors other than TGF-β receptors in EC function
As addressed previously endoglin is required for VEGF-induced sprouting, however the exact 
mechanism remains unknown. Apart from its function as co-receptor for TGF-β/BMP receptor 
complexes, endoglin interacts with VE-cadherin (27). Our preliminary data suggested that 
endoglin-deficiency reduced the endogenous interaction between VE-cadherin and VEGFRII in 
ECs (unpublished data). Moreover VE-cadherin modulates the sensitivity of VEGFR2 signalling to 
cell density (55). These results suggest the possibility of a potential association between endoglin 
and VEGFR signalling activity via its interaction with VE-cadherin (Fig.1A). It would be interesting 
to investigate the effect of endoglin deficiency on VE-cadherin signalling as VE-cadherin fine tunes 
VEGFR2 and TGF-β signalling (Fig.1B).
Fig 1 Schematic possible roles of VE-cadherin and endoglin in controlling the angiogenic balance by regulating VEGF and 
TGF-β signalling pathways. (A) Clustered VE-cadherins may potentiaate TGF-β signalling and exert inhibitory effect on 
VEGFR2 signalling in ECs at high cell density, resulting in vessel stabilization. (B) Endoglin is indispensable for VEGF-induced 
angiogenesis. However, it is not well understood how endoglin deficiency affects VEGF-induced angiogenesis. It is possible that 
the endoglin may release the inhibitory effect of VE-cadheirn on VEGF signalling by altering the receptor complex composition.
To further investigate the mechanism of the impact of endoglin on VEGFR2 signalling, we 
examined the effect of endoglin deficiency on VEGFR2. As tyrosine 1175 of VEGFR2 is an essential 
phosphorylation site for VEGFR2 activation (56, 57), the phosphorylation level of this site was 
examined in ECs with endoglin deficiency. Surprisingly, the tyrosine 1175 phosphorylation level was 
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strongly reduced in endoglin knockdown cells at 5 min of VEGF stimulation (Fig. 2). Subsequently 
we studied the phosphorylation level of downstream signalling components of VEGFR2 such as ERK 
and p38 MAP kinases. Unfortunately no changes in ERK and p38 phosphorylation were observed in 
endoglin deficient ECs upon VEGF stimulation (data not shown). It is possible that the ERK and p38 
MAP kinases were not affected in this particular experimental setting due to the high amount of 
VEGF stimulation (25ng/ml), which may saturate the sensitivity of VEGF-induced MAP Kinase activity. 
Furthermore, a previous study showed that VEGFR2 preferentially signals to PI3 Kinase in confluent 
endothelial cells but promotes MAP Kinase activation in the sparse cells or VE-cadherin deficient ECs 
(55) (Fig. 1A). Thus VEGFR2 signalling may behave differently dependent on the local cell condition. 
In order to further characterize the influence of endoglin on VEGF signalling future studies should 
include the other downstream cascades of VEGFR2 such as FAK, AKT, eNOS, Src and PLCγ. Finally, it is 
not yet known whether lack of endoglin will influence the effect of VE-cadherin on VEGFR2 signalling.
Fig. 2 Phosphorylation level of VEGFR2 is reduced upon VEGF stimulation in endoglin knockdown ECs. HUVEC cells were 
stimulated with VEGF (25ng/ml) for 5min and 10 min. Non-infected cells (cell), control shRNA infected cells (Ctrl shRNA) 
and shRNA-mediated endoglin depleted cells (Eng shRNA) were used. Afterwards cells were lysed and samples subjected 
to SDS-PAGE and subsequent western blotting. Membranes were either probed with an antibody that specifically 
recognizes phosphorylated VEGFR2 at the site of 1175 and with an antibody directed against endoglin. An anti-β-actin 
antibody was used to confirm equal loading.
The interaction between endoglin and VE-cadherin also provides a hint that endoglin may be 
involved in cell junctions/contacts. Our preliminary data of electron microscopic analysis showed 
that endoglin was localized at the cell-cell contacts (data not shown). Tight alignment of endoglin 
at the cell-cell contact in addition to its interaction with VE-cadherin could further enhance TGF-β 
signalling in EC stabilization (Fig. 3A). Furthermore, endoglin has been shown to be situated at the 
cell membrane and to control focal adhesion via its interaction with zyxin (58), and mediate the 
General Discussion
155
Ch
ap
te
r 
7
activation of PI3 kinase and AKT at the cell membranes, leading to the stabilization of EC sprouting 
(59). These studies demonstrate the possible function of endoglin in EC junction, which can be 
important for vessel integrity during angiogenesis. 
It is reported that endoglin not only interacts with integrin α5β1 to modulate the crosstalk 
between TGF-β/ALK1 signalling and fibronection/α5β1signalling, but also co-internalize with α5β1 
to propagate integrin α5β1 signalling (4). The fibronection/α5β1signalling suppresses TGF-β induced 
EC migration in endoglin-depending manner, which could also be in part the explanation of the 
opposing role of endoglin in EC function in different experiment settings. Of note, the co-localization 
of endoglin and α5β1 in endocytosis is required for developmental angiogenesis in zebrafish (4), 
take together with the evidence that VEGF promotes α5β1 internalization to induce EC migration, It 
is plausible that endoglin could regulate VEGF-induced angiogenesis via its co-endocytotic partner 
integrin α5β1 leading to enhanced ALK1 signalling (Fig. 3B). 
 
In summary, all these results indicate that endoglin does not function merely as a co-receptor for 
TGF-β signalling in controlling EC function. Endoglin appears to be involved in EC cell junctions and 
endocytosis. Current understanding of this possible function is limited. Screening for novel endoglin 
interactors will provide more insight in endoglin biology. Novel interactors and/or regulators may 
reveal a new function of endoglin in angiogenesis, in TGF-β/BMP signalling and beyond.
Fig. 3. Possible role of endoglin in EC functions. (A) Endoglin is situated at the cell-cell contacts. Similar to clustered VE-
cadherin, it is possible that the clustered endoglin contribuates to the vessel stabilization. (B) Fibronectin/α5β1 promotes 
ALK1signalling in a endoglin-dependet fashion, thereby promoting angiogenesis (Tian et al, 2012).
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The emerging therapeutic value of soluble endoglin and its 
pathological role in pre-eclampsia
Soluble endoglin (sol-Eng) is a circulating factor in serum (60). Elevated levels are observed in 
patients with pre-eclampsia (60, 61), cancer patients with metastasis (62, 63) and diabetic patients (64). 
Sol-Eng can be generated via matrix metalloproteinase (MMP)-14 mediated shedding of membrane 
bound endoglin on endothelial cells in colorectal cancer. The MMP14-mediated cleavage occurs at 
a site close to the transmembrane domain of endoglin (Chapter 5). Interestingly, it has been shown 
recently that MMP-14 can induce the release of soluble endoglin in pre-eclamptic placenta (65). The 
cleaved sol-Eng contains the extracellular domain, retaining the ability of binding to TGF-β and BMP-9 
(32, 61). The reported sizes of sol-Eng appear to be variable in different studies. The sol-Eng from pre-
eclampsia patients is around 65kDa; but the one cleaved by MMP14 is around 80kDa in tumor cells. 
This suggests that the endoglin may harbor multiple potential cleavage sites and that the generation 
of sol-Eng in tumors and pre-eclampsia may occur via different mechanisms. In chondrocytes an 
increase in the ALK1/ALK5 ratio leads to MMP13 production (66), but it is not known yet whether 
MMP13 harbors cleavage potential for endoglin. Yet it remains to be examined whether the ALK1/
ALK5 ratio regulates MM14 production resulting in modulation of sol-Eng production.
Circulating sol-Eng may have systemic effects on angiogenesis. Sol-Eng contributes to 
pre-clampsia in concert with soluble VEGFR1 (solFlt1) (61). Elevated sol-Eng levels in the brain 
causes brain arteriovenous malformation via modulation of MMP activity but without changing 
the expression of membrane bound forms of endoglin (67). Yet further studies are required to 
establish a comprehensive understanding of the role of sol-Eng in vivo. High levels of circulating 
sol-Eng might lead to EC dysfunction due to its anti-angiogenic effect, which provides a potential 
therapeutic window for the endoglin neutralizing antibody to restore EC function. On the other 
hand, the anti-angiogenic effect of sol-Eng may be interesting for cancer treatment in the future, 
as an adjuvant therapy to selectively ablate blood vessels and thereby limiting tumor growth. 
Future Perspective: TGF-β signalling shapes the sprout tip
A vessel sprout consists of tip and stalk cells. Tip cells are localized at the leading edge of vessel 
sprouts. The gradient of VEGF guides the direction of tip cells (68). With enriched filopodia-like 
cell protrusion at their migrating front tip cells are sensitive to local directional cues and thereby 
orientate the direction of sprouts accordingly (68, 69), while adjacent stalk cells contribute to the 
extension of the nascent sprouts (Fig. 4). However, the tip and stalk cell phenotypes are subject to 
a highly dynamic process of phenotype selection along vascular sprouts. As discussed before, in 
addition to their direct effects on EC behavior, a role for TGF-β family members in other events of 
vascular modeling is emerging, such as tip-stalk cell phenotype specification.
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The TGF-β downstream components Id-1 and its upstream phosphorylated Smad1/5 (p-
Smad1/5) exhibit distinct localization patterns in EC sprouts. At embryonic day 9.5 phosphorylated 
Smad1/5 is ubiquitously expressed in tip and stalk cells, whereas Id-1 is only distributed in the 
stalk cells (70). In the absence of Smad1/5 signalling, the stalk cells acquire plasticity, becoming 
tip-cell-like cells (70). This suggests that Smad1/5 signalling is important for stalk/tip cell selection 
and that Smad1/5 and Id-1 may exert divergent roles in the modulation of tip and stalk cell behavior. 
Moreover, p-Smad1/5 interacts with the Notch intracellular domain (NICD) to potentiate the 
expression of the Notch signalling downstream targets Hey1 (Herp2) and JAG1 (71, 72), while Id-1 
form heterodimers with Hes-1 for Hes-1 stabilization in ECs (70). It thus appears that the interaction 
between Smad1/5 and Notch signalling regulates tip and stalk cell morphogenesis. Any impairment 
of the interplay may affect downstream target gene expression, and thereby result in loss of tip 
and stalk cell specification. Along with this notion, Larrviée et al. reported that blockade of ALK1 in 
tip cells displayed loss of stalk cell phenotype (39). Hence, TGF-β superfamily signalling cooperates 
with Notch signalling to specify the tip and stalk cell selection in early vascular sprouting events.
Fig. 4 Scheme of stalk/tip cell phenotype selection. Stalk cell (orange) and tip cell (green) are under dynamic selection 
by several signalling pathways. The VEGF pathway drives the transformation of stalk cells into tip cells. ALK1-Smad1/5 
signalling integrated with Notch signalling to maintain the adjacent stalk cell phenotype. Impaired ALK1 or Notch signalling 
turns the adjacent stalk cells into tip-like cells with hypervascularization, resulting in the loss of directed EC migration. 
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Chapter 4 demonstrated the requirement of endoglin for VEGF-induced EC sprouting both 
in vitro and ex vivo. In vivo endoglin deficiency mice displayed abnormal vascular structure 
development upon VEGF stimulation. In addition, endoglin is reported to promote EC proliferation 
and migration (2, 54). These studies open the possibility that endoglin may hold an important 
function in tip cell development as it is a critical determinant in controlling endothelial behavior.
The crucial role of TGF-β superfamily signalling in angiogenesis has been underlined by 
numerous studies both in vivo and in vitro. The exact molecular mechanisms of TGF-β superfamily 
signalling in vascular development remain complex and require further elucidation. However, the 
increasing knowledge of TGF-β superfamily signalling and its crosstalk with other signalling pathways 
rationalize its physiological and pathological contributions to vascular remodeling. Intervention of 
TGF-β holds great potential as therapeutic agents in anti-angiogenesis therapy of cancer.
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Abbreviations
ACE Angiotensin converting enzyme
ActR Activin Receptor
AGT Angiotensinogen 
AGTR Angiotensinogen receptor
AKT Protein Kinase B
ALK/ACVL Activin receptor-Like Kinase
AT-AAs Angiotensin receptor activating autoantibodies
BAEC Bovine aortic endothelial cell
Bax Bcl2 associated X gene
Bcl2 B-Cell CLL/Lymphoma 2
bFGF Basic Fibroblast Growth Factor 
BMP Bone morphogenetic protein
BMPER BMP endothelial cell precursor-derived regulator
BMPRII BMP receptor II
BRE BMP reporter element
caALK5 Constitutivelt active ALK5
CASP6 Caspase 6
CCL5 Chemokine (C-C Motif) Ligand 5
CRC Colorectal cancer
E Embryonic day
EB Embryonic body
EC Endothelial cell
ECM Extracellular matrix
ELISA Enzyme-linked immunosorbent assay
Endo-MT Trans-differentiation of endothelial cell
Eng-Fc recombinant endoglin-Fc chimera
eNOS Endothelial nitric oxide synthase
ERCF Immortalized HUVEC
ERK Early response kinase/mitogen-activated protein kinase 1
ESC Embryonic stem cell
FACS Fluoresceent-activated cell sorting
FAK Focal adhesion kinase
FBS Fetal bovine serum
Flk-1 Fetal liver kinase 1/ Vascular endothelial growth factor receptor 2
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
HELLP Hemolysis, elevated liver enzymes and low platelets
HHT Hereditary Hemorrhagic Telangiectasia 
HO-1 heme-oxygenase 1
HUVEC Human umbilical vein endothelial cell
ID1 Inhibitor of DNA binding 1
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Abbreviations
Ig Immunoglobullin
IL interleukin
I-Smad Inhibitory Smad
ITGA5 Integrin α5
ITGB3 Integrin β3
IUGR Intrauterine growth restriction
LTBP Latent TGF-β binding protein
MAEC Mouse aortic endothelial cell
MEEC Mouse embryonic endothelial cell
MEF Mouse embryonic fibroblast
MFS Marfan Syndrome
MMP Matrix metallopeptidase
MVEC Human normal dermal microvascular endothelial cell
PAH Pulmonary arterial hypertension
PAI-1 Plasminogen activator inhibitor type 1
PBS Phosphate Buffered Saline
PCR Polymerase chain reaction 
PDCD4 Programmed cell death 4
PECAM-1/CD31 Platelet/endothelial cell adhesion molecule 1
PI3 Kinase Phosphoinositide-3-kinase
PLCγ Phospholipase C gamma
PlGF Placental growth factor
qPCR Real-time quantitative reverse transcription PCR
RAS The renin-angiotensin system
R-Smad Regulatory Smad
RT-PCR Reverse transcription PCR
RUPP Reduced uterine perfusion pressure
sEng soluble Endoglin
sFlt-1 Solub;e fms-related tyrosine kinase 1/soluble VEGFR1
shRNA short hairpin RNA
Smad Small mothers against decapentaplegic
SMC Smooth muscle cell
Src V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog
StAMP Statin to ameliorate early onset pre-eclampsia
TBST Tris-buffered saline and tween 20
TGF-β Transforming growth factor β
TβRI Transforming growth factor β receptor I
TβRII Transforming growth factor β receptor II
VEGF Vascular growth factor
VEGFR2 Vascular growth factor receptor 2
VSMC Vascular smooth muscle cell
ZP Zona pellucida
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Summary
New blood vessels arise from pre-existing vessels when the supply of oxygen and nutrients and 
removal of waste products for the formation of new tissues is limited by diffusion (also termed as 
angiogenesis). Upon activation and under the guidance of vascular growth factors, endothelial cells 
(ECs) sprout from mother vessels and branch into nascent vessels. Subsequently pericytes/smooth 
muscle cells are recruited to the newly formed sprout for vessel stabilization. The primary vascular 
plexus is remodeled into a highly hierarchical vascular tree. Whereas angiogenesis is beneficial 
during wound healing, pregnancy, etc. and a prerequisite for development, abnormal angiogenesis 
is implicated in numerous vascular disorders, such as tumor angiogenesis, atherosclerosis, 
hypertension and other cardiovascular diseases.
The transforming growth factor (TGF)-β signalling pathway plays a major role in angiogenesis. It has 
been shown that TGF-β signalling affects both endothelial and mural cell function in genetic studies and 
in vitro cell culture models. Aberration of the TGF-β signalling cascade leads to abnormal remodeling 
and maturation of the primitive vascular plexus and decreased vessel wall integrity in adults. Targeted 
deletion of TGF-β signalling receptors in mice, such as ALK1, ALK5, TβRII or endoglin, results in embryonic 
lethality due to impaired vascular development. In humans, mutations in ALK1, ALK5, TβRII or endoglin 
are associated with human vascular diseases such as HHT and pulmonary hypertension (PAH). Vascular 
endothelial growth factor (VEGF) is a multifunctional molecule that is involved in vascular growth and 
remodeling. Similarly, in genetic mouse models abnormalities in or mis-regulation of the VEGF signalling 
pathway results also in embryonic death or severe vascular dysfunction. Perturbation in VEGF signalling 
also contributes to the pathology of tumor angiogenesis and cardiovascular diseases in humans.
This thesis is focused on the characterization of the crosstalk between the TGF-β and VEGF 
signalling pathways, on EC function, the effect of bone morphogenetic protein (BMP)9 on EC 
function and the role of endoglin in VEGF-induced angiogenesis. The results of these studies may 
give us insights into the impacts/effects of these two angiogenic signalling cascades on EC function. 
This can be beneficial for the understanding of the etiology of certain vascular diseases and the 
development of new treatment modalities in the future. 
The key findings in this thesis are:
• Inhibition of the TGF-β type I receptor by a pharmaceutical kinase inhibitor enhances VEGF-
induced angiogenesis both in vitro and in vivo. The crosstalk between TGF-β and VEGF leads 
to the induced expression of the pro-angiogenic integrin α5. [Chapter 2]
• BMP-9 is a potent stimulator of the ALK1 signalling pathway in endothelial cells and it inhibits 
VEGF-stimulated angiogenesis at high dosing. [Chapter 3]
168
Summary
• BMP-9 directly binds to endoglin and it potently induces endoglin expression at the 
transcriptional level. [Chapter 3]
• Endoglin is required for VEGF-induced angiogenesis in endothelial cells. VEGF-induced 
EC sprouting is decreased in ECs with endoglin-specific knockdown, but reduced endoglin 
expression does not affect major VEGF-induced signalling cascades. [Chapter 4]
• Absence of endoglin impairs the remodeling of vascular structures embryoid bodies, but 
doesn’t affect endothelial cell differentiation in embryoid bodies. [Chapter 4]
• Shedding of endoglin is mediated in part by MMP14. [Chapter 5]
• The soluble form of endoglin exerts inhibitory effects on VEGF-induced angiogenesis. 
[Chapter5]
Our studies demonstrate that a crosstalk at the receptor level between VEGF signalling and 
TGF-β signalling affects EC function and angiogenesis in vitro and in vivo. In other words, these two 
signalling pathways work, together with other pathways, in a coordinated manner to maintain the 
balance in EC function or the optimal angiogenic output via the regulation of gene expression. Once 
the balance between TGF-β and VEGF signalling is disturbed, downstream gene expression profiles 
change followed by cell morphology, as well as cell functions such as migration and proliferation. 
These changes affect EC function and vessel formation. Consequently the development of the 
vasculature will be modified accordingly. Therefore, the studies described in this thesis further 
confirm the crucial role of TGF-β in EC function and provide some novel molecular mechanisms. On 
endothelial cells, TGF-β transduces its effect by binding to two distinct TGF-β type I receptors, ALK1 
and ALK5. The two receptors result in distinctive impacts on endothelial cell behavior due to the 
local environment. Activation of ALK1 by BMP9 leads to inhibition of VEGF-induced angiogenesis, 
but the inhibition of ALK5 by pharmacological compounds results in enhancement of vascular 
network stimulated by VEGF. 
Endoglin, an auxiliary TGF-β receptor, has been well studied and is considered as an important 
angiogenic molecule. It is shown in this thesis that endoglin is required for efficient VEGF-induced 
angiogenesis. The role of endoglin in VEGF signalling further supports the notion for interplay 
between the TGF-β and VEGF pathways in controlling EC function. Moreover, we show that soluble 
endoglin (sEng) and an endoglin neutralizing antibody (Tracon105) function as a suppressor/inhibitor 
of VEGF-induced angiogenesis (chapter 4). sEng negatively influences the angiogenic potential of 
EC and elevated level of sEng was found to be associated with EC dysfunction in pregnant women 
with hypertension and pre-eclampsia. Interestingly, aberrant concentrations of soluble fms-like 
tyrosine kinase 1(sFlt-1), also known as the soluble form of the VEGF receptor, contributes the 
onset of pre-eclampsia as well. This indicates again the interplay and non-redundancy of these two 
pathways in maintenance of EC homeostasis. Detection of circulating sEng and sFlt-1 hold promise 
for the early diagnostic potential for patients with pre-eclampsia. 
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Nieuwe bloedvaten ontstaan uit reeds bestaande als tijdens de ontwikkeling van nieuwe 
weefsels de toevoer van zuurstof en voedingsstoffen en de afvoer van afvalstoffen beperkt wordt 
door diffusie (bekend als angiogenese). Endotheel cellen ontspruiten dan uit de moeder-vaten 
en vertakken zich in beginnende nieuwe vaten wanneer ze geactiveerd en beïnvloed worden 
door vasculaire groeifactoren Voor stabilisatie van de nieuw gevormde vertakkingen worden 
vervolgens pericyten en vasculaire gladde spiercellen (murale cellen) gerecruteerd. De primaire 
vasculaire plexus wordt gehermodelleerd via een zeer hierarchische vasculaire genealogie. Waar 
angiogenese normaal gesproken gunstig is tijdens bijvoorbeeld wondheling en zwangerschap, is 
het zelfs een vereiste voor ontwikkeling. Abnormale angiogenese daarentegen wordt gerelateerd 
aan talrijke vasculaire afwijkingen zoals tumor-angiogenese, atherosclerose, hypertensie en ander 
cardiovasculaire aandoeningen.
De transforming growth factor (TGF)-β signaaltransductie route speelt een belangrijke rol in 
angiogenese. Het is aangetoond in genetische studies en in vitro celkweek modellen dat TGF-β 
signaaltransductie effect heeft op de functie van zowel endotheel als murale cellen. In volwassenen 
leidt aberratie in de TGF-β sigaaltransductie cascade tot een abnormale hermodellering en 
maturatie van de primitieve vasculaire plexus en een verlaging van de integriteit van de vaatwand. 
Gerichte deletie van TGF-β signaleringsreceptoren in muizen, zoals ALK1, ALK5, TβRII of endoglin, 
resulteert in embryonale lethaliteit door verstoorde vasculaire ontwikkeling. In mensen worden 
mutaties in ALK1, ALK5, TβRII of endoglin geassocieerd met humane vasculaire ziekten zoals 
hereditary hemorragic telangiectasia (HHT) en pulmonaire hypertensie (PAH). Vascular endothelial 
growth factor (VEGF) is een multifunctioneel molecuul betrokken bij de groei en hermodellering 
van bloedvaten. In genetische muismodellen ontstaat op vergelijkbare wijze embryonale lethaliteit 
of ernstige vasculaire afwijkingen wanneer er sprake is van misregulatie in VEGF signaaltransductie. 
Verstoring in VEGF signaaltransductie in mensen draagt tevens bij aan de pathologie van tumor-
angiogenese en cardiovasculaire aandoeningen.
In dit proefschrift wordt de interferentie tussen de signaaltransductie routes van TGF-β en VEGF, 
het effect van bone morphogenic protein (BMP)-9 op endotheelcel functie, en de rol van endoglin 
in VEGF-geïnduceerde angiogenese gekarakteriseerd. De resultaten van deze studies kunnen ons 
inzicht geven in de angiogenese-gerelateerde effecten van deze twee signaaltransductie cascades 
op endotheel cel functie, wat van toegevoegde waarde is voor het begrijpen van de etiologie 
van bepaalde vasculaire afwijkingen en de ontwikkeling van nieuwe behandelmogelijkheden in 
de toekomst.
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De belangrijkste bevindingen in dit proefschrift zijn:
• Inhibitie van de TGF-β type I receptor door een farmaceutische kinase inhibitor versterkt VEGF-
geïnduceerde angiogenese zowel in vitro als in vivo. Interferentie tussen TGF-β en VEGF leidt 
tot een inductie van de expressie van pro-angiogeen integrin α5. [Hoofdstuk 2]
• BMP-9 is een krachtige stimulator van ALK1 signaaltransductie in endotheelcellen en blokkeert 
VEGF-gestimuleerde angiogenese in hoge dosering. [Hoofdstuk 3]
• BMP-9 gaat een directe binding aan met endoglin en geeft een sterke inductie van endoglin 
expressie op transcriptioneel niveau. [Hoofdstuk 3]
• Endoglin is noodzakelijk voor VEGF-geïnduceerde angiogenese in endotheelcellen. VEGF-
geïnduceerde endotheelcel-ontspruiting is gereduceerd in endotheelcellen met een 
endoglin-specifieke knockdown, maar gereduceerde endoglin expressie heeft geen effect op 
de belangrijkste VEGF-geïnduceerde signaaltransductie routes. [Hoofdstuk 4]
• Het ontbreken van endoglin verhinderd hermodellering van vasculaire structuren in embryoid 
bodies, maar heeft geen effect op endotheelcel diferentiatie in embryoid bodies. [Hoofdstuk 4]
• ‘Shedding’ (verwijdering van het actieve gedeelte van het molecuul van het celmembraan) van 
endoglin wordt deels gereguleerd door MMP14. [Hoofdstuk 5]
• De oplosbare vorm van endoglin heeft een remmend effect op VEGF-geïnduceerde 
angiogenese. [Hoofdstuk 5]
Ons onderzoek demonstreert dat endotheelcel functie en angiogenese zowel in vitro als in vivo 
beïnvloed wordt door interferentie tussen VEGF en TGF-β signaaltransductie op receptor niveau. 
Met andere woorden, deze twee signaalroutes werken op een gecoördineerde manier samen (ook 
met andere routes) om zodoende de balans tussen endotheelcel functie en de optimale angiogene 
output te behouden via de regulatie van genexpressie. Zodra deze balans wordt verstoord, worden 
wijzigingen in het genexpressie profiel geïnduceerd, gevolgd door aanpassingen in de celmorfologie 
en eveneens in celfuncties zoals proliferatie en migratie. Deze veranderingen hebben invloed op 
endotheelcel functie en de vorming van vaten. Als gevolg hiervan zal de vasculatuur zich vormen 
naargelang de veranderingen in signalering.
De studies beschreven in dit proefschrift geven verdere bevestiging van de cruciale rol van 
TGF-β in de functie van het endotheel en voorziet in enkele nieuwe moleculair-mechanistische 
inzichten. TGF-β signaaltransductie in endotheelcellen verloopt via binding aan twee verschillende 
TGF-β type I receptoren, ALK1 en ALK5. Deze twee receptoren hebben een andere uitwerking 
op het gedrag van de endotheelcel, afhankelijk van het lokale milieu waarin de cel zich bevindt. 
Activatie van ALK1 door BMP-9 leidt tot remming van VEGF-geïnduceerde angiogenese, echter, 
inhibitie van ALK5 met farmacologische stoffen resulteert in een versterking van het vasculaire 
netwerk, gestimuleerd door VEGF.
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Endoglin, een TGF-β co-receptor, wordt reeds lang bestudeerd en beschouwd als een 
belangrijk angiogeen molecuul. In dit proefschrift wordt bewezen dat endoglin noodzakelijk is 
voor efficiente VEGF-geïnduceerde angiogenese, wat nogmaals de relatie tussen de VEGF en TGF-β 
signaaltransductie routes in endotheelcel functie onderstreept. Bovendien demonstreren wij dat 
oplosbaar endoglin (sol-Eng) en een endoglin neutraliserend antilichaam functioneren (TRC105) als 
een remmer van VEGF-geïnduceerde angiogenese (hoofdstuk 4). Sol-Eng beïnvloedt het angiogene 
potentieel van endotheel cellen negatief en gevonden is dat een stijging van het niveau van sol-Eng 
is geässocieerd met dysfunctie van endotheelcellen in zwangere vrouwen met hypertensie en 
pre-eclampsie. Interessant hierbij is dat afwijkende concentraties van oplosbaar fms-like tyrosine 
kinase-1 (sFlt-1), ook bekend als de oplosbare vorm van de VEGF receptor, ook bijdragen aan het 
ontstaan van pre-eclampsie. Dit is opnieuw een duidelijke indicatie van het samenspel tussen 
deze twee signaaltransductie routes, en van hun noodzakelijkheid in het onderhouden van de 
endotheelcel homeostase. De mogelijkheid tot het detecteren van circulerend sol-Eng en sFlt-1 
beloven dan ook een belangrijke bijdrage te leveren aan het in een vroeg stadium kunnen 
diagnosticeren van pre-eclampsie in patiënten.
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